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BACKGROUND: p38 mitogen activated protein kinases (p38 MAPKs) respond to 
stress stimuli and play a role in cell differentiation and apoptosis. Four isoforms of p38 
MAPKs have been found; p38-α/β/γ/δ and this project focuses on the role of p38α. 
There are three pathways leading to p38α activation, the canonical pathway, the ZAP70-
mediated pathway and the TAB1-mediated pathway. The latter has been found to occur 
during myocardial ischaemia. Therefore, if this direct effect of TAB1 on p38α can be 
controlled and prevented, there might be a potential way to stop or minimise myocardial 
ischaemic injury. The aim of this project is to investigate the effect of TAB1 on p38α 
autophosphorylation, as well as assessing competition between this pathway and the 
canonical cascade of activation. Another signalling pathway, which involves p38α, with 
a potential role in heart failure, is the amino acid response pathway (AAR). 
Halofuginone, a compound which activates the AAR pathway, has been implicated in 
improved cardiac function. Exploring this system by using halofuginone as a tool would 
provide further insight into whether the activation of this pathway could lead to 
improvements in several aspects of heart failure, such as hypertrophy, autophagy and 
inflammation.  RESULTS: Using HEK293 cells, co-expression of TAB1 and p38α 
results in increased phosphorylation of p38α. This phosphorylation is reduced by the 
p38 inhibitors SB203580 and BIRB796. Mutations in TAB1, preventing p38 binding, 
diminish TAB1-mediated p38α phosphorylation. Despite spatial overlap in docking 
domains on p38α, TAB1 does not compete with MKK3b in a mammalian 
overexpression model. TAB1 and MKK3b induce phosphorylation of p38 
independently and this is probably due to their differential in-cell locations, with p38 




p38 appears to be activated in response to halofuginone, and the simultaneous activation 
of the AAR pathway leads to increased autophagy, changes in the mRNA levels of 
inflammatory genes, as well as a potential p38-mediated negative feedback mechanism 
on the AAR pathway. 
 CONCLUSIONS: There is a TAB1-mediated, SB203580-sensitive p38α 
phosphorylation mechanism which involves direct binding of TAB1 to p38α and 
induction of p38α autophosphorylation. p38 is activated in response to halofuginone and 
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1.1 Mitogen activated protein kinases (MAPKs) 
Mitogen activated protein kinases (MAPKs) are widely conserved Ser/Thr kinases that 
play a major role in cells by regulating, activating and inhibiting other pathways. There 
are three families of MAPKs consisting of c-Jun N-terminal kinase (JNK), extracellular 
signal regulated kinase (ERK) and p38. All three families have similar activating stimuli 
ranging from cytokines to bacterial or viral infection.  They are involved in cell growth, 
proliferation, differentiation, apoptosis, gene expression and respond to stress 
conditions depending on stimuli and cell-type (1). There are diverse stimuli activating 
these MAPKs and their pathways are intricately linked (see Figure 1.1). Transforming 
growth factor beta–activated kinase 1 (TAK1) is activated by many stimuli and goes 
onto activate several members of the MAPK kinases (MKKs) family including MKK3, 
MKK6, MKK4 and MKK7, which in turn activate p38α and/or JNK (2). TAK1 also 




Figure 1.1 Diagram illustrating the intricate links between cell signaling pathways. 
Osmotic stress, inflammatory cytokines and bacterial factors trigger a stress-response 
system in the cell. These signals diverge at TAK1, which plays a role in several 
pathways including nuclear factor  kappa B (NFκB), JNK, ERK1/2 and the p38 system 
to adequately generate responses depending on cell-type and stimulus. (4) 
1.2 p38α 
1.2.1 Isoforms and expression 
p38α is a 38kDa MAPK which was identified in 1994 as becoming phosphorylated on 
Tyr residue in macrophages following bacterial endotoxin lipopolysaccharide (LPS) 
exposure (5) and as being activated by interleukin 1 (IL-1) and subsequently activating 
MAPK activated protein kinase 2 (MAPKAP-K2) (6, 7). It is also referred to as 
MAPK14 and stress activated protein kinase 2a (SAPK2a), and p38α is the homologue 
of the Hog1 protein in S.cerevisiae (8). It is 60% identical in sequence to the other p38 
isoforms; β/γ/δ and ERK6 (9). The different p38 isoforms are encoded by different 
genes and have different tissue expression patterns. p38α and p38β are ubiquitously 
expressed, p38γ is abundant in skeletal and cardiac muscle and p38δ is expressed in the 
Pelin Arabacilar 
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lung, gut, pancreas, testes and kidney (10, 11).  p38α also has alternatively spliced 
versions; Mxi2 has reduced binding to substrates and plays a role in ERK1/2 regulation 
(12) and Exip is not phosphorylated by the usual activating treatments of p38α and has 
been shown to regulate the nuclear factor κB (NFκB) pathway (13). 
1.2.2 Activation and structure 
During immune and stress responses involving p38α, there is a complex interaction of 
different kinases, scaffold proteins and receptor associated factor proteins. p38α 
pathway consists of a cascade of kinases, ultimately resulting in MKK3/6 
phosphorylating p38α at its activation lip. One of the key players of the canonical p38α 
pathway is TAK1, a central effector that crosslinks different pathways involved in the 
stress response.  TAK1 is activated by phosphorylation and protein-protein interactions. 
TAK1-binding proteins (TAB) 1/2/3 play a role in the tight control of TAK1 activation 
(4). TAK1 is known to be involved in the c-Jun N-terminal kinase (JNK), p38α and 
nuclear factor κB (NF- κB) pathways and intracellular signals diverge at TAK1-TAB1 
association (2-4, 14). TAK1 is part of a complex with TAB1 and either TAB2 or TAB3. 
TAB2 and TAB3 are homologous proteins with C-terminal zinc-finger motifs acting as 
docking domains for Lys63–linked polyubiquitination by the E3-ligases such as TNF 
receptor associated factors (TRAF) 6 and 2 which induce autophosphorylation of TAK1 
(15, 16). TAK1 appears to form a complex with its specific activator TAK1 binding 
protein 1 (TAB1) which facilitates activation of TAK1 (17). TAB1 does not recruit 
TAK1 to receptors of the immune response, but instead it is able to bind directly and 
activate TAK1. Recently, it has been reported that TAB1 is modified with N-
acetylglucosamine (O-GlcNAc) on a single site, Ser395, which is required for full 
TAK1 activation upon stimulation with IL-1 or osmotic stress (4).   
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p38α has 2 distinct lobes with a catalytic groove in between and has a larger ATP-
binding pocket than p38β (18). Its N-terminal lobe is predominated by β-pleated sheets 
and has a larger C-terminal lobe made up mostly of α-helices (19) (see Figure 1.5 and 
Figure 1.6) with a hinge linking these two lobes. p38α is activated by phosphorylation 
on Thr180 and Tyr182 in a Thr-Gly-Tyr motif in a surface loop close to the active site, 
also known as the activation lip. Activation of p38α can result from the canonical kinase 
cascade or autophosphorylation (20, 21).  The canonical pathway of p38α activation 
involves TAK1 being activated by extracellular stimuli such as transforming growth 
factor-β (TGF-β), bone morphological protein (BMP) and tumour necrosis factor-α 
(TNF-α) (22-24). TAK1 goes onto phosphorylate MKK3/6, which can then go onto 
phosphorylate the TGY motif on p38α. Activated p38α then relocates to the nucleus or 
cytoplasm depending on the stimulus, cell-type and its specific function (25). 
Unstimulated p38α is found in the both the cytoplasm and the nucleus and upon 
stimulation it relocates depending on the stimulus. For example it will be retained in the 
nucleus if there is damage to DNA, but when bound, TAB1 will locate p38α in the 
cytoplasm (26). 
1.2.3 Alternative activation mechanisms 
Nonetheless, the MKK-mediated cascade is not the sole activation mechanism of p38α 




Figure 1.2 Schematic representation of the p38α activation pathways.  
p38α is usually activated by environmental stress, inflammatory cytokines and virus 
infection. Main pathway of activation is via TAK1 in the canonical MKK system 
involving MKKs 3/6, which are in turn activated by MEKKs, MLKs and ASK1. A 
second activation mechanism is via direct interaction by the scaffold protein TAB1 
inducing autophosphorylation of Thr180 and Tyr182 in the activation lip. A third 
mechanism also exists by ZAP70 tyrosine kinase which phosphorylates p38α on Tyr323 
inducing its autophosphorylation of the TGY motif. (19) 
 
There is a zeta-chain-associated protein kinase (ZAP70) mediated autophosphorylation 
mechanism which has so far not been identified to be involved in cardiac 
pathophysiology. ZAP70 is the tyrosine kinase subunit of the T-cell receptor (TCR) and 
once activated ZAP70 phosphorylates p38α on Tyr323 leading to p38α 
autophosphorylation (27).  
Another mechanism of p38α activation involves direct binding between TAB1 and 
p38α. TAB1 is a scaffold protein, which plays a role in the canonical p38α activation 
pathway as already mentioned. However, it has also been found to interact with p38α 
directly and this mechanism is best described in ischaemia (28, 29). In ischaemia-
reperfusion studies of MKK3-/- and MKK3+/+ mice hearts, infarction volume was 
similar despite undetectable activation of MKK3/6 in MKK3-/- hearts (29). Using 
mutated forms of p38α, it has been reported that phosphorylation of the activation lip is 
Pelin Arabacilar 
29 
not a prerequisite for the binding of TAB1 to p38α and the amount of p38α 
phosphorylation mediated by TAB1 is comparable to that mediated by the dominant 
active MKK6 (30). Recently, novel phosphorylation sites in the TAK1-binding domain 
of TAB1 have been discovered which appear to affect TAB1-dependent p38 
phosphorylation and p38-bound TAB1 localisation (31). In cultured neonatal 
cardiomyocytes, TAB1 binds to p38, disrupts p38 interaction with MKK3 and leads to 
the relocalisation of p38 in the cytosol (32). Therefore it is possible that TAB1 
competes with MKK3 in binding to p38 and altering its downstream effects depending 
on the stimuli.  
There are indirect regulatory processes that also influence p38α activation. One such 
process reported in recent studies is the action of the E3 ubiquitin ligase, Itch. Itch binds 
directly and ubiquitinates TAB1, inhibiting p38α signaling and skin inflammation (33).  
In addition, through chemical-genetic approaches and coexpression in mammalian, 
bacterial and cell-free systems, it has been reported that p38 autophosphorylation occurs 
in cis by direct interaction with TAB1 (34). Crystallography revealed that TAB1 docks 
onto p38α C-terminal in a bipartite manner, stabilises active p38α and induces 
conformational changes leading to the extension of the activation lip allowing 
autophosphorylation (34). This study has reported that TAB1 residues 371-416 are 
sufficient to induce phosphorylation of p38α, and our genetic modifications in TAB1 




Figure 1.3 Schematic showing the different domains of TAB1 (amino acids 1-504).  
Amino acids 25-365 constitute the PP2C-like pseudophosphatase domain, amino acids 
373-418 are involved in p38α-binding and the TAK1-binding domain is made up of 
amino acids 437-504. p38α phosphorylates TAB1 at S423 and T431, whereas both 
ERK1/2 and JNK1/2 phosphorylate at S438  (4). ITCH protein interacts at the Y148 
(33) and O-GlcNAcylation takes place at S395 (4). 
 
TAB1 has three domains; PP2C-like pseudophosphatase domain, p38α-binding domain 
and TAK1-binding domain (see Figure 1.3). Although the fold in protein phosphatase 
2C is conserved in TAB1, through structural analyses and mutagenesis it was observed 
that TAB1 lacks the key residues required for dual metal-binding and catalysis (3). 
There is a splice variant, TAB1β, which lacks exons 10 and 11, which correspond to the 
TAK1-binding domain and has a different exon, β, instead (see Figure 1.4). TAB1β 
differs from TAB1, as it cannot bind or activate TAK1, but maintains the ability to 
induce p38α activation (35). 
 
Figure 1.4 Sequence and structure of TAB1β, the splice variant of TAB1.  
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(A) amino acid sequences of TAB1β and TAB1. (B) structure of exon and intron in 
TAB1β and TAB1. (35) 
 
TAB1 is involved in crosslinking/integrating several pathways within a cell and has 
several phosphorylation sites which are acted upon by different kinases. p38α has been 
found to phosphorylate TAB1 at Ser423 and Thr431, whereas ERK1/2 phosphorylates 
Thr431 and JNK1/2 acts on Ser438. Nevertheless, TAB1 has not yet been widely 
studied so its function and relation to other proteins within a cell is not completely 
understood.  
It is not yet clear exactly how TAB1 binding to p38α induces p38α autophosphorylation 
on the TGY motif. It is of interest to investigate this interaction further as it has the 
potential to have an important role in ischaemic injury and could reveal targets for 
treatment of cardiovascular diseases. 
1.2.4 Substrates 
It is evident that in order to be efficient and specific, an important aspect of a signalling 
pathway is the presence of specialised interaction and docking domains in scaffold 
proteins and substrates. p38α is a Ser/Thr kinase associated with phosphorylation of 
Ser-Pro and Thr-Pro motifs. However, there are several other domains on downstream 
substrates necessary for interaction with, and subsequent phosphorylation by p38α. 
Docking domains (D-domains) are positively charged regions surrounded by 
hydrophobic residues and are involved in p38α binding besides the enzyme-substrate 
interaction at the active site of the kinase (36). A C-terminal docking (CD) motif is a 
region of acidic and hydrophobic residues outside the catalytic region of p38α, which is 
necessary for hydrophobic and electrostatic interactions with D-domain residues (37, 
38). Different substrates utilise different motifs to facilitate p38α binding, but these 
conserved features are heavily exploited for specificity and efficiency of p38α function. 
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Some of p38α substrates are other protein kinases such MAPKAPK2 (or MK2) and 
MK3 which were found to phosphorylate heat shock protein 27 (Hsp27), activating 
transcription factor 1 (ATF1) and cAMP responsive element-binding protein (CREB). 
Other protein kinases activated by p38α include mitogen- and stress-activated protein 
kinase 1 (MSK1), MSK2 and MAPK-interacting serine/threonine-protein kinase 1 
(MNK1). Transcription factors are another major group of substrates for p38α and these 
include ATF1, ATF2 and ATF6, CCAAT-enhancer-binding protein homologous protein 
(CHOP), p53 and myocyte enhancer factor 2C (MEF2C). p38α substrates identified to 
date are listed (see Table 1.1). 
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Table 1.1 Identified substrates of p38α and their corresponding phosphorylation sites  
(adapted from http://www.kinasource.co.uk/Database/S%20Substrates/SAPK2a%20substrates.html) 
 
Substrates Sites Reference 
ATF-2 Thr 69 and Thr 71 van Dam et al., 1995 EMBO J. 14:1798-811 
Cdc25B   Bulavin et al., 2001 Nature 411:102-107 
Cdc25C   Bulavin et al., 2001 Nature 411:102-107 
CHOP-1, GADD153 Ser78, Ser81  Wang et al., 1996 Science 272:1347-9 
Cyclin D3 Thr283 Casanovas et al., 2004 Oncogene 23:7537-44 
MAPKAP K2 Thr222, Ser272, Thr334 Rouse et al., 1994 Cell 78, 1024-1034 
Ben Levy et al., 1995 EMBO J. 14, 5920-5930 
Xu et al., 2006 Oncogene. 25:2987-98. 
Kumar et al., 2010 Cancer Res. 70:832-41 
MAPKAP K3 Thr201, Ser251, Thr313 McLaughlin et al., 1996, JBC 271, 8488-8492 
MAPKAP K5, PRAK Thr182 New et al., 1998, EMBO J. 17, 3372-3384 
MSK1 Ser 360, Thr 581 Deak et al., 1998 EMBO J. 17;:4426-41 
McCoy et al., 2005 Biochem J. 387:507-17 
MITF Ser 307 Mansky et al., 2002, JBC 277, 11077-11083 
MNK1 Thr221 Waskiewicz et al., 1997 EMBO J. 16:1909-20 
MNK2 Thr 197, Thr 202 and Thr 332 Waskiewicz et al., 1997 EMBO J. 16:1909-20 
C/EBP beta Thr45 Horie et al., 2007, Microbes Infect. 9:721-8 
Cyclin D1  Thr 286 Casanovas et al., 2000 JBC 275:35091–7 
MEF2A Thr312, Thr319 Zhao et al., 1999 Mol Cell Biol. 19:21-30 
MEF2C Thr293, Thr300, Ser 387? Han et al., 1997 Nature 386:296-9 
Zhao et al., 1999 Mol Cell Biol. 19:21-30 
Khiem et al., 2008 Proc Natl Acad Sci. 105:17067-72 
PLA2 (Ca 21 -sensitive 85-kDa 
cytosolic phospholipase A2) 
Ser 505 Kramer et al., 1996 JBC 271:27723–9 




Ser6, Ser12, Ser21 Barger et al., 2001 JBC 276:44495–501 
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p47phox Ser345, Ser348 Manke et al., 2005 Mol Cell 17:37-48 
p53 Ser 33 Sanchez-Prieto et al., 2000 Cancer Res. 60:2464-72 
RSK-B Ser 343, Thr 568 and Thr 687 Pierrat et al., 1998 JBC 273:29661-71 
Tomas-Zuber et al., 2001 J Biol Chem. 276:5892-9 
Sap-1a Ser381, Ser387 Jahnknecht & Hunter, 1997 EMBO J.16:1620-7 
STAT1 Ser727 Kovarik et al., 1999 Proc Natl Acad Sci U S A. 96:13956-
61 
TAB1 (TAK1 binding protein) also 
isoforms 2 & 3 
Ser 423 and Thr 431 Cheung et al., 2003 EMBO J. 22:5793-805 
De Nicola et al., 2013 Nat Struct Mol Biol. 20:1182-90 
Tau Thr 181, Ser 202, Thr 205, Ser 
396 and Ser 422 
Reynolds et al., 1997 J Neurochem. 69:191-8 




1.2.5 In-cell localisation 
As a signalling molecule, the localisation of the p38 in the cell is not fixed and highly 
dependent on the stimulus and cell type. It shuttles between the nucleus and cytoplasm 
depending on the response required to the particular prevalent stimuli. 
In a study in 293T cells, basally p38 is distributed throughout the cell with the exposure 
to UV irradiation or X-radiation triggering accumulation of it in the nucleus (26). Basal 
phosphorylation of p38 was low, and increased, specifically in the nucleus, in response 
to these stimuli. Other activators of p38 MAPK; TNFα and Fas ligand induced p38 
phosphorylation but did not result in its nuclear-relocation.  
One of p38 substrates MK2, has been reported to form a complex with p38 and 
facilitate its nuclear-export upon the phosphorylation of MK2 (25). The p38 activators 
MKK3 and MKK6 are present in both the nucleus and the cytoplasm, consistent with 
their role in the induction of p38 activity leading to the activation of a wide range of 
substrates and effectors. 
A recent study has reported that the autophosphorylation of ERK1/2 on its Thr188 
residue leads to its relocalisation to the nucleus to induce the phosphorylation of its 
nuclear targets known to cause cardiac hypertrophy (39). A corresponding residue is 
found on p38α (Thr185), and it is possible that the phosphorylation state of this residue 
plays a role in determining the localisation of p38 in the cell, which is an aspect that 
will be investigated in this thesis. 
1.2.6 Inhibitors 
p38α utilises ATP to phosphorylate its substrates and is therefore a target of 
pyridinylimidazole drugs as competitive inhibitors. SB203580 being an example of 
these ATP-mimetic molecules, competes with ATP and binds specifically to the ATP-
binding site of p38α and p38β and inhibits phosphorylation of downstream substrates 
Pelin Arabacilar 
36 
such as MAPKAP kinase 2 and heat shock protein 27 (20, 40). SB203580 only inhibits 
isoforms p38α and p38β and its selectivity is due to a gatekeeper residue, Thr106, 
guarding a hydrophobic pocket at the margin of the ATP-binding pocket (41, 42) (see 
Figure 1.5). A bulkier Met residue is substituted in p38γ and p38δ rendering these 
isoforms resistant to inhibition (41). Another ATP-mimetic p38 inhibitor is SB236093 
which displays more than 220-fold selectivity over ERK, JNK1 and other kinases and is 
~3-fold more selective than SB203580.  
 
 
Figure 1.5 Structure of the Type I p38α inhibitor SB203580.  
(A) chemical structure, (B) spacefill structure bound to ribbon structure of p38α. Black 
circle numbers 1 and 2 are the Thr180 and Tyr182 on the activation lip where p38α is 
phosphorylated, 3 is Tyr323 where ZAP70 induces autophosphorylation and 4 is the 





Another series of p38α inhibitors are diaryl urea compounds, which are structurally 
different to pyridinylimidazoles. BIRB796 is one of the most potent examples of this 
class of inhibitors and inhibits p38α activity by indirectly hindering ATP-binding. p38α 
has a DFG motif as part of its activation loop and this motif is believed to enable 
flexibility for conformational rearrangement upon activation (44). BIRB796 binds to the 
Phe residue of the DFG motif in a hydrophobic pocket between the two lobes of p38α 
(see Figure 1.6) leading to reorganisation of the activation loop resulting in a 
conformation unable to bind ATP (45). As well as p38α, all isoforms of the p38 family 
are also inhibited by BIRB796 (46). However, BIRB796 more potently inhibits p38α 
and p38β compared to p38γ and p38δ potentially due to the fact that this inhibitor 
exploits the hydrophobic pocket surrounding Thr106 residue not present in p38γ and 
p38δ (46). 
 
Figure 1.6 Structure of the Type II p38α inhibitor BIRB796. 
(A) chemical structure, (B) ball and stick structure bound to ribbon structure of p38α. 
Image A - Pubchem Compound, NCBI; image B- (47) 
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1.2.7 In physiology 
p38α has been implicated in many aspects of cell biology including inflammation, gene 
expression, the cell cycle, cell differentiation and apoptosis. Some of the stimuli which 
activate p38α are inflammatory cytokines, environmental stress, ischaemia, UV 
irradiation, oxidative stress, hypoxia, TGF-β and lipopolysaccharide (LPS) (7, 48). 
There is a strong link between p38α and inflammation and it has been found to play a 
role in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel 
disease (49).  
Some of the main functions of p38α are to induce enzymes involved in inflammation 
such as cyclooxygenase-2 and inducible NO synthase, regulate cell adhesion proteins 
and promote the secretion of inflammatory cytokines such as interleukin-1 (IL-1) and 
tumour necrosis factor-α (TNFα). The role of p38α in apoptosis has been found to 
depend on cell type and stimulus (50, 51). In some cells it induces cell death through the 
apoptotic pathway involving caspases (52), while in other cell types it promotes cell 
differentiation (53).  
In addition, p38α activity has been reported to be decreased in tumours and dysfunction 
of the p38α pathway caused an increase in cell proliferation and tumorigenesis 
suggesting that p38α has tumour suppressive qualities (54-56). Moreover, p38α plays a 
role in development as loss of p38α causes embryonic death in mice due to placental 
defects (57-59). This also infers the lack of compensation for p38α in development by 
its other isoforms. Nonetheless upon loss of the other isoforms, p38α can compensate 
for them and development is not perturbed. 
p38α plays a role in myocardial ischaemia, its activation induces lethal injury (60-62) 
and inhibition is cardioprotective (62-65). Nonetheless, p38α has also been found to 
play a role in ischaemic preconditioning (IPC) associating p38α activation with 
protection of the cardiac tissue (66-69). IPC is a mechanism where a short duration of 
Pelin Arabacilar 
39 
ischaemia during which p38α has been found to be activated, protects against 
subsequent periods of prolonged ischaemia.  
The main activation pathway of p38α is through MKKs in the canonical mechanism as 
already mentioned. However this pathway was not found to be involved in the 
activation of p38α during ischaemia. Instead, TAB1 was found to mediate 
autophosphorylation of p38α observed during myocardial ischaemia (29). 
1.3 Cardiovascular disease and myocardial ischaemia 
Cardiovascular disease is a general term used to refer to numerous diseases of the heart 
and the circulatory system. It includes stroke, coronary heart disease, angina and heart 
attack and was the most common cause of death in the world in 2008 (74). The common 
factor of these conditions is their association with atheromas, which are the deposit of 
fatty plaques in blood vessels, making it more difficult to carry blood along the arteries. 
These atherosclerotics plaques can rupture leading to platelet activation and thrombus 
formation. The consequent cessation of blood flow down the conduit artery restricts the 
perfusion of the distal tissue. This results in the tissue being deprived of nutrients 
(oxygen and substrates for metabolism) and a means to washout metabolites (carbon 
dioxide and lactic acid), a condition referred to as ischaemia (72). During ischaemia 
many processes within a cell are activated causing injury. These include but are not 
limited to a switch to anaerobic metabolism producing lactic acid, failure of ATP-
dependent ion transport pumps, induction of excess calcium entry into cells causing 
excitotoxicity, stimulation of caspase-dependent apoptosis and an inflammatory 
response (70). Many protein pathways are involved in this ischaemic response including 
the recently identified TAB1 -mediated p38α activation pathway (71). 
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1.4 Heart failure 
Chronic heart failure, also referred to as congestive heart failure, is a progressive 
condition that occurs when the heart at a normal filling pressure is unable to pump 
sufficient blood to meet the body’s requirements. The syndrome is multifaceted 
including abnormalities in heart muscle, valves and/or pericardium as well as systemic 
disturbances in neuro-humoral, cytokine and/or vascular function (72-75). The changes 
can include but are not limited to deterioration in the force of contraction and vascular 
tone and alterations in hypertrophy, apoptosis, fibrosis, autophagy and inflammatory 
cytokines as will be discussed further. 
1.5 Evidence for p38 activation in heart failure 
The mitogen-activated protein kinase p38 is a key Ser/Thr kinase that responds to a 
variety of the multifaceted abnormalities contributing to heart failure (see Figure 1.7). 
There have been extensive studies on the role of p38 in different disease states, 
primarily ischaemic heart disease in the cardiac setting. Though not as thoroughly 
explored as ischaemia, the role of p38 has been investigated in heart failure. Activation 
of p38 has been observed in animal models of heart failure and studies on myocardial 
biopsies from heart failure patients show increased p38 activity in comparison to 
“healthy” hearts (76-78). In cultured cardiomyocytes, p38 activation augments 
hypertrophy and pharmacologic inhibition attenuates hypertrophy occurring in response 
to stimuli such as endothelin-1 and phenylephrine (79). Whilst inhibiting p38 activity 
using SB203580 in adult rat cardiomyocytes, increases contractility (80).Variations in 
patient populations and genetic differences between animal models make it challenging 
to determine the precise role of p38 in heart failure. Collectively, it appears that p38 
plays an important role in the progression of heart failure. The structure and function of 
p38 has been recently reviewed in the cardioprotective context (81). The mechanisms 
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and consequences of p38 activity in heart failure with the aim of highlighting areas for 
further research required to clarify future potential therapeutic benefit is discussed in 
this thesis. 
 
Figure 1.7 The downstream effects of p38 in cardiomyocytes, fibroblasts and 
vasculature during heart failure.  
A) Emphasised in red are the effects of p38 which are associated with the progression of 
heart failure. p38 activity has been linked to increased interstitial fibrosis, reduced 
vasoreactivity and increased ROS production. The effects on the force of cardiomyocyte 
contraction are mediated by the effect of p38 on the Ca2+ transient and the sensitivity of 
the sarcomeres. B) Schematic showing balance between stresses on the heart that lead to 
healthy adaptation and the pathological increases in cytokines and neurohormones that 
lead to, or aggravate, heart failure. The question is whether these pathological signals 
can be reversed by inhibiting p38? 
1.6 Pathological features of heart failure that may lie downstream of 
p38 
1.6.1 The force of contraction 
An intricate protein signalling cascade exists to control the contraction of 
cardiomyocytes. The increase in cytosolic Ca2+ ions in the cell leads to actin interacting 
with myosin and the power stroke that shortens the sarcomere. Most heart failure is 
characterised by decreased contractility and reduced ejection fraction and the most 
common underlying process is pressure overload due to hypertension or cavity 
dilatation after myocardial infarction acting through the Law of LaPlace. Pressure 
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overload in turn leads to hypertrophy and loss of contractile function (82, 83). It appears 
that activation of the p38 pathway depresses contractility and enhances matrix 
remodelling (84). In studies involving the activation of this pathway through gene 
transfer of the activated upstream kinases of p38 (mitogen-activated protein kinase 
kinase 3/6 (MKK3/6)) or blocking the pathway through dominant negative p38 mutants 
and pharmacologic inhibition, it is evident that p38 activity leads to negative inotropic 
effects (80, 85). More than one mechanism has been proposed through which p38 
decreases contractility. Such mechanisms include prolongation of the decay phase of the 
cardiac calcium transient increasing diastolic Ca2+ concentration and relaxation. This is 
thought to be mediated through downregulation of sarcoplasmic/endoplasmic reticulum 
calcium ATPase (SERCA2), responsible for the translocation of Ca2+ from the cytosol 
to the sarcoplasmic reticulum (86, 87). In support of this, tumour necrosis factor α 
(TNFα)-induced contractile dysfunction in isolated hearts is attenuated in MKK3 knock 
out mice and by pharmacologic inhibition (77). Furthermore other studies suggest that 
there may be an additional contribution through p38 activity diminishing the Ca2+ 
sensitivity of the sarcomere (80, 85, 88).  
1.6.2 Vascular tone 
p38 is activated in the vessel wall in response to pressure overload, hypoxia and heart 
failure (89, 90) and also by neurohormonal stimuli such as angiotensin II or endothelin-
1; both associated with vasoconstriction and ventricular remodelling (91, 92). 
Vasoreactivity is improved, and survival is increased, by pharmacologic inhibition of 
p38 in several different models involving these stressors (90, 93, 94). In a rat model of 
heart failure, inhibition of p38 with SB239063 normalises vascular p38 activity and 
endothelial dysfunction is prevented (95). Current literature mainly focuses on the 
activation mechanisms of p38 during heart failure and less on the downstream 
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mechanisms which may lead to the pathological features of the syndrome. Though 
further investigation is required, it appears that SB239063 leads to a decrease in 
vascular superoxide anion formation, suggesting that p38 plays a role in generation of 
reactive oxygen species (ROS) during heart failure (95). Furthermore, one of the main 
subsets of p38 substrates are transcription factors, such as myocyte enhancer factor 2A 
(MEF2A) and myocyte enhancer factor 2C (MEF2C), that are implicated in the 
regulation of vascular tone (96-98), as well as ROS generation. In summary, the 
dysfunction mediated in part by p38 appears to be via ROS generation and possibly an 
effect on downstream transcription factors (93, 99, 100). 
1.6.3 Hypertrophy  
The data concerning the role of p38 in hypertrophy are difficult to reconcile; there is 
evidence both for and against its involvement (101-103). Perhaps due to differences in 
models and experimental detail, substantial variability of p38 activity in heart failure 
and/or hypertrophy has been observed.  
In an adenoviral-mediated overexpression system in cardiomyocytes expressing 
upstream activators for p38; MKK3 and MKK6, leads to a pro-hypertrophic response 
including increase in cell size and atrial natriuretic factor expression, suggesting a 
causative role (104). However, in an in vivo model with transgenic mice expressing the 
dominant-negative mutants of MKK3, MKK6 and p38α, cardiac hypertrophy following 
aortic banding is enhanced, potentially through the regulation of nuclear factor of 
activated T cells (NFAT) (105). In vivo studies, and data acquired from heart failure 
patients, suggest that p38 contributes to the progression of heart failure but that this is 
not through the aggravation of hypertrophy (76, 94, 102, 106). For example, p38 does 
not appear to be activated in hypertrophied hearts, but in failing hearts a two-fold 
increase in p38 phosphorylation is observed (101).  
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Overall, in isolated cardiomyocytes p38 activation appears to increase hypertrophy and 
its inhibition, using pharmacological compounds or genetic methods, attenuates the 
development of hypertrophy in response to hypertrophic stimuli (79, 104, 107). 
However, the picture is more complex in in vivo models and it is not clear that 
hypertrophy in the absence of heart failure causes p38 activation in patients. 
1.6.4 Apoptosis  
Cardiomyocyte death is an integral component of decompensated cardiac hypertrophy 
and the dysfunction leading to heart failure (108). Three systems of cell death exist, 
namely, necrosis, apoptosis and autophagy. Cardiac apoptosis is regulated by an 
elaborate array of stress-activated signalling pathways. p38 has been associated with 
both anti- and pro-apoptotic downstream effects depending on the upstream stimulus 
and cell type (109-112). However, in the cardiac setting, the role of p38 in regulating 
apoptosis is still under investigation. The apoptotic effects of anisomycin and 
overexpressing activated mitogen-activated protein kinase kinase kinase 1(MEKK1) are 
reversed by overexpressing constitutively active MKK6 (113) and a similar result is 
observed with the augmentation of norepinephrine-induced apoptosis by a p38 inhibitor 
in cardiac myocytes (114). It appears that the protective role of MKK6 overexpression 
is, in part, mediated through NFκB activation, interleukin 6 (IL-6) induction and αB-
crystallin phosphorylation (113, 115-117).  
 
Nonetheless, there are a few reports contradicting these findings, suggesting that p38 
activation is, in fact, pro-apoptotic in cardiomyocytes. In transgenic mice with cardiac-
specific expression of a dominant-negative mutant form of p38α after experimental 
diabetes; myocardial apoptosis, the number of caspase-3-positive cells, and the 
downregulation of antiapoptotic protein B-cell lymphoma-extra large (Bcl-XL) are all 
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attenuated, suggesting a pro-apoptotic role for p38 (118). In addition, it has been 
previously reported that apoptosis is reduced by p38 inhibitors; SB203580, SB239063 
or FR167653 in cardiac cells in response to several stimuli (63, 119-123). In isolated 
perfused hearts, p38 inhibitors are also cardioprotective (62, 64, 124). In bovine aorta 
endothelial cells, p38 involvement on β2AR-mediated caspase-3 cleavage is suggested 
via negative regulation by the p38 inhibitor SB203580 (125). In Raf-1-knockout mice 
which demonstrated left ventricular systolic dysfunction, heart dilatation and an 
increase in apoptosis was associated with an increase in p38 kinase activity (126). 
Furthermore, overexpression of p38α or activated MKK3b in cultured neonatal 
cardiomyocytes (104) and expression of transforming growth factor-β-activated kinase-
1 (TAK1) in the mouse heart by transgenesis, are associated with increased cardiac 
apoptosis (127).  
The opposing findings on the role of p38 in apoptosis could be attributed to variation 
among genetic models and nonspecific effects of pharmacologic compounds. 
Nonetheless, the literature in models utilising more specific methods which are less 
prone to off-target effects, such as overexpression of wild-type or dominant-negative 
mutants, indicates that its activation plays a pro-apoptotic role in the cardiac setting. 
1.6.5 Fibrosis  
As already discussed, in cultured cardiomyocytes p38 activity is associated with 
myocyte hypertrophy and apoptosis. It also appears that p38 activity in cardiomyocytes 
contributes to remodelling in the adult heart. In intact mouse hearts although p38 
overexpression/activation does not lead to hypertrophy, it increases remodelling of the 
extracellular matrix and diminishes contractile function (80, 128, 129). In a p38α knock 
out mouse model exposed to pressure overload, increased interstitial fibrosis is observed 
(102) whilst a mouse model expressing dominant-negative p38α displays resistance to 
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fibrosis in response to pressure overload (130). Furthermore, p38 activation using 
cre/loxP-based gene switch to create transgenic animals expressing the activated 
upstream kinases of p38, MKK3b and MKK6, leads to the induction of interstitial 
fibrosis, depresses contractility and compromises diastolic function (128).  
In a recent study, overexpression of myostatin, a member of the TGF-β superfamily that 
is up-regulated under disease conditions, is shown to cause interstitial fibrosis via 
activation of the TAK1-MKK3/6-p38 pathway suggesting that upstream effectors also 
play a role in p38 activation leading to fibrosis. In addition, mitogen activated protein 
kinase-activated protein kinase 2 (MK2) is an important substrate of p38 that is 
associated with heart failure; since cardiac fibrosis and dysfunction are diminished in 
MK2 knockout mice (131, 132) potentially through an involvement of SERCA2 
regulation. Treatment of hamster hearts with SB203580 reduces the area of fibrosis and 
heart /body weight ratio, increases LV ejection fraction and contractility (119). These 
findings provide evidence that p38 activation can contribute to fibrosis in the failing 
heart. 
1.6.6 Autophagy 
Autophagy serves as a double-edged sword with both anti and pro-apoptotic functions. 
In patients with heart failure, an increase in autophagy is observed and is associated 
with left ventricular systolic dysfunction (133, 134). There are studies suggesting that 
autophagy is a maladaptive process during the progression of heart failure and others 
which propose a protective role. In vivo studies blunting autophagy using 3-
methyladenine, an inhibitor of class III phosphoinositide-3-kinase (PI3K), show heart 
failure progression is accelerated with an increase in interstitial fibrosis, worsening 
ventricular function and early mortality (135). In addition, a decrease in autophagy has 
been implicated in cardiac hypertrophy whilst an increase in autophagy in transgenic 
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mouse models has been linked to cardio-protection (136). However, excessive 
autophagy has been associated with the progression of cardiac remodeling and heart 
failure in response to pressure overload (137). Molecular studies of biopsy samples of 
left ventricular myocardium from patients with idiopathic dilated cardiomyopathy 
before the implantation, and after the removal, of a left ventricular assist device suggest 
that mechanical unloading of the heart leads to a decrease in markers of autophagy 
(138). In this study, it is suggested that autophagy may serve an adaptive purpose during 
the progression of heart failure. 
Autophagy-related genes are upregulated in response to H2O2 treatment in myotubes, 
with a positive correlation to p38 activity. Inhibition of p38 using SB202190 decreases 
H2O2-induced expression of Atg7 (139). However in senescent human CD8
+ T cells, 
p38 inhibition using BIRB796 inhibits autophagy (140). In addition, in cultured 
neonatal rat cardiomyocytes exposed to 48 hours of mechanical stretch and in mice 
following transverse aortic constriction, p38 inhibition causes a decrease in the 
autophagy marker microtubule associated protein 1 light chain 3 β II (LC3b-II) (141). 
As the impact of autophagy in heart failure itself is controversial, it is difficult to assess 
whether the effect of p38 activation is protective or detrimental in heart failure. 
Nonetheless, it is apparent that p38 plays a role in the mechanism of autophagy. 
1.6.7 Inflammation and cytokine signalling 
Increasing evidence indicates that inflammatory cytokines, including TNF-α, interleukin 
1β (IL-1β) and IL-6, are elevated in, and may contribute to, heart failure. TNF-α levels 
increase in patients with advanced heart failure and correlate with prognosis (142-145). 
TNF-α is not expressed in the non-failing heart, but is significantly increased in the end 
stage failing human hearts (146). This has been associated with negative inotropic 
effects, with the IL-1β-mediated expression of SERCA and phospholamban prolonging 
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the Ca2+ transient (143, 147). In addition, TNF-α induction in failing hearts leads to a 
further loss of contractility and worsening of extracellular matrix remodelling (148, 
149). Interestingly, a similar array of pathological alterations is observed in response to 
p38 activation (128). Due to more than one inflammatory cytokine being associated 
with the progression of heart failure, studies involving manipulation of only one factor 
might not be the most effective way to investigate their summative effect on heart 
failure. Thus p38, by regulating varied inflammatory cytokines, becomes a more 
attractive therapeutic target and consequently has been explored in a number of studies 
(150, 151). In SB239063-treated spontaneously hypertensive stroke-prone rats, pro-
inflammatory gene expression is attenuated and survival is increased (152). In 
transgenic mice expressing active MKK6, TNF-α and IL-6 induction and extracellular 
remodelling is increased (153). Administration of SB239068 in the same transgenic 
model reduces plasma levels of these cytokines, interstitial fibrosis and cardiac 
remodelling. In a MKK3 knock out model, similar results to pharmacologic inhibition 
of p38 are observed with a reduction in TNF-α-induced contractile dysfunction (77). 
Furthermore, knocking out MK2 in mice prevents the TNF-α-induced negative inotropic 
response (77). Other than the direct induction of inflammatory cytokine production, p38 
is implicated in the amplification of ROS generation; a principal feature of vascular 
inflammation (154-157). These studies suggest that p38 inhibition in the stressed heart 
will be beneficial, at least in part through the suppression of inflammatory cytokines 
and consequent improvement in myocardial remodelling. 
1.7 Clinical trials 
With detrimental effects observed in in vivo and in vitro studies, clinical trials were 
performed using the agents, etanercept, a decoy approach to block TNF-α interaction 
with its receptor, and infliximab, a monoclonal antibody to neutralise TNF-α. 
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Unfortunately, results of either no benefit or harm were observed (158). A clinical trial 
for semapimod, an anti-inflammatory agent which inhibits p38 activity, was started for 
heart failure patients, but was apparently terminated upon the disclosure of the 
discouraging results of the TNF-α-targeted clinical trials (84). 
Currently, there is an ongoing phase 3 clinical trial running with losmapimod 
(LATITUDE-TIMI 60, NCT02145468), which could potentially benefit acute coronary 
syndrome (ACS) patients. Losmapimod is an anti-inflammatory medication which 
inhibits p38 and may improve vascular function and reduce subsequent cardiac events 
following ACS.  
Though further research is required on the mechanisms and consequences of p38 
activation in heart failure, the substantial evidence for an important role of p38 in the 
development of heart failure and its potential as a therapeutic target has been discussed. 
1.8 Amino acid response pathway and GCN2 
Mammals have adaptive mechanisms to detect and regulate amino acid homeostasis in 
response to deficiencies in the diet. As multicellular organisms cannot make all amino 
acids and due to a lack of an amino acid store within cells, certain signalling pathways 
must be activated in order to adapt to the stress induced by imbalanced diet and 
starvation. During starvation, there is an amino acid response (AAR) pathway which is 
activated as an adaptive response (159) conserved from yeast to mammals. The key 
protein responsible to sense amino acid deficiency is the Ser/Thr kinase general control 
nonderepressible 2 (GCN2).  
1.8.1 Aminoacyl tRNA synthetases  
The structure and function of proteins are dependent on the accuracy of their amino acid 
sequence determining primary structure and errors can have severe consequences. 
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Aminoacyl tRNA synthetases play a major role in translation to ensure the specificity 
required to prevent errors in protein synthesis. Aminoacyl tRNA synthetases are the 
enzymes responsible for catalysing the linkage of tRNAs and their respective amino 
acids in order to produce amino-acyl tRNAs which can then be incorporated into 
proteins by the ribosome. The selectivity in this process of both the amino acid and the 
cognate tRNA is essential to maintaining the fidelity of the genetic code. To initiate this 
process, a particular aminoacyl tRNA synthetase binds a specific amino acid and a 
molecule of ATP at the active site of the aminoacyl tRNA synthetase, forming a 
covalent bond between the AMP and the carboxyl terminal of the amino acid and 
releasing a pyrophosphate. There is a specific anticodon on the tRNA that corresponds 
to the particular amino acid facilitating the binding of the correct tRNA to the 
aminoacyl tRNA synthetase. Once the tRNA is bound, the bond between the AMP and 
the amino acid is broken, releasing the AMP. A covalent bond is formed between the 3’ 
end of the tRNA and the amino acid, and the tRNA is now referred to as being 
‘charged’. Following release from the aminoacyl tRNA synthetase, the charged tRNA is 
used to form proteins in the process of translation on a ribosome.  
1.8.1.1 Prolyl-tRNA synthetase 
There are two classes of aminoacyl-tRNA synthetases based on their sequence motifs 
and structure. Class I enzymes possess the Rossmann fold, whilst the class II enzymes 
contain a different fold around a six-stranded antiparallel beta-sheet (160). In addition, 
though both classes of enzymes catalyse the same reaction of charging tRNAs with their 
corresponding amino acid, they differ in the positioning of the amino acid on the tRNA, 




In higher eukaryotes, glutamyl- (class I) and prolyl- (class II) tRNA synthetases have 
been observed in a single peptide chain. The N-terminal of this glutamyl-prolyl tRNA-
synthetase (EPRS) comprises the glutamyl-tRNA synthetase and the C-terminal 
specifies the prolyl-tRNA synthetase. It has been proposed that the association of these 
two enzymes is due to a gene fusion event to form a bifunctional synthetase with the 
two subunits acting independently as the two enzymes do not share functional domains 
and their separate expression has previously been observed (161, 162).  
1.8.2 Role of eIF2 in protein translation 
Protein translation is the step following the transcription of genes, in order to create 
functional proteins, which can perform their role within the cell. In simple terms, 
transcription is the transfer of the information contained in the DNA to a messenger 
RNA (mRNA) molecule using DNA as a template for complementary base pairing with 
an enzyme called RNA polymerase II playing a major role. Consequently, this mRNA 
copy of the gene is used for protein translation. 
Eukaryotic translation of mRNA is an intricate process involving at least 12 proteins 
which cooperate to bring the mRNA, initiator Met-tRNA and the two ribosomal 
subunits together to form the 80S complex that can perform peptide chain elongation 
(163, 164). The assembly of the translation initiation machinery on the mRNA involves 
eukaryotic initiation factors (eIFs). eIF2 is a major component of the ternary complex 
required for the initiation of translation. eIF2 binds GTP and the initiator Met-tRNA 
forming a complex which consequently contributes to the 43S preinitiation complex 
(PIC) with the 40S ribosomal subunit. eIF4s facilitate the unwinding of the secondary 
structure in the 5’ untranslated region of the mRNA, which enables the binding of the 
PIC and subsequent scanning of the mRNA for the initiator AUG codon (165). Once the 
AUG codon binds to the complementary Met-tRNA, eIF5 induces the hydrolysis of the 
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GTP on eIF2, leading to the release of eIF2-GDP. The 60S ribosomal subunit is then 
recruited to form the 80S initiation complex and translation can begin. The guanine 
exchange factor eIF2B catalyses the exchange of GDP to GTP on eIF2 in a regulated 
manner, to initiate a new round of translation (166). 
1.8.3 Activation of General Control Nonderepressible (GCN2) 
Limitation of amino acids within the cell causes an increase in uncharged tRNA which 
bind to GCN2 and induce its autophosphorylation. Uncharged tRNA binds to a region 
homologous to histidyl-tRNA synthetase (HisRS) at the C-terminal of the kinase 
domain, which is essential for tRNA binding to GCN2 (167-169). It has been reported 
that GCN2 binds different uncharged tRNAs with similar affinities though as expected, 
it can distinguish between charged and uncharged forms of tRNA (170). The kinase 
domain of GCN2 is basally inert and requires interactions with four other domains to 
achieve activation (171). A rigid hinge between the N- and C- lobes of the kinase 
domain aids the occlusion of the ATP-binding site and promotes the closed state of the 
active site (172).  Binding of uncharged tRNA to the HisRS-like domain leads to a 
conformational change facilitating autophosphorylation of the kinase at the activation 
loop. This can in turn promote the required alignment of residues involved in substrate 
binding and phosphoryl transfer (173, 174). 
1.8.4 eIF2alpha phosphorylation and downstream of the AAR pathway 
eIF2 is a heterotrimer consisting of an alpha, a beta and a gamma subunit. Once 
activated GCN2, phosphorylates the alpha subunit of eIF2 (eIF2alpha), thereby halting 
global translation while paradoxically increasing the translation of selected mRNA 
species. As previously mentioned, to initiate translation GDP on eIF2 must be 
exchanged for GTP by eIF2B. The phosphorylation of eIF2alpha prevents this GDP-
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GTP exchange by stabilizing the eIF2-GDP-eIF2B complex, therefore halting global 
translation (175). 
This consequently induces the translation of a subset of proteins that enable the cell to 
cope with starvation. Amongst these proteins are activating transcription factor 4 
(ATF4), activating transcription factor 5 (ATF5) and growth arrest and DNA damage-
inducible 34 (GADD34). GADD34 is involved in recruiting protein phosphatase 1 
(PP1) to phosphorylated eIF2alpha, which is then dephosphorylated and general 
translation can resume along with the upregulated stress-responsive genes in response to 
starvation (176-178). Among the upregulated genes are;  
DDIT3 (gene name for C/EBP homologous protein (CHOP-1)) known for its role in 
apoptosis, inflammation and regulation of transcription (179-182);  
TRIB3 (gene name for tribbles pseudokinase 3) reported to regulate apoptosis, cell 
survival and stress-induced transcription (183, 184);  
and ASNS (gene name for asparagine synthetase) catalysing the synthesis of asparagine 
to aid the cell to survive through starvation-induced stress (185). 
1.8.4.1 Mechanism of induction of gene upregulation via amino acid response 
elements (AARE) 
In response to starvation, gene upregulation is facilitated by amino acid response 
elements (AARE) in the promoter sequences of the targets genes. AARE act as 
enhancer elements to increase transcription (185, 186) and are made up of 9 base pair 
core elements (5′-A/GTTG/TCATCA-3′). It is widely recognised that protein complexes 
bind to AARE elements in order to regulate transcription including a combination of 
ATF4, ATF2, ATF3 and/or CHOP. Importantly, all of the known AAREs have been 
reported to bind to ATF4, the key player in the regulation of AAR genes. Nonetheless, 
the combination of transcription factors and the effect of positive or negative regulation 
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of transcription are determined by the AARE sequence and chromatin structure. For 
example, both ATF4 and ATF2 are required to bind to the AARE of the DDIT3 
(CHOP) gene for its induction (186, 187). In addition, CHOP interaction with ATF4 
leads to the negative regulation of the ASNS gene through interaction with its promoter 
(188). 
1.8.4.2 DDIT3 (CHOP) 
The CCAAT-enhancer binding proteins (C/EBP) are a group of transcription factors 
that bind to CCAAT motifs in DNA and play an important role in cell differentiation 
(189-191). The prototype of a C/EBP protein contains a transcriptional 
activation/repression domain and a bZIP region with a basic DNA binding domain and a 
leucine zipper motif required for dimerisation. Proline and glycine substitutions exist in 
CHOP at the sites of conserved residues essential for C/EBP to interact with DNA (192, 
193). It has been proposed that the reason why CHOP lacking the DNA binding activity 
exists, is to form nonfunctional dimers and sequester the activity of bZIP proteins. 
Despite studies showing evidence for this negative regulation by CHOP (192), other 
studies have provided a platform where CHOP could induce the transcription of other 
genes, depending on its binding partner and the target gene (194, 195).  
1.8.4.3 TRIB3 
TRIB3 is a pseudokinase associated with roles in the stress response, apoptosis and 
metabolic processes induced by its interaction with several transcription factors, kinases 
and other proteins (195-197). Within the starvation response, it has been reported to 
perform negative feedback on the ATF4-mediated control of stress-regulated genes 
(198), as well as a role in cardiovascular disease (199). TRIB3 has been reported to bind 
to ATF4 at AARE sequences, potentially performing its negative feedback through this 
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interaction to inhibit the induction of other genes, two of which are CHOP and ASNS 
(183). 
1.8.4.4 ASNS 
As already mentioned ASNS is the enzyme required for the synthesis of asparagine and 
metabolically the increase in this gene in response to stress  is associated with cells 
lacking adequate ASNS activity reaching cell cycle arrest and apoptosis (200, 201). 
1.8.5 Other upstream kinases of eIF2alpha 
Phosphorylation of eIF2alpha has previously been found to be a common mechanism to 
downregulate global protein synthesis under certain stress conditions (159). In addition 
to GCN2, three other kinases upstream of eIF2alpha share sequence and structural 
similarities but differ in their regulatory domains. These kinases are the interferon-
induced double-stranded RNA (dsRNA)-dependent protein kinase R (PKR), 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) in the unfolded protein 
response and haem regulated inhibitor kinase (HRI) in response to haem deficiency. 
There is a high extent of similarity in the catalytic domains of these proteins and they all 
phosphorylate Ser51 of eIF2alpha (202). Nonetheless, the regulation of each upstream 
kinase of eIF2alpha and their downstream responses are different and circumstance-
specific. 
1.9 Halofuginone 
Plant bioactives have been used extensively as a source of new drugs and many current 
commonly prescribed drugs are derived from plants.  Febrifugine is a piperidine 
quinazolinone alkaloid isolated from the Chinese herb chang shan, Dichroa febrifuga 
(203) used in Chinese medicine for over 2,000 years to treat malaria-induced fever. 
Febrifugine has been important for its therapeutic activity despite lack of information on 
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its exact molecular target in part related to side effects impeding relevant studies.  
Halofuginone is a racemic halogenated derivative of this plant bioactive, designed to 
overcome the toxic effects of febrifugine whilst still providing the protective 
characteristics (204). Halofuginone has recently progressed to phase 2 clinical trials for 
its potential therapeutic applications in cancer and fibrotic disease (205-208). 
1.9.1.1 Mechanism of action 
Halofuginone plays a role in inhibiting TH17 cell differentiation by inducing the amino 
acid response pathway (209). The mechanism of action of halofuginone is through the 
inhibition of prolyl-transfer RNA synthetase (ProRS) leading to an accumulation of 
uncharged tRNAs within the cell (159, 204). It has been recently reported that 
unhydrolysed ATP is required for halofuginone-mediated inhibition of the ProRS. ATP 
is involved in directly binding to halofuginone via hydrogen bonds and orienting it onto 
the ProRS in a conformation that will allow halofuginone to mimic proline and 3’ end 
of tRNA simultaneously (210)  inhibiting ProRS in a bipartite manner (see Figure 1.8). 
 
Figure 1.8 Chemical structure of halofuginone and its similarities to proline and 3’ 
end of tRNA.  
Halofuginone is composed of a hydroxypiperidine ring joined by bridging atoms to a 
double-ring halogenated 4-quinazolinone. The piperidine ring mimics the pyrrolidine 
ring of proline, whereas the halogenated quinazolinone has a similar structure to the 
conserved adenine at the 3’ end of tRNA. These similarities of halofuginone to the two 
substrates of ProRS, enable its mechanism of blocking their binding to the ProRS, 
leading to an accumulation of uncharged tRNA. 
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1.9.1.2 Role in fibrotic diseases 
Collagen and other matrix proteins are important in the development and repair systems 
of organs. However, excessive accumulation of these proteins leads to fibrosis resulting 
in an overload of extracellular matrix (ECM) deposition with collagen type I being the 
key player. Excessive production of connective tissues regardless of the organ involved 
leads to the tissue damage, loss of structure and function, consequently resulting in 
organ failure (211). The mechanism of fibrosis typically involves the continual 
activation of the transcription of the ECM genes, increased deposition as well as 
inefficient degradation and removal of the ECM, a function of the matrix 
metalloproteinases (212). 
Several studies have reported an antifibrotic role for halofuginone through inhibition of 
TGF-β-mediated collagen synthesis in a variety of conditions (205, 206, 213, 214). The 
increase in collagen synthesis due to chronic graft versus host disease and scleroderma 
is abrogated with halofuginone treatment in mice (205, 215). In addition, halofuginone 
results in a reduction in pulmonary and liver fibrosis (213, 216), peritoneal adhesions 
(217) and colitis in rats (218). Overall, halofuginone plays an antifibrotic role in a wide 
range of organs in acute and chronic conditions. 
Duchenne muscular dystrophy (DMD) is a recessive X-linked disease caused by a 
mutation in the dystrophin gene (219) leading to a deficiency of this protein, which is an 
essential component of muscle tissue. In addition to skeletal muscle, dystrophin plays a 
fundamental role in stabilising the cardiac cytoskeleton. DMD has been associated with 
dilated cardiomyopathy and left ventricular dysfunction with an increased correlation in 
the later stages of the disease (220, 221). The mdx mouse is an extensively studied 
model of DMD, as it has a point mutation in its dystrophin gene resulting in the absence 
of the functional dystrophin in its striated muscles mimicking the phenotype observed in 
DMD patients. In a study on mdx mice, halofuginone decreased fibrosis, collagen I and 
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III gene expression and collagen protein levels, as well as improving cardiac and 
respiratory function (222).  
The activation of phosphoinositide 3'-kinase/Akt (PI3K/Akt), ERK and p38 are crucial 
for myotube fusion. In a C2 muscle cell line and in primary myoblasts from wild-type 
and mdx mice diaphragms, halofuginone lead to a reduction in Smad3 phosphorylation 
levels mediated by the activation of these kinases (223). Therefore, besides its 
antifibrotic activity halofuginone also has muscle regenerative effects. 
1.9.1.3 Clinical trials 
In addition to the evidence in animal models, antifibrotic effect of halofuginone in early 
clinical studies of topical administration (NCT00064142) and anti-angiogenic effects in 
progressive advanced solid tumours (NCT00027677) were reported in patients treated 
with halofuginone. Recently, a phase 2 clinical trial has been proposed to evaluate the 
safety, tolerability and pharmacokinetics of halofuginone in patients with DMD (HT-
100, NCT01847573). 
1.9.1.4 Halofuginone and p38 
There are only a few studies implicating a role for halofuginone in regulating p38 
activity. Halofuginone appears to have anti-inflammatory properties in rats with 
experimental colitis, involving suppression of neutrophil accumulation and inhibition of 
reactive oxidant generation (218). With this observation and given the role p38 plays in 
inflammation (224), it is logical to expect halofuginone to inhibit p38. Indeed, 
halofuginone treatment inhibits activated peripheral blood T cell functions as well as 
proinflammatory cytokine production by inhibiting NF-kappaB activation and p38 
MAPK phosphorylation (225). 
Nonetheless, this halofuginone-mediated inhibition of p38 is not the case in all cells of 
the body and it appears that halofuginone has a cell-type specific effect. The anti-
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fibrotic effects of halofuginone have been associated with its regulation of matrix 
metalloproteinases (MMPs); enzymes capable of degrading extracellular matrix 
proteins. In rat hepatic stellate cells, halofuginone up-regulates MMP-3 and MMP-13 
expression between 10- and 50-fold, and accordingly increases interstitial collagenase 
activity mediated by p38. This increase in mRNA expression of MMP-3 and MMP-13 
was also present at 1.5- and 2-fold, respectively in the in vivo setting in rats with 
established liver fibrosis. A causal role for p38 in this setting was established using the 
p38 inhibitor, SB203580 (226). 
Perhaps more related to this thesis is the observation that halofuginone enhances p38 
phosphorylation and inhibited Smad3 phosphorylation in myotubes (223). This would 
explain the improvements observed in cardiac and skeletal muscle in the DMD setting. 
Nonetheless, the effects of halofuginone have not yet been investigated in the context of 
cardiomyocytes. Given the importance of p38 in a wide range of processes and 
established role in heart failure, besides the observed improvements in cardiac function 
in mdx models of mice by halofuginone, I decided to investigate the effects of 
halofuginone treatment on p38 activity in cardiomyocytes. 
1.10 Endothelin-1 
Endothelin (ET) is a 21 amino acid peptide secreted by vascular endothelial cells (227). 
It is produced from a 39 amino acid precursor, big ET, by proteolytic processing 
activity of an enzyme called endothelin converting enzyme (ECE) found on the 
endothelial cell membrane. Once released, ET binds receptors on target cells in order to 
trigger downstream events. Three isoforms of the ET family exist; ET-1, ET-2 and ET-3 
and different responses can be evoked depending on the receptors they bind (228). 
There are two types of ET receptors found in mammals; ETA and ETB, of which both are 
G-protein coupled seven transmembrane receptors. ETA receptors are localised on 
Pelin Arabacilar 
60 
smooth muscle cells and ETB receptors are found on endothelial cells, smooth muscle 
cells and macrophages (229, 230). ETA receptors bind to ET-1 and ET-2 with a 100 
times higher affinity than ET-3, while ETB receptors have similar affinity for all three 
ET isoforms (231). Both receptors are coupled to a phospholipase C (PLC)-coupled Gq-
protein involved in the formation of inositol 1,4,5-trisphosphate (IP3) from 
phosphatidylinositol biphosphate (PIP2) through the activity of phospholipase C (PLC). 
Increased levels of IP3 within the cell induce calcium
 release from the sarcoplasmic 
reticulum and causes smooth muscle contraction. Under normal conditions, ETA plays a 
dominant role in determining the tone of blood vessels. However, ETB receptors are also 
present on the endothelium and upon binding of ET-1 to these receptors, intracellular 
calcium levels increase, resulting in the activation of the enzyme, nitric oxide synthase 
producing nitric oxide (NO). NO then diffuses to the vascular smooth muscle cells 
leading to the activation of soluble guanylate cyclase to form cyclic GMP (cGMP) 
which initiates vasodilatation. 
The initial vasodilatation followed by prolonged vasoconstriction in response to 
systemic administration of ET-1 can be explained by the distribution of the endothelial 
and smooth muscle cell receptors (232, 233). Baroreceptor reflexes regulate the 
response of the heart by altering arterial pressure upon treatment with ET-1. Other 
effects of ET-1 include aldosterone secretion, renal blood flow regulation and release of 
atrial natriuretic peptide (ANP) (234-236). 
Regulation of signalling pathways is important in maintaining control of processes 
within a cell and stimulating downstream changes in a stimulus dependent manner. 
Negative feedback systems must exist to enable the cessation of action when it is no 
longer necessary or needs to be diminished to basal levels. Receptor internalisation is 
one of the essential processes required to control the effects of ligands. Receptor-bound 
ligands are internalised by endocytosis and the ligand is recycled or degraded by the 
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lysosome. It has previously been reported that ET does not dissociate easily from its 
receptors (237) and induces long-lasting vasoconstriction. Receptor internalisation is 
one system that has been proposed as a negative feedback on the ET-mediated changes 
as it appears that ET-1 triggers ETA internalisation in a time-dependent manner (238) 
possibly via β-arrestin binding(239). In addition to this distal regulatory process; 
receptor down-regulation (240), and desensitisation through phosphorylation of the 
ETA receptor by G-protein coupled receptor kinase 2 (GRK2) are other negative 
feedback mechanisms proposed. 
In previous studies, ET-1 has been implicated in the development of cardiovascular 
diseases including hypertension, vascular remodelling, myocardial infarction and heart 
failure (241-244). Increased ET-1 production has been reported in heart failure patients 
(241) and animal models (245, 246) and circulating ET-1 correlates with symptoms 
(247, 248). 
1.11 Summary of introduction 
p38α is involved in innumerable cellular processes and is exquisitely controlled through 
at least 3 different mechanisms of activation. During myocardial ischaemia the 
mechanism of activation is unusual, differing from the usual MKK-dependent canonical 
pathway, and is instead reliant on an association with TAB1. The purpose of this thesis 
was to examine this association with the ultimate aim of understanding and preventing 
it. If this could be achieved it is possible it would be of benefit to patients with 
ischaemic myocardium where the association between TAB1 and p38α has been shown 
to aggravate injury. 
Another signalling pathway involving p38α, with a potential role in heart failure, is the 
AAR pathway. Halofuginone, a compound which activates the AAR pathway, has been 
implicated in improved cardiac function in mdx models of mice. Exploring this system 
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by using halofuginone as a tool compound could provide further insight as to whether 
the activation of this pathway can influence hypertrophy, autophagy and inflammation, 
processes relevant to heart failure. The main purpose of the research presented within 
this thesis is to understand and manipulate the activation of p38α in myocardial 
ischaemia and heart failure. 
1.12 Aims 
The specific aims of the thesis are; 
1. To confirm whether TAB1 overexpression causes a pattern of p38α 
phosphorylation consistent with autophosphorylation 
2. To understand the residues and regions of TAB1 responsible for p38α activation 
and whether these affect p38α phosphorylation and TAB1 substrate presentation  
3. To determine whether TAB1 phosphorylation state affects the canonical 
activation pathway 
4. To examine whether there is competition between TAB1 and MKK3b in binding 
to p38α 
5. To investigate the role of Thr185 in p38α in-cell localisation 
6. To investigate the activation of the AAR pathway with halofuginone in 
cardiomyocytes 
7. To observe the effects of AAR pathway activation on autophagy and 
inflammation 
8. To observe the effect of halofuginone on p38α activity and the relation of this to 




2 MATERIALS and METHODS 
2.1 Recombinant protein expression 
2.1.1 The principle 
Recombinant DNA methods describe the processes of combining DNA from two or 
more sources in order to create a unique protein. In our case, a recombinant plasmid was 
constructed using a pET vector in order to express the mammalian gene of interest in 
Escherichia coli (E.coli) cells. The pET vector contains the antibiotic resistance gene, 
lac repressor gene (lac I) and the T7 promoter. The gene of interest is inserted just after 
the ribosome binding site, which is downstream of the T7 promoter and lac operator 
DNA sequences. As the target gene is controlled by the T7 promoter, T7 polymerase 
must be present for its transcription. In order to manipulate this system for the induction 
of the gene of interest, the T7 polymerase gene has been inserted downstream of the lac 
promoter in the E.coli genome.  
In the absence of lactose (a combined galactose-glucose disaccharide), the lac repressor 
binds to the lac operator and prevents the T7 polymerase gene being expressed. 
However, when lactose is present, it binds to the lac repressor and changes its 
conformation rendering it unable to bind to the lac operator. The galactose analog 
isopropyl β-D-1-thiogalactopyranoside (IPTG) also induces this conformational change 
in the lac repressor and cannot be metabolised by E.coli, making it possible to keep 
IPTG concentrations constant. IPTG enables the transcription of the T7 polymerase, 
which in turn induces the transcription of the gene of interest. Therefore, the 
transcription of the gene of interest is indirectly inducible by IPTG. 
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The induction of this system by IPTG is performed at the mid-log phase of growth when 
the OD600nm is between 0.3 and 0.8, in order to maximize the yield of the transcribed 
protein. 
2.1.2 The protocol 
E.coli Rosetta (DE3) strain (Bioline) was used to express the recombinant protein 
encoded by the pETDuet-1 vectors. 50 μl of E.coli was transformed with the vectors as 
in section 2.5.2 and 100 μl of the final culture was spread onto lysogeny broth (LB) 
plates (containing 1% (w/v)  NaCl, 1% (w/v) Tryptone, 0.5% (w/v) yeast extract and 
1.5% (w/v) agar) with Ampicillin (100 μg/ml) (Sigma) and incubated at 37oC overnight. 
5 ml of previously autoclaved LB broth (containing 1%(w/v)  NaCl, 1% (w/v) Tryptone, 
0.5% (w/v)  yeast extract with Ampicillin (100 μg/ml) was inoculated with a single 
colony from each plate and incubated at 37oC under gentle agitation and optical density 
at 600 nm (OD600) was measured at 20 minute intervals until it reached 0.3-0.4. Then, 
1 ml of the culture was aliquoted to induce the protein expression by 1 mM IPTG 
(Sigma) for 5 hours and another 1 ml aliquot was kept without IPTG induction as a 
negative control, and the rest of the culture was kept as a stock. Pellets were obtained by 
centrifuging at 16,400 rpm for 1 minute at 4oC. The supernatant was removed and the 
pellet was resuspended in 1 ml cold lysis buffer (containing 1 mM EDTA, 1 mM 
EGTA, 20 mM HEPES, 150 mM NaCl, 50 mM NaF, 1 Mm Na3VO4 and 1 tablet (per 
50 ml of lysis buffer) of protease inhibitor cocktail (Roche Diagnostics)). Equal 
amounts of the lysate and 2X sample buffer (containing 20% glycerol, 6% SDS in 0.12 
M Tris, pH 6.8 with 10% 2-mercaptoethanol (BME) (Aldrich)) were boiled for 10 
minutes and then loaded onto a polyacrylamide gel for western blotting. 
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2.2 In vitro kinase assay 
2.2.1 The principle 
The role of protein kinases is to phosphorylate their substrate by transferring the γ-
phosphate group of an ATP molecule to an acceptor site on their substrate (249). An 
vitro kinase (IVK) assay is a commonly used method to measure the activity of a 
protein kinase by observing the phosphorylation level of the substrate. The method is 
based on combining the kinase, substrate, and ATP in the presence of MgCl2 in a tube 
and incubating it at an optimal temperature for the kinase to undertake its function and 
phosphorylate its substrate. The samples can then be analysed by Western blotting using 
phospho-specific antibodies to detect changes in the level of phosphorylation of the 
substrate under different conditions. 
2.2.2 The protocols 
2.2.2.1 Different TAB1 peptides to mediate p38 phosphorylation  
Three TAB1 peptides were ordered from Activotec and diluted in peptide dilution buffer 
(20 mM Tris-HCl pH 7.5). These peptides were: 
 46mer peptide including both p38 binding regions (common docking domain 
and unique hydrophobic domain): 
[NH2-EMSQPTPTPAPGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMV-
COOH] 
 13mer peptide binding to the common docking domain of p38α: [NH2-
KTSVTLSLVMPSQ-COOH] 




8.5 µl 10X kinase buffer (KB) (containing 250 mM Tris-HCl (pH 7.5), 50 mM beta-
glycerophosphate, 1 mM Na3VO4, 100 mM MgCl2 and 20 mM dithiothreitol (DTT)), 
600 µM ATP, 3 µM p38α (non-active, unless a control), 15 µM substrate (TAB1 
peptides – only one in their respective samples) and peptide dilution buffer up to 85 µl 
were mixed in a tube and the kinase reaction was performed at 37oC for differing 
lengths of time for comparison of phosphorylation. 15 µl aliquots were taken at each 
time point. 3.75 µl of 5X sample buffer were added and samples were boiled at 100oC 
for 10 minutes and stored at -20oC until analysis by Western blotting.  
2.2.2.2 Competition between TAB1 peptide and MKK3b to mediate p38 
phosphorylation 
In IVK experiments examining the competition between TAB1 and MKK3b, p38 was 
incubated with TAB1 before the addition of MKK3b. In addition, due to the different 
efficiencies of phosphorylation of p38 mediated by MKK3b and TAB1, a lower 
concentration of MKK3b protein than TAB1 peptide was used. This was to allow TAB1 
a chance to compete with MKK3b and minimise phosphorylation bias based on 
efficiencies, as we were purely interested in the binding site competition between 
MKK3b and TAB1. 8.5 µl 10X KB, 600 µM ATP, 3 µM p38α (non-active) were mixed 
in a tube and for treatments involving p38 inhibition, samples were pretreated with 10 
uM SB203580 for 10 minutes at 37oC, before the addition of the 29mer TAB1 peptide, 
[NH2-RVYPVSVPYSSAQSTSKTSVTLSLVMPSQ-COOH]. Upon TAB1 addition, the 
samples were incubated at 37oC for 4 hours. Then, 0.00847 μM (determined by titration 
of MKK3b concentration to a low enough concentration where p38 begins to be 
phosphorylated) of constitutively active form of MKK3b (MKK3bEE S218E/T222E), 
recombinant protein previously made by Dr Denise Martin, and activation buffer 
(containing 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% BME, 10 mM MgAc and 
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0.1 mM ATP) was added to the samples. After a further 30 minute (unless otherwise 
stated) incubation at 37oC, 2X sample buffer was added to samples and boiled at 100oC 
for 10 minutes and then loaded onto a polyacrylamide gel for Western blotting. 
2.3 Subcloning inserts from a bacterial vector (pETDuet-1) to a 
mammalian vector (pcDNA3) 
In scientific research, simple models are utilised to gain a better understanding of 
certain mechanisms. In vitro assays, bacterial protein expression systems, tissue culture 
and working with animals are a few of the methods used for this purpose. However, 
depending on the different methods employed, specific tools must be used. IVK assays 
require purified proteins whereas bacterial transformation and cell transfection systems 
will only express the protein of interest if the specific promoter is present in the plasmid 
before the gene of interest. Therefore, in our case the plasmids containing the mutant 
versions of TAB1 used to transform bacteria cannot be used to transfect mammalian 
cells, as they lack the mammalian promoter and the bacterial promoter cannot induce 
expression in the mammalian system. To confirm the effect of the TAB1 mutations 
observed in section 3.4, the effect of the mutations in TAB1 must be investigated in a 
mammalian cell line; e.g. Human Embryonic Kidney (HEK) 293 cells. Nonetheless, as 
already mentioned the bacterial plasmid does not have the features to be expressed in 
the mammalian cell line, and the TAB1 mutant genes must be cloned into a mammalian 




Figure 2.1 Schematic showing subcloning of an insert from a bacterial vector into a 
mammalian vector 
 
The bacterial vector pETDuet-1 (see Figure 2.2), has two multiple cloning sites (MCS) 
making it possible to have two inserts in the same vector, in our case these genes are 
p38α and wild-type (WT) or mutants of TAB1. Being given pETDuet-1 containing 
p38α and the WT or mutated versions of TAB1 by Dr Gian Felice de Nicola, it was 
known that p38α was inserted between the BamHI and PstI restriction enzyme sites and 
the TAB1 genes were inserted between NdeI and XhoI sites.  
2.3.1 Introducing new restriction enzyme sites by Polymerase Chain Reaction 
2.3.1.1 The principle of PCR 
Polymerase chain reaction (PCR) was developed in the 1980s by Kary Mullis and is a 
widely used technology in biological research (250). PCR exploits the enzyme, DNA 
polymerase, in order to synthesise DNA fragments by replicating genetic material. A 
primer, an oligonucleotide specific to the target gene, is used to target the polymerase to 
the site chosen on one of the original DNA strands to start the synthesis. Primers enable 
the replication of only the chosen sequences and the result is vast number of copies of 
the target DNA sequence (251). A thermal cycler is used for PCR reactions and there 
are four main steps in the process. The initialization step is usually required to activate 
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DNA polymerases and consists of increasing the temperature to around 94oC. After 
holding, the cycles are started with the denaturation step to separate the DNA template 
into single-stranded DNA molecules by disrupting the hydrogen bonds for 20-30 
seconds. The following annealing step consists of lowering the temperature to allow the 
annealing of the primers to the single-stranded DNA template. Hydrogen bonds 
between the primer and template DNA are formed when the primer sequence closely 
matches the template. Then, the DNA polymerase binds to this hybrid and begins 
copying the template DNA. The next step is for the elongation of the sequence by the 
DNA polymerase and is performed at the optimal temperature for the specific 
polymerase being used. The enzyme works by adding deoxynucleotide triphosphates 
(dNTPs) that are complementary to the template in a 5’ 3’ fashion, joining the 5’ 
phosphate group of the free dNTPs with the 3’ hydroxyl group of the nucleotide on the 
existing DNA strand. Under optimum conditions, after each extension step DNA is 
doubled leading to an exponential amplification of the template DNA. A final 
elongation step is often performed to ensure that any remaining single-stranded DNA is 
fully extended.  
2.3.1.2 The protocol 
Observing the destination mammalian vector map (see Figure 2.3), it is clear that NdeI 
enzyme cleaves at middle of the cytomegalovirus (CMV) promoter. Removing a section 
of this promoter would prevent the cells transfected with this vector expressing the gene 
of interest as the function of a promoter is driving gene expression. Therefore, the insert 
needs to be inserted elsewhere in the pcDNA3 MCS and the NdeI restriction enzyme 
must be substituted by the new chosen restriction enzyme site.  BamHI was chosen for 
this purpose. The second restriction enzyme was kept as XhoI, which is at the carboxyl 
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terminal of the TAB1 insert in the pETDuet-1 vector. Two different restriction enzyme 
sites were used to prevent religation of the vector onto itself. 
 
 
Figure 2.2 Map of the bacterial expression vector pETDuet-1. Novagen 
 
 




The TAB1 inserts were amplified by PCR using the pETDuet-1 plasmids as template. 
10 μl of 5X RANGER reaction buffer (Bioline), 20 μM of forward primer, 20 μM of 
reverse primer, 5 ng DNA, 1 μl of Ranger DNA polymerase (Bioline) were combined in 
a PCR tube and made upto a final volume of 50 μl with ddH2O. The PCR cycling 
conditions are shown in Table 2.1. 
Table 2.1 PCR cycling conditions 
Step Temperature Time Cycles 
Initial denaturation 95oC 1 min 1 
Denaturation 98oC 10 sec  
 
30 
Annealing 77oC 30 sec 
Extension 68oC 7 min 
Final Extension 68oC 10 min 1 
 
 The templates and primers were provided by Dr Gian Felice de Nicola and have the 
following sequences: 
Forward primer introducing the BamHI site highlighted in pink and the ‘^’ symbol 
indicates point of cleavage: 
ATATATG^GATCCGCCATGGCAGCACAACGTCGTTCTCTGC 
Reverse primer with the XhoI site highlighted in blue and the ‘^’ symbol indicates point 
of cleavage: 
TATATC^TCGAGTTATTACGGGGCGGTCATCACAG 
Following PCR, the products were run on a 0.7% agarose gel (AGTC Bioproducts Ltd) 
(see Figure 2.4) to ensure they were the correct size, excised and purified using High 




Figure 2.4 PCR products.  
20 µl of PCR products were ran on a 0.7% agarose gel. Lane 1: 1 kb ladder (Promega), 
lane 2: positive control – PCR product from a previous positive clone, lane 3: empty, 
lane 4: WT TAB1 PCR product, lane 5: CM mutant TAB1 PCR product, lane 6: NCM 
mutant TAB1 PCR product, lane 7: CM/NCM mutant TAB1 PCR product, lane 8: 1 kb 
ladder. 
2.3.2 Gel extraction of DNA 
Once the band of interest was excised, High Pure PCR Product Purification Kit (Roche) 
was employed to purify the DNA. The excised gel was placed in a 1.5 ml tube and gel 
mass was determined by first pre-weighing the tube and the reweighing the tube with 
the gel slice. 300 μl Binding Buffer for every 100 mg agarose gel slice was added to the 
tube. The agarose gel slice was dissolved to release the DNA by vortexing the tube 15-
30 seconds first then once every 2-3 minutes during the incubation of the tube at 56oC 
for 10 minutes. Once the agarose gel slice was completely dissolved, 150 μl isopropanol 
for every 100 mg agarose gel slice was added to the tube and vortexed thoroughly. The 
entire contents of the tube were pipetted into a High Pure Filter tube placed in a 
collection tube. The tubes were centrifuged at maximum speed for 30-60 seconds at 
room temperature (RT) and the flowthrough solution was discarded. 500 μl of wash 
buffer was added to the tube and centrifuged for 1 minute at maximum speed, as above. 
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The flowthrough solution was discarded and this step was repeated once again with 200 
μl of wash buffer. The filter tube was combined with a clean 1.5 ml tube. 50-100 μl of 
elution buffer was added and the tube was centrifuged at maximum speed for 1 minute 
at RT and the resulting DNA was either stored at -20oC or used as required. 
2.3.3 Restriction enzyme digestion 
Following purification, 1 µg of each PCR product and the pcDNA3 vector was double 
digested independently using 1 µl of each of the restriction enzymes BamHI (New 
England Biolabs) and XhoI (New England Biolabs) with 4 µl of 10X Buffer 4 (New 
England Biolabs) and 4 µl of bovine serum albumin (BSA) (New England Biolabs) 
made upto 40 µl with ddH2O and incubated at 37
oC for 3 hours. The restriction enzymes 
were then heat inactivated for 20 minutes at 80oC.  
2.3.4 Ligation 
Digested vector and each of the inserts (PCR products) were combined at a 1:3 ratio 
respectively, to a total of 100 ng DNA in a 1.5 ml tube with 5 µl 5X Quick-Stick ligase 
buffer (Bioline), 1 µl Quick-Stick ligase (Bioline) and ddH2O upto 20 µl. The mixtures 
were incubated at RT for 5 minutes and the whole mixture was used to transform E.coli 
cells as described in section 2.5.2. Several clones for each insert were picked to 
inoculate LB with 100 µg/ml Ampicillin in the 37oC shaking incubator overnight. DNA 
was extracted from this bacterial culture using the Plasmid DNA Purification kit 
(Macherey-Nagel) and digested by restriction enzymes as described in section 2.3.3 and 
ran on a 0.7% agarose gel to reveal which clones had successfully incorporated the 
insert (see Figure 2.5). As can be seen, some clones only have a higher band which 
indicates the vector alone, and these are false positives. Whereas, other clones have the 




Figure 2.5 Ligation products double digested to check presence of insert. 
Lane 1: 1 kb ladder (Promega), lane 2: positive control – PCR product from a previous 
positive clone, lane 3-5: WT TAB1 clones, lane 6-8: CM mutant TAB1 clones, lane 9-
11: NCM mutant TAB1 clones, lane 12-14: CM/NCM mutant TAB1 clones. Lanes 3-5, 
8-13 contain the positive clones whereas lanes 6, 7 and 14 contain false positives. 
 
These positive clones were sent for DNA sequencing to ensure they have the correct 
TAB1 insert and the only changes in amino acid sequence are the ones designed. 
Once sequencing was correct, the DNA was used for transfection of HEK293 cells. 
2.4 DNA sequencing 
DNA sequencing was performed using the ‘value read’ service of Eurofins MWG 
Biotech (Germany). Tubes containing 50-100 ng/μl of DNA in a total volume of 15 μl 
were prepared per sequencing reaction and sent off. The sequencing results were 
analysed by a comparison to their WT counterpart. DNA was sequenced using the 
primers T7 and Sp6 from the Eurofins MWG Biotech for forward and reverse 
orientations respectively.  
2.4.1 TAB1 sequences 
Below is the sequence of mouse WT TAB1 and highlighted in yellow is the region 
previously identified to interact with p38 (34). Highlighted in pink is the region which 
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binds to the unique hydrophobic groove in p38 and in turquoise is the region which 
interacts with the common docking domain of p38. 
 1  MAAQRRSLLQSEQQPSWTDDLPLCHLSGVGSASNRSYSADGKGTESHPPEDNWLKFRSEN 









The p38 interacting region and the mutations in TAB1 are presented below and the 
mutations to generate the canonical mutant (CM), noncanonical mutant (NCM) and the 
mutant with both set of mutations (CM/NCM) are underlined. These mutants were used 
to perform transformations and transfections which will be discussed in detail in section 
3. 
WT:     EMSQPTPTPAPGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMV 
NCM:    EMSQPTPTPAPGGRVYPVSAPASSAQSTSKTSVTLSLVMPSQGQMV 
CM:     EMSQPTPTPAPGGRVYPVSVPYSSAQSTSKTSVTLSLGAPSQGQMV 
CM/NCM: EMSQPTPTPAPGGRVYPVSAPASSAQSTSKTSVTLSLGAPSQGQMV 
2.5 DNA amplification and purification using bacteria 
2.5.1 The principle 
Through attachment to the bacterial membrane, divalent cations facilitate the uptake of 
plasmid DNA into a competent strain of E.coli that can absorb foreign DNA (252). 
Instant heating of E.coli permeabilises the membrane, enabling the entry of the DNA 
into the cell. Then, bacteria are grown in LB media containing the antibiotic against 
which the plasmid provides resistance so selectively amplifying those which have 
acquired the gene of interest. Once exponential growth of bacteria has occurred, 
meanwhile amplifying the DNA, a modified alkaline lysis procedure followed by 
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binding of DNA to a resin under appropriate low-salt and pH conditions is employed in 
order to purify the DNA. RNA, proteins, dyes, impurities and chromosomal DNA are 
removed by series of washes and plasmid DNA is eluted at the end in high-salt buffer 
and concentrated and desalted by isopropanol precipitation. 
2.5.2 Transformation 
E.coli DH5α strain (Invitrogen) was used to amplify DNA. 100 ng of DNA was added 
to 50μl of E.coli and left on ice for 30 minutes. Heat shock was performed at 42oC for 
45 seconds and tubes were returned to ice for another 2 minutes. 1ml LB without 
antibiotics was added to cells and left at 37oC for 45 minutes on a shaker. 100μl of the 
mixture was spread on agar plates containing 100 μg/ml Ampicillin and kept at 37oC 
overnight.  
2.5.3 DNA amplification and purification by a Maxi Prep 
A single colony was picked from the agar plate and 5 ml of LB (with Ampicillin) was 
inoculated using aseptic technique and incubated overnight at 37oC in an orbital 
incubator, at 220 rpm. The plasmid DNA was then amplified in a large scale 
preparation. 4 ml of the previous culture was added to 200 ml LB (with Ampicillin) and 
incubated overnight at 37oC in an orbital incubator, shaking at 220 rpm. The next day, 
plasmid DNA was purified using the HiSpeed Plasmid Purification Maxi Kit (Qiagen). 
Bacterial cells were harvested by centrifugation at 600 x g for 15 minutes at 4oC. The 
bacterial pellet was resuspended in 10 ml resuspension buffer P1. 10 ml lysis buffer P2 
was added and the mixture was inverted 4-6 times and incubated at RT for 5 minutes. 
During this incubation the QIAfilter cartridge was prepared by screwing the cap onto 
the outlet nozzle. 10 ml of chilled neutralisation buffer P3 was added and the mixture 
was mixed thoroughly by inverting 4-6 times and the contents were immediately placed 
into the QIAfilter cartridge. The mixture was incubated at RT for 10 minutes, during 
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which time the HiSpeed maxitip was equilibrated with 10 ml equilibration buffer QBT. 
The supernatant of the mixture was applied to the Maxitip and allowed to enter the resin 
by gravity flow. The Maxitip was washed in 30 ml wash buffer QC, and this was 
repeated. The DNA was then eluted with 15 ml elution buffer QF and precipitated with 
10.5 ml isopropanol by incubating at RT for 5 minutes. During this incubation, 
QIAprecipitator Maxi module was attached to a 30 ml syringe. The eluate/isopropanol 
mixture was filtered through the module using constant pressure. 2 ml 70% ethanol was 
added to the syringe and the DNA was washed by pressing the ethanol through the 
module using constant pressure. The membrane was air-dried by pressing air through it 
quickly and forcefully. This step was repeated. The module was attached to a 5 ml 
syringe and 1 ml elution buffer TE was added to elute the DNA into a clean 1.5 ml tube. 
The yield of DNA was determined using a spectrophotometer with TE buffer as blank. 
2.5.4 DNA purification by a Mini Prep 
In experiments where only a small yield of DNA was sufficient such as for sequencing 
or cloning, a mini prep instead of the above maxi prep method was used. NucleoSpin 
Plamid kit (Macherey-Nagel) was used for this procedure. 1 ml of bacterial culture was 
centrifuged at 11000 x g for 30 seconds to pellet cells. The supernatant was removed 
and the pellet was resuspended in 250 μl of buffer A1 in order to lyse the cells. Then, 
250 μl of buffer A2 was added to the tube and inverted several times to ensure thorough 
mixing. Samples were incubated at RT for 5 minutes and 300 μl of buffer A3 was 
added, mixing thoroughly by inversion. Cell lysates were clarified by centrifugation at 
11000 x g for 5 minutes, and supernatants transferred to NucleoSpin® Plasmid 
Columns. Columns were centrifuged at 11000 x g for 1 minute and flow through was 
discarded. Samples were washed with 600 μl of buffer A4 and centrifuged at 11000 x g 
for 1 minute. The flowthrough was discarded and the membrane was dried by 
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centrifugation at 11000 x g for 2 minutes. 50 μl of buffer AE was added to each tube 
and after an incubation of 1 minute DNA was eluted into a clean tube by centrifugation 
at 11000 x g for 1 minute.  
2.6 Tissue culture 
2.6.1 Human embryonic kidney cells 
2.6.1.1 Origins of cell line 
Human embryonic kidney 293 (HEK293) cells were generated and established in 1977 
by transformation of cultures of normal human embryonic kidney cells with sheared 
DNA of adenovirus 5 (253). The transformation led to the incorporation of 
approximately 4.5 kilobases from the viral genome into the human chromosome 19 of 
the HEK293 cells (254). For many years, it was assumed that HEK293 cells had 
epithelial, endothelial or fibroblastic origin as these cells are abundant in the kidney. 
Nonetheless, the group which originally transformed the cells provided evidence that 
these cells might have originated from neurons as the cells share many properties with 
immature neurons, suggesting that the adenovirus has transformed a neuronal cell in the 
original kidney culture (255). 
HEK293 cells are popular in biological research for their ease of growth and 
maintenance, as well as their biochemical machinery that can perform most of the post-
translational modifications and correct folding of both mammalian and non-mammalian 
proteins (256). As well as studying intracellular signaling, HEK293 cells are commonly 
used to produce exogenous proteins or viruses for biomedical research purposes. 
2.6.1.2 Culture conditions 
HEK293 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (PAA) 
containing L-glutamine (584 mg/l) with 10% (v/v) foetal bovine serum (FBS) (PAA) 
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and antibiotics (1% v/v streptomycin/penicillin) (PAA). When the cells reached 
approximately 80% confluency, cells are transferred to a new flask with fresh media. In 
order to split HEK293 cells, first they were washed twice in phosphate buffered saline 
(PBS) (Gibco). Following the PBS wash, cells were then trypsinised with 1 ml of 
prewarmed Trypsin/EDTA (PAA) and incubated at 37oC in a 5% CO2 incubator for 5-10 
minutes. Following incubation, cells were checked under the microscope to confirm loss 
of adhesion to the surface of the flask. 9 ml of prewarmed DMEM was used to 
resuspend the trypsinised cells, separate adherent cells and to dilute the trypsin/EDTA. 
Different dilutions of cells were seeded as required. Cells were incubated at 37oC in a 
5% CO2 incubator. 
When required cells were trypsinised, centrifuged at 1000rpm for 5 minutes, media 
aspirated to remove cell debris and dead cells and were resuspended in fresh DMEM. 
According to requirements cells were aliquoted in different plates.  
2.6.2 H9c2 rat cardiomyoblast cells 
2.6.2.1 Origins of cell line 
H9c2 myoblast cell line was derived from the embryonic rat heart tissue in 1976 (257) 
and is widely used in cardiac and skeletal muscle-based research (258, 259) as they 
exhibit many of the properties observed in these type of cells. 
2.6.2.2 Culture conditions 
H9c2 were cultured in DMEM supplemented with 10% FBS and antibiotics (1% v/v 
streptomycin/penicillin) at 37oC in a 5% CO2 incubator. H9c2 cells were cultured in 6-
well or 12-well plate formats depending on the requirements. 
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2.6.3 iPS cardiomyocytes from Cell Dynamics International 
2.6.3.1 Origins of cell line 
Induced pluripotent stem (iPS) cardiomyocytes are highly purified, human 
cardiomyocytes derived from iPS cells (Cellular Dynamics International’s (CDI)). 
These cells have been obtained by CDI’s proprietary differentiation and purification 
protocols. iPS cardiomyocyte-like cells are a mixture of atrial, nodal, and ventricular-
like myocytes which are spontaneously electrically active and possess biochemical, 
electrophysiological, and mechanical characteristics similar to those expected of a 
cardiomyocyte. Depending on the stimulus, they display the expected responses and 
provide a platform which can be used as a surrogate for cardiac cells. Therefore, these 
cells are widely used as a reliable source of human cardiomyocytes suitable for use in 
cardiac-based research. 
2.6.3.2 Culture conditions 
In order to facilitate optimal cell viability and performance, the CDI instructions for 
thawing and plating iPS-cardiomyocytes were followed. The frozen iPS cardiomyocyte 
vial was placed in a 37oC water bath for 4 minutes and held stationary. The contents of 
the vial were gently transferred to a 50 ml tube using a 1 ml pipette. The empty vial was 
rinsed using 1 ml of RT plating medium to recover residual cells from the vial. The 
rinse from the vial was transferred to the 50 ml tube in a drop-wise manner over 90 
seconds, gently swirling the tube after each drop. 8 ml of RT plating medium was added 
to the 50 ml tube in a drop-wise manner with the first 1 ml being added over 60 seconds 
and the rest of the media over the next 30 seconds. The contents of the tube were gently 




48 hours after plating, the cells were washed twice with maintenance media and fresh 
37oC maintenance media was added to wells. The iPS-cardiomyocytes were maintained 
in culture for two weeks at 37oC in a 7% CO2 incubator, replacing the maintenance 
media every other day. 
2.7 Neonatal rat ventricular myocyte isolation 
2.7.1 Harvesting neonatal rat heart ventricles 
Neonatal rat ventricular myocytes (NRVM) were isolated from Sprague Dawley 
neonatal rat pups, which were 0–3 days of age. Sterilized surgical instruments, a beaker 
containing 70% ethanol, a 90 mm culture dish containing ADS buffer (containing 
0.68% NaCl (w/v), 0.476% HEPES (w/v), 0.012% NaH2PO4 (w/v), 0.1% glucose (w/v), 
0.04% KCl (w/v), 0.01% MgSO4 (w/v), pH 7.35) and a 150 mm sterile culture dish 
were placed on the bench. Following euthanasia, the chest of the animal was opened 
with the surgical scissors and the forceps were used to remove the heart. The heart was 
transferred into the dish containing the ADS buffer after the scissors were used to 
remove the atria, as well as slice the heart into 1 mm pieces. This procedure was 
repeated for all the pups. Throughout the procedure, surgical equipment not being used 
was kept in 70% ethanol.  
In a tissue culture hood, curved and sharp scissors were used to slice the hearts into very 
fine pieces. The heart-ADS solution was transferred to a 50 ml tube and allowed to 
settle. 
2.7.2 Enzymatic dissociation of cardiac tissue 
The ADS was carefully aspirated and 7 ml of the enzyme solution was added to the 
heart pieces. This mixture was placed in the 37oC water bath for 7 minutes, swirling the 
tube from time to time. After the heart pieces had settled, the solution was aspirated and 
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7 ml of the enzyme solution was added, repeating the 7 minute incubation step. After 
this step, the true digestions were started. The supernatant was aspirated and 7 ml of the 
enzyme solution was added to the heart pieces. The tube was incubated at 37oC for 15 
minutes, swirling the tube from time to time. After the hearts settled, the supernatant 
was transferred to a 15 ml tube containing 2 ml filtered FBS, this was the first digest. 7 
ml of enzyme solution was added to the tube containing the heart pieces and incubated 
at 37oC for a further 15 minutes. The 15 ml tube containing the supernatant and FBS, 
was centrifuged at 1000 rpm for 6 minutes at RT and the supernatant was discarded. 
The cell pellet was resuspended in 6 ml pre-plating media and transferred to a 50 ml 
tube. The above steps were repeated until 8 digestions were completed and all the 
digests were pooled in the 50 ml tube. 
2.7.3 Separation of fibroblasts and NRVMs 
The pooled digest was centrifuged at 1000 rpm for 6 minutes at RT and the supernatant 
was aspirated. The pellet was resuspended in a 50 ml solution of equal volumes of 
plating media and pre-plating media. The cells were resuspended gently and transferred 
to a 90 mm culture dish in order for non-myocyte cells to attach. Dishes were incubated 
at 37oC for 60-90 minutes. After the incubation, the media containing the myocytes was 
transferred to a 50 ml tube. 
2.7.4 Determination of cell yield and seeding 
Cell viability was determined using Trypan Blue (Sigma) and cells were counted using a 
hemocytometer. Cells were seeded on gelatin-coated plates depending on requirements. 
The plating media was replaced with maintenance media 24 hours after plating and 
experiments were performed 48 hours after the isolation procedure. 
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2.8 Cell counting and seeding 
Cells were counted by preparing a 1 in 10 dilution of cells in media. An equal volume 
of this dilution and Trypan Blue (Sigma) was added to a 1.5 ml tube. 20 μl of this was 
then mounted on a hemocytomter (VWR) and observed under a light microscope. Viable 
cells have a round shape and white outline, whereas dead cells appear blue and usually 
have lost their round shape. Only the viable cells within the grid were counted. 
2.9 Cation-mediated DNA Transfection 
2.9.1 The principle 
TurboFect Transfection Reagent (Thermo Scientific) is a polymer of cations in water.  
The DNA forms stable, positively charged complexes with the cationic polymer, which 
protect it from degradation by nucleases and increase the internalization of the DNA 
into eukaryotic cells.  
2.9.2 The protocol 
Cells were placed in serum-free medium (SFM) (PAA) with antibiotics (1% v/v 
streptomycin/penicillin) and were at 50-80% confluency prior to transfection. 100 μl 
Optimem (Gibco), 1 μg of DNA and 2 μl Turbofect were added to a 1.5 ml tube and 
mixed. The mixture was incubated at RT for 20 minutes. The solution was made upto 1 
ml per reaction with Optimem. SFM was aspirated from wells and the cells were 
washed with warm PBS. The Optimem/DNA mixture was added to cells in a drop-wise 
manner. Cells were incubated at 37oC in a 5% CO2 incubator for 24 hours. The 
transfection mixture was removed and replaced with SFM. If required cells were 
exposed to p38 inhibitors (10 μM SB203580 (Sigma) or 20 μM BIRB796 (Prof P. 
Cohen, Dundee University)) and incubated for the required amount of time (see Table 
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2.6). 24 hours after transfection cells were ready to be collected for Western blot 
analysis. 
These were the conditions to transfect 1 μg DNA into 1 well of 6-well plate, if more 
than 1 μg DNA was used the reaction components were scaled as required. 
2.10 Cell lysis 
To run a Western blot, cell lysates must be obtained with the cell proteins in solution. 
Cells were washed with cold PBS and 200 µl 2x concentrated sample buffer was added 
to each well. The cells were harvested using a scraper (Fisher Scientific) and collected 
into 1.5 ml tubes. The samples were boiled at 100oC for 10 minutes and shaken on the 
vortex for 10 seconds. The tubes were frozen at -20oC until used for Western blot 
analysis. 
2.11 BCA assay 
2.11.1 The principle 
Total protein in cell lysate was determined using the BCA Protein Assay (Thermo 
Scientific Pierce).This assay is based on bicinchoninic acid (BCA) for the colorimetric 
detection of total protein and works by combining the biuret reaction of the reduction of 
Cu2+ to Cu+ by protein in an alkaline medium, with the selective and sensitive detection 
of the Cu+ cation. Chelation of two molecules of BCA with one Cu+ cation leads to the 
purple reaction product, which displays a strong absorbance at 562 nm that appears to 
be linearly related to protein concentrations in the range 20-2000 μg/ml. 
The protein concentrations are determined with a reference to standards of bovine serum 
albumin (BSA) (Thermo Scientific Pierce). A series of dilutions of BSA are measured 
besides the samples of interest and unknowns are calculated from the standard curve.  
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2.11.2 The protocol 
Reagents A and reagent B were mixed in a tube to a ratio of 50:1 to prepare the working 
reagent. Replicates of 20 μl of each standard and unknown sample were pipetted into a 
96-well plate. 200 μl of the working reagent was added to each well and the contents of 
the wells were mixed briefly on a shaker for 30 seconds. The plate was covered with the 
lid and incubated at 37oC for 30 minutes. The absorbance at 562 nm was measured 
using a plate reader. The average 562 nm reading for standards and the unknown 
samples was subtracted from the blank measurement. A standard curve was plotted and 
was used to determine concentrations of the unknown samples. 
2.12 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
2.12.1 The principle 
Polyacrylamide Gel Electrophoresis (PAGE) is a commonly used technique for the 
separation of proteins based on their size. Electrophoresis enables charged molecules to 
migrate in an electric field towards the electrode with the opposite charge and this forms 
the basis of PAGE. The mobility of a protein depends on both its charge and size. 
Sodium dodecyl sulfate (SDS) is an anionic detergent, which is used to treat the samples 
in order to denature the proteins and coat them with a negative charge. This overcomes 
the issue of differential charge of proteins within a sample and allows them to go 
through electrophoresis in a comparable manner. The electrophoresis is carried out by 
applying the denatured samples through a porous matrix such as polyacrylamide. Under 
the influence of applied voltage, different proteins move through the polyacrylamide gel 
towards the anode due to their negative charge, at different speeds depending on their 
size. A known set of standards is loaded beside the samples as a reference molecular 
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weight ladder, which facilitates the identification of proteins of interest by comparison 
to the standards. 
2.12.2 The protocol 
Samples were run on a pre-cast polyacrylamide gel. The polyacrylamide gel was 
prepared using glass plates at the desired thickness with the recipe shown in Table 2.2 
depending on the percentage of gel.   
Table 2.2 Recipe for different percentage polyacrylamide gels 
Reagent 5% gel 10% gel 12.5% gel 15% gel Stack 
(4%) 
MW range (kDa)   10-100 5-70  
ddH2O (ml) 7 5 4 3 7 
30% acrylamide (ml) 
(National Diagnostics) 
2 4 5 6 2 
1.5M Tris-HCl -pH 8.8 
(ml) (Sigma) 
3 3 3 3 - 
1.0M Tris-HCl -pH 6.8 
(ml) (Sigma) 
- - - - 3 
10 % Ammonium 
Persulphate (µl) (Sigma) 
60 60 50 50 100 
TEMED (µl) (Fisher 
Scientific) 
15 15 15 15 10 
 
15 µl of each sample was loaded in the wells and 5 µl of pre-stained PageRuler 
prestained protein ladder (Thermo Scientific) was used as a marker of molecular weight. 
The gel was electrophoresed in 1X running buffer containing 25 mM Tris, 0.192 M 
glycine, 0.1% (w/v) SDS, pH 8.3 at 90 V until the samples reached the stacking and 
resolving gel interface and then 120 V for 1 hour and 30 minutes. 
2.13 Western blotting 
2.13.1.1 The principle 
Following SDS-PAGE, the proteins are transferred onto a membrane, such as 
polyvinyledene fluoride (PVDF) or nitrocellulose. This transfer process is based on a 
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similar method to SDS-PAGE, with an electric current being applied across the gel 
towards the membrane, moving the proteins across. The membrane with the 
immobilized proteins is blocked with blocking buffer to minimize nonspecific binding 
of the antibody to proteins other than the targeted one. The antibody is then applied 
allowing it to bind specifically to its target under optimal conditions. After this step, the 
membrane is washed to remove residual antibody and the membrane is incubated with a 
secondary antibody which is specific to the species used to raise the primary antibody 
and will therefore bind the primary antibody. The secondary antibody is usually 
conjugated to the enzyme horseradish peroxidase, which will catalyze the oxidation of 
substrates by hydrogen peroxide, which will yield a signal as a byproduct which can be 
detected.  
2.13.1.2 The protocol 
The gel from SDS-PAGE was used to transfer the proteins onto a polyvinylidene 
fluoride (PVDF) membrane (GE Healthcare) through semi-dry transfer with the Semi-
dry transfer system (Bio-Rad). Filter papers and the gel were soaked in 1X transfer 
buffer containing 25 mM Tris, 192 mM glycine,   and 20% methanol per litre dH2O. 
The PVDF membrane was activated in methanol, and soaked in buffer. Electrophoresis 
was undertaken at 24 V for 1 hour. 
Following transfer of proteins onto the membrane, the membrane was blocked in 4% 
milk (Marvel) and 1% bovine serum albumin (BSA) (PAA) in 1X Tris-Buffered Saline 
containing 20 mM Tris Base, 140 mM NaCl  pH 7.4 and 0.1% Tween 20 (Sigma-
Aldrich) (TBST0.1%) for 1 hour at RT with gentle agitation. The membrane was then 
incubated at 4oC, with gentle agitation overnight with the primary antibodies at correct 
concentrations (see Table 2.5). 
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The following day, the membrane was washed with TBST0.1% for 10 minutes three 
times under gentle agitation. This was followed by incubating the membrane with 
secondary antibodies with their complementary dilutions (see Table 2.5) under gentle 
agitation for 1 hour. The washing step was repeated following secondary antibody 
incubation again with TBST0.1% for 10 minutes three times under gentle agitation.  
Enhanced chemiluminescence reagent (GE Healthcare) was used to develop the 
membrane via exposure to X-ray film (GE Healthcare). Differing time durations were 
used to develop films in order to find the best signal with little background. 
2.14 Immunofluorescence 
Cells were seeded and grown on glass cover slips until they were 40-50% confluent. 
After treatments, cells were washed with cold PBS and fixed in cold 4% 
paraformaldehyde in PBS for 10 minutes. Care was taken not to move the cells during 
this incubation. The cells were washed two more times with PBS for 5 minutes each 
time. Permeabilisation was achieved with 0.2% v/v Triton X100 for 20 minutes at RT. 
Cells were washed two times in cold PBS for 5 minutes each. Blocking was performed 
by a 2 hour incubation in blocking buffer (PBS, 0.2% Triton X100, 2% w/v BSA) at 
RT. Cells were probed with the primary antibody at the appropriate dilution (see Table 
2.5) in 2% w/v BSA overnight at 4oC. 
The next day, cells were washed with cold PBS three times for 5 minutes each time. 
The following steps were all performed in the dark unless otherwise stated. Cells were 
incubated with the suitable secondary antibody at the required dilution (see Table 2.5) 
in PBS with 2% w/v BSA at RT. Three washes in cold PBS were performed. The cover 
slip was taken out and air-dried. 3 drops of Vectashield + DAPI solution was placed on 
the cover slip and it was mounted on a microscope slide, fixing the corners with nail 
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varnish. After the nail varnish had set, the slides were stored in the dark at 4oC until 
images were taken. 
2.15 RNA extraction 
2.15.1 The principle 
The RNeasy procedure represents a widely used method for RNA purification. Using 
selective binding properties of a silica-based membrane and a high-salt buffer system 
enables the extraction of up to 100 μg of RNA longer than 200 bases. Samples are first 
lysed and homogenised in a highly denaturing guanidine-thiocyanate-containing buffer, 
rendering RNAses inactive to enable purification of undamaged RNA. After addition of 
ethanol to enable binding, the sample is transferred to an RNeasy Mini spin column to 
which total RNA binds and the waste is removed. RNA is then eluted in water. 
2.15.2 The protocol 
The QIAvac 96 vacuum manifold was prepared by placing the waste tray inside the base 
and the top plate was placed over the base tightly. The QIAvac 96 manifold was 
attached to the vacuum source. The media in the sample wells were aspirated and 150 μl 
of Buffer RLT with 10% 2-mercaptoethanol (BME) was added to each sample well. The 
plate was shaken vigorously for 20 seconds. 150 μl 70% ethanol was added to each well 
and mixed by pipetting up and down 3 times. The samples were transferred onto the 
columns in the RNeasy 96 plate and the vacuum source was switched on until the 
sample had passed through the column. 80 μl DNase I incubation mix was applied onto 
the column and the plate was sealed with an AirPore tape sheet and incubated at RT for 
15 minutes. The tape sheet was removed and 1 ml of Buffer RW1 was added to each 
column. The plate was incubated at RT for 5 minutes before the vacuum source was 
switched on until transfer was complete. 1 ml of Buffer RPE was added to each column 
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and the vacuum source was switched on until the transfer was complete. Another 1 ml 
Buffer RPE was added to each column and the plate was sealed with an AirPore tape 
sheet. The plate was centrifuged at 6000 rpm for 10 minutes to dry the membranes. The 
RNeasy plate was placed on top of an elution microtube rack and the RNA was eluted 
with 30 μl RNase-free water by centrifugation at 6000 rpm for 4 minutes at RT. The 
elution step was repeated with a second volume of 30 μl RNase-free water. The RNA 
was stored at -20oC until required. 
2.16 Real time reverse transcription-PCR analysis 
2.16.1 The principle 
2.16.1.1 Reverse transcription 
Reverse transcriptases are a group of enzymes which generate complementary DNA 
from a RNA template and are mainly associated with retroviruses. This activity is used 
by retroviruses to convert their single stranded RNA into double-stranded cDNA which 
can then integrate into the host genome, enabling viral replication using the host 
transcription and translation machinery (260). This system is exploited by researchers 
for use in molecular cloning and RNA sequencing as well as genome analysis. 
2.16.1.2 Reverse transcription PCR 
PCR has previously been described in section 2.3.1.2. Reverse transcription PCR (RT-
PCR) is a commonly used technique to measure RNA expression (261). RT-PCR results 
in the formation of cDNA from RNA by a reverse transcriptase and the DNA then 
amplified by PCR for analysis. This technique is often used to determine gene 
expression in an organism or cell-type under control or treatment conditions. 
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2.16.1.3 Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) is used to quantitatively measure the amplification 
of DNA with fluorescent probes. The TaqMan solutions contain a primer, specific to the 
gene of interest to target the Taq polymerase, and a probe, to bind to the gene of interest 
downstream of the primer. TaqMan probes, which are sequence-specific 
oligonucleotides with a fluorophore and a quencher moiety attached, are utilised to 
determine the amount of DNA in the sample. The signal from the fluorophore 
fluorescein (FAM) at the 5’ end of the probe is quenched by the nonfluorescent 
quencher (NFQ) when the gene is not amplified and therefore no signal is detected. 
However during the extension phase of PCR, Taq polymerase cleaves the probe due to 
its exonuclease activity and this results in the separation of the fluorophore and the 
quencher leading to a signal proportional to the amount of PCR product from the DNA 
of that specific gene. Relative quantification of the DNA of the gene of interest is 
determined with an internal reference house-keeper gene to determine fold-differences 
in expression of the target gene.  
2.16.1.4 Reverse transcription quantitative PCR 
RT-PCR and qPCR can be combined to measure the relative RNA amounts within a 
sample and this method is termed RT-qPCR. QuantiTect Probe RT-PCR kit (Qiagen) 
allows both reverse transcription and qPCR to be performed in the same tube. All the 
components required for both methods are added at the beginning of the experiment and 
several precautions are taken to ensure the correct order of events. For reverse 
transcription to occur at the beginning, one cycle of 50oC for 30 minutes is added to the 
PCR cycling conditions. The polymerase used is HotStarTaq polymerase, and does not 
interfere with the reverse transcription as it has been modified to be activated after the 
reverse transcription step, at the 95oC for 15 minutes part of the PCR cycle. This high 
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temperature step also inactivates the reverse transcriptase ensuring temporal separation 
of the two steps. 
2.16.2 The protocol 
QuantiTect 2 x Probe RT-PCR Master Mix, RT Enzyme Mix, template RNA, Taqman 
probe & primer solution and RNase free water were thawed and reaction mixture was 
set up as in Table 2.3. The reaction was mixed thoroughly and appropriate volumes 
were dispensed into PCR plates. The real-time cycler Taqman 7900HT console (Applied 
Biosystems) was set up as in Table 2.4 and the cycling program was started.  
Table 2.3 RT-qPCR reaction setup 
  Stock Final Volume per reaction (μl) 
QuantiTect 2x Master Mix 2x 1x 5 
RT Enzyme Mix   0.1 
Taqman Prime & Probe mix 20x 1x 0.5 
RNA (10 ng/μl)   1.25 
H2O     3.15 
Final     10 
 
Beta-2-microglobulin (B2M) readout was used as a housekeeper control and relative 
RNA amplification of genes of interest were plotted.   
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Table 2.4 qPCR cycling conditions 
Step Temperature Time Cycles 
Reverse transcription 50oC 30min 1 
Initial denaturation 94oC 15min 1 
Denaturation 94oC 15sec  
 
40 
Annealing/Extension 60oC 60sec 
Final Extension 60oC 10min 1 
2.17 Adenylate kinase assay of cytotoxicity 
2.17.1 The principle 
Cytotoxicity of NRVMs and iPS cardiomyocytes was observed using the ToxiLight™ 
non-destructive bioassay (Lonza). Adenylate kinase (AK) is an enzyme present in all 
cells and the bioluminescent measurement of it is the basis of this assay. Upon 
cytotoxicity, cell integrity is lost and the plasma membrane dissociates, leading to the 
leakage of certain components of the cell into the surrounding environment, in this case; 
into the media in the wells. Therefore the measurement of AK release enables us to 
determine cytotoxicity accurately. 
There are two steps to this system. Firstly, ADP, which is a substrate of AK, is added, 
which is then converted to ATP by the enzyme AK.  
    Adenylate kinase 
Mg2+ADP + ADP       Mg2+ATP + AMP 
 
The bioluminescent part of this assay uses the enzyme luciferase in order to create light 
from ATP and luciferin as below: 
           Luciferase 




    Mg2+ 
 
As a result of these two reactions, the light emitted is linearly correlated to the release of 
AK. The resulting light is measured using a luminometer. 
2.17.2 The protocol 
All the reagents were brought to RT. The AK detection reagent (AKDR) was 
reconstituted in the assay buffer and left at RT for 15 minutes to ensure complete 
rehydration. The culture plate was removed from the incubator and allowed to cool to 
RT for at least 5 minutes. The luminometer was programmed to take an immediate 1 
second integrated reading of the appropriate wells. 20 µl of cell supernatant was 
transferred to a compatible 96 well plate and 100 µl of the AKDR was added to each 
well. The plate was incubated at RT for 5 minutes and the readings were taken using the 
luminometer. 
2.18 Caspase assay of cytotoxicity 
2.18.1 The principle 
Caspase-Glo 3/7 Assay (Promega) is a luminescent assay measuring cytotoxicity 
through observing the activities of cysteine aspartic acid-specific protease (caspase) 3 
and 7. Caspases are a family of proteases with an essential role in apoptosis and 
necrosis in mammalian cells (262, 263). The assay contains a luminogenic substrate of 
caspases-3/7 with the sequence DEVD. After adding the reagent, cells are lysed and the 
contents are released, enabling the active caspases-3/7 within the cells to cleave the 
substrate and generate a luciferase-mediated signal. The luminescent signal is 
proportional to the caspase activity. 
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2.18.2 The protocol 
In order to support observations from the AK assay described in section 2.17.2, another 
cytotoxicity assay, Caspase-Glo 3/7 Assay (Promega) was employed. Before starting 
the assay, Caspase-Glo reagent was prepared by allowing it to equilibrate to RT and 
mixing well. 96-well plates containing cells were removed from the incubator and 
allowed to equilibrate to RT. 100 μl of the reagent was added to each well of a white-
walled 96-well plate containing 100 μl of blank, negative control cells or treated cells in 
culture medium. The plate was covered with a lid. To avoid cross-contamination, care 
was taken to ensure that the pipette tips did not touch the wells. The contents of the 
wells were gently mixed at 300-500 rpm for 30 seconds using a plate shaker. Plates 
were incubated at RT for 30 minutes. Luminescence of each sample was measured in a 
plate-reading luminometer. 
2.19 Lentivirus production 
2.19.1 The principle 
There are several features of lentiviral vectors that make them attractive tools for 
biological research. They can transduce both dividing and non-dividing cells due to the 
ability of their pre-integration complex to efficiently pass from the cytoplasm into the 
nucleus through the nuclear pores and integrate into the genome of the target cell (264). 
In addition, they provide a research platform with low toxicity, the ability to 
accommodate large inserts (up to 8kb) and they achieve stable expression of transgenes 
in a broad range of host cell types (265-268).  
Lentivirus generation systems rely on transfecting multiple plasmids harbouring 
different infectious yet replication-incompetent components of the lentivirus. HEK293T 
cells are a variant of the HEK293 cells, which constitutively express the Simian Virus 
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40 (SV40) large T antigen enhancing transfection of these cells. HEK293T cells are 
widely used for lentiviral production due to their increased transfection efficiency, high 
propagation of viral particles from plasmids harbouring the SV40 episomal replication 
origin and ability to grow rapidly in basic cell culture medium containing 5-10% serum 
(269, 270). 
2.19.2 The protocol 
MISSION Lentiviral Packaging Mix (Sigma Aldrich) was used to produce lentiviruses 
in HEK293T cells. On day one, HEK293T cells were plated in complete DME medium 
supplemented with 10% fetal bovine serum and 4 mM L-glutamine, 24 hours prior to 
transfection. Cells were at 50-70% confluency the day of transfection.  
On day two, the vial of Lentiviral Packaging Mix was thawed at RT and added to a 
sterile polypropylene tube for each transfection. Transfer vector was added to the 
lentiviral packaging mix and FuGENE 6 transfection reagent, previously prepared in 
serum-free media, was added to the tube. The contents of the tubes were mixed gently 
by pipetting up and down. The transfection cocktail was incubated at RT for 15 
minutes. The transfection cocktail was added to flasks containing HEK293T cells. 
On day three, 16 hours post-transfection, the media was removed without disturbing the 
cells and replaced with an equal volume of pre-warmed DME complete media. Cells 
were incubated at 37°C in a 5% CO2 incubator for an additional 24 hours. 
On day four, between 36-48 hours post-transfection, viral particles were collected by 
carefully removing the media and placing it in a collection tube. An equal volume of 
fresh pre-warmed complete media was added to the cells and the flasks were incubated 
for a further 24 hours. Between 60-72 hours post-transfection, viral particles were 
collected by carefully removing the media and pooled with the first harvest. The viral 
particles were titrated by performing the HIV p24 Antigen ELISA assay after pooling. 
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2.20 Lentiviral transduction 
96-well plates were coated with 0.1% gelatin at 37oC for 1 hour and iPS cardiomyocytes 
were seeded in CDI plating media. After culturing for two weeks, the cells were ready 
for treatment. Transduction mixtures were prepared by combining a predetermined ratio 
of the lentiviruses and CDI maintenance media. To this mix, polybrene was added at a 
final concentration of 5 µg/ml. 48 hours after transduction; media was removed and 
replaced with an equal volume of fresh maintenance media. Cells were cultured for a 
further 24 hours and then treated as required. 
2.21 Isothermal titration calorimetry 
2.21.1 The principle 
Isothermal titration calorimetry (ITC) is a method to observe the change in enthalpy as a 
result of an interaction between two molecules. Through this thermodynamic 
characterization protein-protein interactions can be determined revealing intermolecular 
changes that occur during the modification of unbound to bound forms of the molecules 
in the assay (271). The number and type of bonds formed between the two components 
are determined and it is the thermodynamic effect of changes in hydrogen bonds, van 
der Waals and hydrophobic interactions which is measured in ITC (272). In a typical 
ITC experiment, using a syringe, one of the molecules is titrated into a calorimetric cell 
containing the other molecule. This is done in a stepwise manner in order to elicit the 
binding process and a cycle of binding to equilibrium occurs in the system determined 
by the association constant. The consequence of this titration is heat being absorbed or 
emitted in direct proportion to the amount of binding that occurs. When the protein in 
the calorimetric cell is saturated by the titrated molecule, the heat signal diminishes 
until a point when only the background heat of dilution is detected (273). Measurement 
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of the heat of the reaction enables the calculation of equilibrium association constant, 
stoichiometry based on the known concentration of the molecules and an appropriate 
model to fit the binding isotherm, as well as the change in entropy and free energy. ITC 
can be used to infer structural alterations upon binding and examine regions of the 
interacting molecules relevant to the interaction. ITC was used to determine the ability 
of TAB1 to compete with MKK3 in binding to p38 and all the ITC experiments were 
performed by Dr de Nicola, King’s College London. 
2.21.2 The protocol 
All ITC experiments were performed using an ITC-200 microcalorimeter from Microgal 
(GE Healthcare). At the beginning of the experiment, the pH of both the protein sample 
and the peptide was observed and adjusted for any discrepancy and the reference cell 
was filled with ddH2O. In order to remove air bubbles, the protein solutions were 
degassed for 2-5 minutes prior to loading into the appropriate sample chamber. Baseline 
stability was confirmed before the first addition of the peptide and analysis did not 
include the first injection in order to ensure artefacts due the diffusion through the 
injection port did not affect protein concentration near the tip of the needle. Before the 
titration was initiated, the sample cell was allowed to equilibrate to the temperature of 
the reference cell.  
In order to investigate the interaction between p38 and TAB1, a computer-controlled 40 
μl microsyringe was used to inject 150 μM p38α which was titrated into an identical 
buffer with 18 μM TAB1 (1-438) and 20 μM TAB1 (371-416). 400 seconds 
interspersed between each injection to allow the system to reach equilibrium before the 
next injection. A control experiment, titrating into buffer alone, under the same 
conditions was performed to verify that the heat produced by titrant dilution was 
negligible. Integrated heat data were corrected for heats of dilution and fitted using a 
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nonlinear least-squares minimisation algorithm to a theoretical titration curve using the 
MicroCal Origin 7.0 software package. The fitting parameters were ΔH° (reaction 
enthalpy change in kcal·mol−1), Kb (equilibrium binding constant in M−1), and n (molar 
ratio between the two species in the syringe and calorimetric cell respectively). The 
entropy of the reaction was calculated using ΔG = −RT·lnKb (R 1.987 cal·mol−1*K−1, T 
298 K) and ΔG = ΔH - TΔS. 
Gibb’s free energy is a thermodynamic potential used to predict how favourable a 
process is at constant pressure and temperature, as well as the chemical potential that is 
minimized when a system reaches equilibrium. It is defined as: 
G (free energy) = H (enthalpy) – T (temperature) S (entropy). 
2.22 Nuclear magnetic resonance 
2.22.1 The principle 
Nuclear magnetic resonance (NMR) was first observed in 1945 and it has become an 
eminent technique for determining structural and chemical properties of organic 
compounds. NMR is based on the ability of nuclei of many elements to absorb and re-
emit electromagnetic radiation when subjected to a magnetic field and makes use of 
atoms with an odd number of protons (1H, 13C, 15N and 31P) and their characteristic 
absorption frequencies depending on their environment (274). For example, hydrogens 
in different locations within a protein will give different peaks according to the 
chemical environment generated by surrounding atoms. In the case of this environment 
having high electron density, an ‘upfield’ peak will be observed and in the case of an 
environment with low density, the peak will be ‘downfield’. As the hydrogen atom has 
two spin states, the spectrum measures the ease of alteration between the different spins 
of the atom, with one spin being aligned with the magnetic field and the other being 
against the field. The higher spin is the one against the magnetic field and when 
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electromagnetic radiation is applied to atoms, the magnetic field can be changed to the 
higher spin by the atoms ability to absorb radiation, which is measured by NMR. If the 
atom in question is in an environment with a high density of electrons, it is shielded 
from the effect of the magnetic field and therefore can absorb less radiation than at a 
location with a low density of electrons (275). This measurement enables the 
determination of structural properties of different atoms within a protein. Combining a 
series of these measurements, interactions between atoms and protein-protein 
interactions can be determined. 
The chemical shift is the resonant frequency of a nucleus compared to a standard and is 
often used to determine the structure of molecules. Due to the dependence of the 
absorption and re-emission of the atoms on their environment, upon a change in this 
environment and the electron distribution, the characteristic frequencies observed are 
altered reflecting their newly acquired surroundings, binding partners, bond types and 
bond lengths and angles, and this is referred to as the chemical shift. 
2.22.2 The protocol 
Spectra of free p38α and of p38α:TAB1(371-416) complex were acquired in buffer 
containing 50 mM NaCl, 20 mM Tris (pH 7.5) and 2 mM DTT, while those of 
TAB1(371-416) were acquired in buffer containing 20 mM Tris (pH 7.5) and 2 mM 
DTT. Concentrations of free p38α and free TAB1(371-416) were 0.5 mM. Samples of 
p38α:TAB1(371-416) where p38α was [2H/15N/13C]-labeled and TAB1 unlabeled were 
prepared by mixing the components in a molar ratio of 1:2 at low micromolar 
concentrations and the complex was concentrated to a final concentration of 0.5 mM. 
An inverted stoichiometric ratio in the same procedure was employed for the complex 
of unlabeled p38α and selectively [15N/13C]-labeled TAB1 (371-416). 
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NMR spectra were recorded at 298 K (24.85oC) on Varian Inova spectrophotometers at 
800 MHz (1H frequency) and Bruker Avance spectrophotomer operating at 700 and 500 
MHz, all equipped with triple resonance cryoprobes. The spectra were processed using 
the manufacturers’ software or using NMRpipe, NMRViewJ, and XEASY. A Gaussian 
or sine –bell window function were applied to the spectra and prior to Fourier 
transformation they were zero-filled to double the size of the data. 15N-TROSY and 13C-
HSQC spectra were acquired in a standard manner.  15N-TROSY spectrum of free p38α 
with that of p38α:TAB1(371-416) were compared in order to obtain the chemical shift 
variations. The weighted average chemical shift variation (ΔδAV) was calculated using 
the formula ([(ΔHN)2 + (ΔN)2/5]/2)½ where ΔHN and ΔN are the chemical shift variations in 
the two dimensions. Chemical shift variations were classified as being weak (ΔδA ≤ 
0.5), strong (ΔδAV > 0.5), undefined (where signals are lost upon interaction) or unclear 
(unassigned peaks and where spectra overlapped prevented the unambiguous analysis). 





Table 2.5 Primary and secondary antibodies with their corresponding conditions and details 
Antigen (clone) Species Application Dilution Source 
p38 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #9212 
phospho Thr180/Tyr182 p38  Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #9211 
true dual phospho Thr180 and 
Tyr182 p38  
Mouse Western blot 1:1000 in 1% BSA in TBST0.1% Sigma #M8177 
TAK1 Rabbit Western blot 1:500 in 1% BSA in TBST0.1% Cell Signalling #4505 
phospho Thr184/Thr187 TAK1 Rabbit Western blot 1:500 in 1% BSA in TBST0.1% Cell Signalling #4531 
TAB1 Sheep Western blot 1:1000 in 1% BSA in TBST0.1% Santa Cruz 
phospho Ser423 TAB1 Sheep Western blot 1:1000 in 1% BSA in TBST0.1% Prof P. Cohen, Dundee 
University, UK 
phospho Thr431 TAB1 Sheep Western blot 1:1000 in 1% BSA in TBST0.1% Prof P. Cohen, Dundee 
University, UK 
MKK3 Rabbit Western blot 1:500 in 1% BSA in TBST0.1% Santa Cruz #sc-13069 
phospho Ser189 MKK3 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #9231 
phospho Ser82 Hsp27 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #2401 
phospho Thr334 MK2 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #3007 
GAPDH Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #2118 
GCN2 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #3302 
phospho Thr899 GCN2 Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Abcam #ab75836 
eIF2alpha Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #9722 
phospho Ser51 eIF2alpha Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #9721 
p62 Guinea pig Western blot 1:1000 in 1% BSA in TBST0.1% American Research 
Products #03-GP62-C 
B-actin Rabbit Western blot 1:1000 in 1% BSA in TBST0.1% Cell Signalling #4967 
LC3A/B (Alexa Fluor 555- Rabbit Immunofluorescence 1:50 in 1% BSA in PBS, 0.3% 
Triton x-100 




Rabbit Isotype Control (Alexa Fluor 
555-conjugated) 
 
Rabbit Immunofluorescence 1:50 in 1% BSA in PBS, 0.3% 
Triton x-100 
Cell Signalling #3969 
HA tag Mouse Immunofluorescence 1:100 in 2% BSA in PBS Cell Signalling #2367 
FLAG tag Rabbit Immunofluorescence 1:250 in 2% BSA in PBS Cell Signalling #2368 
Sheep (Horseradish peroxidise-
conjugated) 








Sheep Western blot 1:4000 in TBST0.1% GE Healthcare #NA931-
1ML 
Mouse (Cy3-conjugated) Goat Immunofluorescence 1:200 in 2% BSA in PBS Jackson Laboratories 
#115-165-205 






2.24 Inhibitors and compounds 
Table 2.6 Compounds used in treatment of cells and their details 
Inhibitor/Compound Function Treatment Source 
SB203580 p38 inhibitor – ATP mimetic 30 mins Sigma #S8307 
SB239063 p38 inhibitor – ATP mimetic 30 mins Sigma #S0569 
BIRB796 p38 inhibitor 2 hr Prof P. Cohen, Dundee 
University 
Halofuginone Prolyl tRNA synthetatse inhibitor 24 hr Sigma #32481 





Table 2.7 Vectors used in transformation and transfection of cells and their details 




WTp38 pcDNA3 p38 HA Mammalian 40 Dr Y Wang, UCLA, 
Los Angeles, CA, 
USA 
pcDNA3  p38 FLAG Mammalian 40 Dr G de Nicola, KCL 
 
pETDuet-1 p38 no tag Bacterial 38 Dr G de Nicola, KCL 
 
DRp38 pACCMVpLpA-SR  p38  
(T106M/H107P/L108F) 
no tag Mammalian 38 Dr J Martin. Loyola 
University, Chicago, 
IL, USA 
KDp38 pAdTrackCMV p38 
(D168A) 
FLAG Mammalian 40 Dr B Foxwell, The 




WT-TAB1 pETDuet-1  TAB1 no tag Bacterial 56 Dr G de Nicola, KCL 
pcDNA3  TAB1 CFP Mammalian 83 Cloned from 
pETDuet-1 version 
CM-TAB1 pETDuet-1  TAB1 
(V408G/M409A) 
no tag Bacterial 56 Dr G de Nicola, KCL 
pcDNA3  CFP Mammalian 83 Cloned from 
pETDuet-1 version 
NCM-TAB1 pETDuet-1  TAB1 
(V390A/Y392A) 
no tag Bacterial 56 Dr G de Nicola, KCL 




CM/NCM-TAB1 pETDuet-1  TAB1 
(V390A/Y392A/V408G/M409A) 
no tag Bacterial 56 Dr G de Nicola, KCL 
pcDNA3  CFP Mammalian 83 Cloned from 
pETDuet-1 version 
MKK3 pcDNA3 MKK3b HA Mammalian 40 Dr R Bassi, KCL 
TAK1 pCMV TAK1 HA Mammalian 80 Dr J Ninomiya-Tsuji, 
North Carolina State 
University, USA 
T185G-p38 pcDNA3 p38 
(T185G) 
HA Mammalian 38 Dr G de Nicola, KCL 
T185D-p38 pcDNA3 p38 
(T185D) 





3 RESULTS – TAB1-mediated p38 activation 
In several studies, employing pharmacologic compounds and transgenic animals, a role 
for p38 has been implicated in myocardial infarction. It has been shown that p38 
interacts with TAB1 directly in ischaemic hearts, but not in normal hearts (28). In 
addition, MKK3 knockout mice do not differ from wild-type mice in infarct size upon 
myocardial infarction, induced through a ligation of the left anterior descending (LAD) 
coronary artery (29). SB203580 treatment lead to a MKK3- independent reduction in 
infarct size in retrogradely perfused mouse hearts subjected to 30 minutes global 
ischaemia and 120 minutes of reperfusion (29). The direct interaction between p38 and 
TAB1 is further confirmed by crystal structures and characterisation in solution, 
revealing a bipartite docking mechanism (34). In order to confirm this interaction and 
TAB1-mediated p38 autophosphorylation, HEK293 cells were transfected and the 
phosphorylation state of p38 and TAB1 were explored in this chapter. In addition, the 
interaction points in TAB1 have been mutated and transfected to explore the effects of 
these mutations on p38 phosphorylation and presentation of TAB1 as a  substrate, as it 
is downstream of p38 besides its role in inducing autophosphorylation. 
MAPK binding partners share conserved docking site sequences which enable 
interactions between their respective MAPKs (276) and these contain a basic region and 
a hydrophobic region (277). One of the consensus motifs shared by some of these 
proteins is R/K-X4-φA-X-φB (where φA and φB are hydrophobic residues [Leu, Ile, or 
Val]), which is present in two of the binding partners of p38; MKK3b and MEF2A 
(278). Despite the similarity in docking sites, different conformation of the active site 
could lead to the differential downstream effects dependent on the binding partner. One 
of the p38 binding sites identified in TAB1 appears to share a region on p38 with these 
other binding partners. In order to answer the question of whether TAB1 and MKK3b 
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compete in binding to p38, we have transfected HEK293 cells and analysed the level of 
phosphorylation of p38. Pharmacologic inhibition and genetic mutations in p38 were 
utilised to explore this further enabling the differentiation between MKK3b-mediated 
transphosphorylation from autophosphorylation induced by TAB1. 
3.1 Optimisation of transfection  
Firstly to establish consistent transfection efficiency, a series of experiments were 
conducted in HEK293 cells with mammalian vectors encoding WTp38 (all ‘p38’ 
mentioned from here on is p38α, unless otherwise stated), WT-TAB1, a drug-resistant 
version of p38 mutated at residues at the ATP-binding site (DRp38 (T106M-H107P-
L108F)) and co-transfections of TAB1 with both versions of p38. The protein 
expression of ectopic WTp38 which runs at a higher molecular weight than the 
endogenous p38 due to a FLAG-tag was lower than expected (see Figure 3.1). 
Successful overexpression from a high-copy plasmid such as the pcDNA3 vector used 
here, usually results in greater protein accumulation than achieved by the endogenous 
gene. In addition, there were inconsistencies in loading in my initial experiments, which 




Figure 3.1 Optimisation of transfection efficiency of p38α and TAB1 in 
mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, 10 µM SB203580 was added as indicated (+) with an 
equivalent volume of DMSO added to the control wells. Cells were incubated for 30 
minutes, after which cell lysates were obtained and phospho-Thr180/Tyr182 p38, total 
p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using appropriate 
antibodies described in the Materials and Methods section 2.23. WTp38 is FLAG-
tagged and therefore runs at 40kDa, higher than the expected 38 kDa for native p38, 
DRp38 and TAB1 are untagged.  
 
In order to reduce variation, it was decided to use a mastermix of transfection reagents 
to achieve consistent efficiencies throughout the samples. The method was further 
improved by adding reagents in a dropwise manner to the cells throughout the 
transfection protocol. Transfection efficiency was more consistent after optimisation 




Figure 3.2 Optimisation of tranfection efficiency of p38α and TAB1 – improved 
transfection efficiency in mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr180/Tyr182 p38, 
total p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using 
appropriate antibodies shown in the Materials and Methods section 2.23.  
3.2 SB203580 reduces TAB1-mediated WTp38 phosphorylation 
To investigate the effect of TAB1 on p38 phosphorylation, HEK293 cells were co-
transfected with TAB1 and p38. In addition, to verify whether this effect of TAB1 on 
p38 phosphorylation is autophosphorylation, the sensitivity of this mechanism to the 
ATP-mimetic p38 inhibitor, SB203580 was examined. Cells were treated with 10μM 
SB203580 half an hour before collection. Addition of SB203580 should block p38 
kinase activity and therefore TAB1-mediated autophosphorylation. TAB1-mediated p38 
phosphorylation increases when p38 is co-transfected with TAB1 (see Figure 3.3). 
Moreover when SB203580 is added TAB1-mediated p38 phosphorylation decreases but 
as expected this is not the case with the drug-resistant p38 (DRp38) as it is mutated at 
the site where SB203580 binds. SB203580 cannot bind drug-resistant p38 therefore p38 
phosphorylation does not decrease when this version of p38 is co-transfected and 
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exposed to SB203580. As discussed in section 1.2.2, TAB1 is also involved in the 
canonical activation pathway of p38. Therefore SB203580 is a logical way to dissect 
transphosphorylation from autophosphorylation in this set of experiments. 
 
 
Figure 3.3 Western blot analysis of the effect of SB203580 on TAB1-mediated 
WTp38α and DRp38α phosphorylation.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, 10 µM SB203580 was added as indicated (+) with an 
equivalent volume of DMSO added to the control wells. Cells were incubated for 30 
minutes, after which cell lysates were obtained and phospho-Thr180/Tyr182 p38, total 
p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using appropriate 
antibodies as described in the Materials and Methods section 2.23. The blot shown is a 
representative of three experiments. 
3.3 BIRB796 reduces TAB1-mediated WTp38α and DRp38α 
phosphorylation 
With the aim to confirm that SB203580 does actually act on the ATP-binding site and 
DRp38 can also be inhibited in an allosteric manner by an unrelated inhibitor of p38, an 
allosteric inhibitor of p38, BIRB796, was employed. When 20μM BIRB796 is added to 
HEK293 cells co-transfected with TAB1 and WT p38, p38 phosphorylation decreases 
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(see Figure 3.4). As expected, this is also the case with DRp38 as BIRB796 binds to a 
different site than the ATP-binding site which is mutated in this version of p38.  
 
Figure 3.4 Western blot analysis of the effect of BIRB796 on TAB1-mediated 
WTp38α and DRp38α phosphorylation.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, 20 µM BIRB796 was added as indicated (+) with an 
equivalent volume of DMSO added to the control wells. Cells were incubated for 2 
hours, after which cell lysates were obtained and phospho-Thr180/Tyr182 p38, total 
p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using appropriate 
antibodies as described in the Materials and Methods section 2.23.  
3.4 Different regions of TAB1 induce p38 phosphorylation at 
different efficiencies 
Through experiments performed in our research group by Dr Gian Felice DeNicola we 
have identified the regions of TAB1 that interact with p38. This identification was 
performed by nuclear magnetic resonance (NMR) and X-ray crystallography and then 
confirmed by isothermal titration calorimetry (ITC). It was found that residues 385-394 
and 404-412 of TAB1 are involved in binding to p38 on the unique hydrophobic groove 
and the common docking domain of p38 respectively.  
An IVK assay was used to assess TAB1 and p38 interaction points without the 
limitation of other proteins within the cell interfering with their binding or in data 
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interpretation by occult activation of TAK1. Full length TAB1 protein was unstable and 
therefore shorter versions of TAB1 were used, as described previously (34). A 46 amino 
acid residue  TAB1 peptide (371-416) with the amino acid sequence 
[EMSQPTPTPAPGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMV] including 
both interaction points, a canonical (C) domain binding 13 amino acid long peptide with 
the amino acid sequence [NH2-KTSVTLSLVMPSQ-COOH] and a noncanonical (NC) 
domain binding 13 amino acid residue peptide with the amino acid sequence [NH2-
RVYPVSVPYSSAQ-COOH] that binds to the aforementioned unique hydrophobic 
groove were ordered (Activotec). The IVK assay products of p38 and these peptides of 
TAB1 were analysed by Western blotting. At earlier time points most p38 
phosphorylation is observed with the 46mer peptide, followed by the C peptide and then 
by the NC peptide compared to basal levels (see Figure 3.5). Nonetheless, after 4 hours 
C peptide seems to have caught up and exceeded the p38 phosphorylation that the 
46mer has induced. The NC peptide does not appear to have a major effect on p38 
phosphorylation even after 4 hours. Nevertheless, a combination of the C and NC 
peptide showed similar results to the canonical peptide alone. The effect of the 
combination of C and NC peptides was variable through several experiments, but it 





Figure 3.5 Western blot analysis of an IVK assay assessing the effect of TAB1 
mutations on p38α phosphorylation.  
IVK assay was performed at 37oC for 0, 30, 60, 120 and 240 minutes for p38α and each 
TAB1 peptide either the (WT TAB1 in the figure above) 46mer consisting of both 
canonical (C) region and noncanonical (NC) region docking peptides or the canonical 
region docking 13mer peptide or the noncanonical region docking 13mer peptide or 
both canonical and noncanonical peptides at the same time. Samples were boiled with 
sample buffer and Western blotting was carried out to determine the phospho-
Thr180/Tyr182 p38, total p38 levels using appropriate antibodies described in the 
Materials and Methods section 2.23. The blot shown is a representative of three 
experiments. 
 
3.5 TAB1 mutations alter its ability to induce p38 phosphorylation in 
the bacterial system 
Mutant versions of TAB1 were made with 2 amino acid substitutions in each of the two 
regions that are involved in p38 binding; the V408G/M409A mutant is referred to below 
as the canonical mutant (CM) and the V390A/Y392A mutant is referred to as the 
noncanonical mutant (NCM), as well as a mutant with both sets of mutations 
V390A/Y392A/V408G/M409A (CM/NCM). 
Escherichia coli (E.coli) lack most of the eukaryotic post-translational machinery such 
as protein kinases and the absence of p38 was verified in the strain Rosetta™ (DE3) by 
antibody recognition before IPTG induction (see Figure 3.6). Following IPTG induction 
and recombinant expression of p38 and WT and mutant TAB1 proteins in the 
transformed E.coli, phosphorylation of p38 and TAB1 were analysed by Western 
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blotting. It appears that the strong p38 phosphorylation by WT TAB1 is reduced with all 
CM, NCM and CM/NCM mutations of TAB1 (see Figure 3.6). Most of the decrease is 
by the CM/NCM mutant; CM/NCM and CM appears to reduce p38 phosphorylation 
slightly more than NCM. This is reflected on TAB1 phosphorylation, with virtually no 
phosphorylation when p38 is co-expressed with the CM/NCM mutant. Due to the 
variability of the bacterial system, the changes of p38 phosphorylation with TAB1 
mutations differed in repeats of this experiment. Nonetheless it is evident that p38 
phosphorylation is reduced by all three of the mutants compared to the co-
transformation with WT TAB1. The effect on TAB1 phosphorylation was similar in 






Figure 3.6 Recombinant protein expression in E.coli assessing the effect of TAB1 
mutations on p38α phosphorylation.  
Rosetta strain of E.coli were transformed with p38α and with either WT or one of the 
mutant versions of TAB1. Following 5 hour IPTG induction of protein expression, cell 
lysates were obtained and phospho-Thr180/Tyr182 p38, total p38, phospho-Ser423 
TAB1 and total TAB1 levels were determined using appropriate antibodies described in 
the Materials and Methods section 2.23. The blot shown is a representative of three 
experiments. Shown in the upper panel is the quantification of three independent 
repetitions of this experiment. *, p<0.05; ANOVA compared to control. †, p<0.05; 
ANOVA compared to WT TAB1. 
 
3.6 TAB1 mutations alter its ability to induce p38 phosphorylation in 
the mammalian system 
To support the results regarding TAB1 mutants observed in the bacterial system, a 
similar investigation was performed in a mammalian cell line. It appears that as in the 
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bacterial system, the strong p38 phosphorylation by WT TAB1 is reduced with all CM, 
NCM and CM/NCM versions of TAB1 in the mammalian system too (see Figure 3.7). 
Most of the decrease is by the CM/NCM mutant; CM and NCM reduce p38 
phosphorylation to similar levels. This is reflected on TAB1 phosphorylation, with 
virtually no phosphorylation when p38 is co-expressed with the CM/NCM mutant. 
 
Figure 3.7 Western blot analysis of the effect of TAB1 mutations on p38α 
phosphorylation in mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr180/Tyr182 p38, 
total p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using 
appropriate antibodies decribed in the Materials and Methods section 2.23. The blot 
shown is a representative of three experiments. Shown in the upper panel is the 
quantification of three independent repetitions of this experiment. ****, p<0.0001; 
ANOVA compared to control. ††††, p<0.0001; ANOVA compared to WT TAB1. 
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3.7 TAB1 mutations affect TAB1 substrate presentation in the 
mammalian system 
As TAB1 is a substrate of p38 as well as an activating binding partner, it was assessed 
whether the reduction in TAB1 phosphorylation was due to reduced p38 
autophosphorylation by the mutated versions of TAB1 or whether it was because the 
mutations were diminishing TAB1 substrate presentation to p38. MKK3b and TAB1 
both bind to the common docking domain of p38. However, the exact contact positions 
are not yet identified, so it is not known whether they compete for interaction points on 
p38. As well as testing whether TAB1 substrate presentation is affected by the 
mutations by using MKK3b to constitutively activate p38 at similar levels throughout 
samples, the experiment below tested whether MKK3b and TAB1 compete for the same 
binding site on p38.  
p38 phosphorylation does not differ upon co-transfection of the different versions of 
TAB1 along with p38 and MKK3b except only a slight decrease with the CM/NCM 
mutant TAB1. Though TAB1 phosphorylation is diminished with the CM/NCM mutant 







Figure 3.8 Western blot analysis of the effect of TAB1 mutations on TAB1 
substrate presentation in mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr180/Tyr182 p38, 
total p38, phospho-Ser423 TAB1, total TAB1, phospho-Ser189 MKK3 and total MKK3 
levels were determined using appropriate antibodies described in the Materials and 
Methods section 2.23. The blot shown is a representative of three experiments. Shown 
in the upper panel is the quantification of three independent repetitions of this 




3.8 The mutations and phosphorylation state of TAB1 have no effect 
on TAK1 activity and phosphorylation 
As discussed previously, TAB1 has a TAK1-binding domain that is separate from the 
p38-binding region and TAB1β lacks the TAK1 binding region (see Figure 1.4) and 
does not activate TAK1 (35). It has previously been shown that the phosphorylation 
state of TAB1 plays a role in its effect on the activity of TAK1; the phosphorylated state 
of TAB1 having a negative impact (279).  Surprisingly, in HEK293 cells 
overexpressing TAK1 and TAB1, we did not see this result. The phosphorylation of 
TAB1 at the p38-mediated phosphorylation site Ser423 was reduced with SB203580 
treatment but this had no effect on the TAB1-mediated TAK1 phosphorylation (see 
Figure 3.9). As expected, TAB1β did not induce TAK1 phosphorylation, therefore it is 
the presence of the TAK1-binding domain of TAB1 rather than its phosphorylation state 




Figure 3.9 Western blot analysis of TAK1 phosphorylation by TAB1 or TAB1β in 
mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr184/Thr187 
TAK1, total TAK1 and phospho-Ser423 and phospho-Thr431 TAB1 levels were 
determined using appropriate antibodies described in the Materials and Methods section 
2.23. The blot shown is a representative of three experiments. Shown in the upper panel 
is the quantification of three independent repetitions of this experiment. ****, 
p<0.0001; ANOVA compared to control. 
 
In addition, in order to investigate whether the mutations in TAB1 explored earlier have 
an effect on its ability to induce TAK1 phosphorylation, TAK1 and TAB1 were co-
transfected in HEK293 cells, and TAK1 and TAB1 phosphorylation were evaluated (see 
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Figure 3.10). It appears that, despite the CM/NCM TAB1 mutant being phosphorylated 
to a much lower level than WT TAB1; TAK1 phosphorylation does not appear to be 
affected by this reduction in phosphorylation of TAB1 or by the mutations that are 
present. Similar levels of TAK1 phosphorylation are also seen in presence of the CM 
and NCM mutants, suggesting that these mutations in p38-binding domain of TAB1 do 
not affect its ability to induce TAK1 phosphorylation. 
 
 
Figure 3.10 Western blot analysis of the effect of TAB1 mutations on TAK1 
phosphorylation in mammalian cells.  
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HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr184/Thr187 
TAK1, total TAK1 and phospho-Ser423 and phospho-Thr431 TAB1, total TAB1 and 
phospho-Thr180/Tyr182 p38 levels were determined using appropriate antibodies 
described in the Materials and Methods section 2.23. The blot shown is a representative 
of three experiments. Shown in the upper panel is the quantification of three 
independent repetitions of this experiment. *, p<0.05; ANOVA compared to control 
3.9 TAB1 displaces MKK3b from its binding partner p38α  
ITC experiments were performed to determine whether TAB1 affects MKK3b binding 
to p38. The results confirmed a direct interaction between  MKK3b and p38, revealing 
in the experimental conditions used, a monophasic 1:1 binding isotherm and a binding 
affinity in the low micromolar range (see Figure 3.11 and Table 3.1). Presence of TAB1 
peptide [NH2-RVYPVSVPYSSAQSTSKTSVTLSLVMPSQ-COOH] led to a change in 
the interaction between MKK3b peptide [NH2-SKGKSKRKKDLRISCNSK-COOH] 
and p38 observed as a change in enthalpy of interaction. Based on these data and the 
fact that the peptide is necessary and sufficient for TAB1-mediated activation of p38 as 
seen in our previous studies (34), we hypothesise that this short polypeptide contains the 
residues required for TAB1 recognition and is sufficient to affect the interaction 







Figure 3.11 Thermodynamic characterisation of p38:MKK3b complex formation 
and competition by TAB1 (29mer). 
ITC analysis of the interaction between p38 and MKK3b. A solution of MKK3b was 
titrated into p38 in the presence (bottom graphs) or absence (top graphs) of 
TAB1(29mer). The values reported are averaged over three experiments, and the errors 
were found to be less than 5%. All the measurements were performed at 25°C. All but 
the first point were used for curve fitting and derived thermodynamic parameters are 
shown in Table 3.1.  
 
 
Table 3.1 Thermodynamic parameters determined by ITC of the association of p38 with 
TAB1 and MKK3 
  
n 






p38α/ MKK3b 1.0 0.27 -8.9 −5.7 3.2 
p38α/ MKK3b/TAB1(29mer) 0.7 0.24 -8.9 5.5 14.4 
3.10 TAB1 and MKK3b compete to phosphorylate p38 in an IVK 
system 
In order to further assess the competition between the two binding partners of p38; 
MKK3b and TAB1, IVK assays were performed using recombinant proteins. A 
constitutively active mutant of MKK3b (S218E/T222E – MKK3bEE) was used in these 
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experiments. The concentration of MKK3bEE low enough to induce phosphorylation of 
p38 without overloading the phospho signal and to enable observation of differences 
between trans and autophosphorylation in TAB1 and MKK3bEE co-expression system, 
was determined from previous experiments in our laboratory. To verify the accuracy of 
this concentration in these experiments, KDp38 (D168A) and several concentrations of 
MKK3bEE were used in an IVK assay observing p38 phosphorylation (see Figure 
3.12). It is evident that 8.47 nM is the optimal concentration to see a clear difference in 
phosphorylation of p38 in comparison to control, as lower concentrations do not appear 
to induce phosphorylation. This concentration of MKK3bEE was used in IVKs with 
TAB1 and p38 to investigate the competition between MKK3bEE and TAB1 in binding 
to p38 and inducing its phosphorylation.  
 
Figure 3.12 Western blot analysis of an IVK assay determining the optimum 
MKK3bEE concentration to induce p38 phosphorylation.  
IVK assay was performed at 37oC for 30 minutes for MKK3bEE and KDp38 
recombinant proteins. Samples were boiled with sample buffer and Western blotting 
was carried out to determine the phospho-Thr180/Tyr182 p38, total p38, and total 
MKK3 levels using appropriate antibodies described in the Materials and Methods 




30 minutes is a commonly used incubation time for IVK assays, and the suitability of 
this was verified by testing a set of incubation times for the induction of p38 by 
MKK3bEE and TAB1. It appears that there is an adequate signal at 30 minutes for both 
TAB1 and MKK3bEE mediated phosphorylation of p38 (see Figure 3.13). Therefore, 
this incubation time was used to induce the MKK3bEE-mediated transphosphorylation. 
Nonetheless, for TAB1-mediated autophosphorylation, the TAB1 and p38 proteins have 
been incubated for 4 hours to allow p38 to accommodate TAB1 and aid the process of 
any potential competition between TAB1 and MKK3bEE, before the addition of 
MKK3bEE which appears to be much more efficient at inducing p38 phosphorylation 
and possibly at binding to p38 as well. 
 
Figure 3.13 Western blot analysis of an IVK assay determining induction time to 
induce substantial p38 phosphorylation by MKK3bEE and TAB1.  
IVK assay was performed at 37oC for 4 hours for p38α alone and in the presence of 
29mer TAB1 peptide. MKK3bEE was added to these samples and they were incubated 
for a further 2, 5, 10 and 30 minutes.  Samples were boiled with sample buffer and 
Western blotting was carried out to determine the phospho-Thr180/Tyr182 p38, total 
p38, and total MKK3 levels using appropriate antibodies described in the Materials and 
Methods section 2.23. 
 
IVK assays show that TAB1 and MKK3bEE both phosphorylate p38, with MKK3bEE 
being more efficient at doing so. Upon addition of MKK3bEE to an assay of TAB1 and 
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p38, the phosphorylation level of p38 appears to be at similar levels with that of the 
MKK3bEE and p38 sample (see Figure 3.14). When SB203580 is added to block the 
TAB1-mediated autophosphorylation, there is a reduction in p38 phosphorylation with 
TAB1 alone to basal levels. A reduction is observed in the TAB1, MKK3bEE and p38 
sample, which is theoretically showing the phosphorylation of p38 mediated by 
MKK3bEE alone. Comparing p38 phosphorylation levels in the samples of MKK3b co-
expressed with p38 and the sample expressing MKK3b, TAB1 and p38, we can deduce 
the difference in phosphorylation as that which is mediated by TAB1, suggesting that in 
this system TAB1 does compete with MKK3b in inducing p38 phosphorylation. 
 
Figure 3.14 Western blot analysis of an IVK assay assessing the competition 
between MKK3b and TAB1 to induce p38 phosphorylation.  
IVK assay was performed at 37oC for 4 hours for p38α alone and in the presence of 
29mer TAB1 peptide. MKK3bEE was added to these samples and they were incubated 
for a further 30 minutes.  Samples were boiled with sample buffer and Western blotting 
was carried out to determine the phospho-Thr180/Tyr182 p38, total p38, and total 
MKK3 levels using appropriate antibodies described in the Materials and Methods 
section 2.23. The blot shown is a representative of three experiments. 
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3.11 TAB1 and MKK3b do not compete in phosphorylating p38 in the 
mammalian system 
It has been attempted to create a constitutively active version of p38 by overexpressing 
p38 and its activator MKK3b in the experiment in Figure 3.8 to investigate whether 
TAB1 mutations alter TAB1 substrate presentation. Following the results of the ITC 
and IVK experiments investigating competition between TAB1 and MKK3b to bind to 
p38, we wanted to verify the results in the in-cell setting. In order to verify that the p38 
phosphorylation in cells co-transfected with MKK3b and TAB1 is via the canonical 
pathway and not autophosphorylation due to TAB1, the TAB1-mediated pathway must 
be blocked to see if the p38 phosphorylation induced by MKK3b is reduced when 
TAB1 is present. For this the p38 inhibitor SB203580 and a kinase-dead (KD) version 
of p38 (D168A mutant) have been used. SB203580 is known to bind p38 and inhibit its 
autophosphorylation mediated by TAB1, yet it does not inhibit the MKK-mediated 
pathway (see Figure 3.15). Therefore using SB203580 blocks the TAB1 mediated p38 
activation whilst keeping the canonical pathway intact, providing results which can be 
interpreted to observe the effect, if any, of TAB1 on p38 phosphorylation when 
transfected along with p38 and MKK3b.  
 
Figure 3.15 Schematic showing whether MKK3 and TAB1 can activate WTp38α 
upon addition of SB203580.  
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SB203580 prevents binding of ATP to p38. p38 must bind ATP in order to 
autophosphorylate whereas this is not required for MKK3-mediated phosphorylation. 
MKK3 is able to phosphorylate p38 in presence of SB203580, whereas TAB1-mediated 
autophosphorylation does not occur, permitting observation of MKK3 activated p38 
alone. 
 
p38 phosphorylation is increased when co-transfected with MKK3b, and this does not 
appear to decrease upon 10μM SB203580 addition (see Figure 3.16). On the contrary, in 
cells co-transfected with p38 and TAB1, the augmented p38 phosphorylation is reduced 
to basal levels upon addition of SB203580. Whereas when both TAB1 and MKK3b, as 
well as p38 are transfected into cells, there is hardly any reduction in p38 
phosphorylation with addition of SB203580. This shows that most of the p38 
phosphorylation we observe is due to the canonical activation pathway and addition of 




Figure 3.16 Western blot analysis of the effect of SB203580 on MKK3-mediated 
and/or TAB1-mediated p38α phosphorylation in mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, 10 µM SB203580 was added as indicated (+) with an 
equivalent volume of DMSO added to the control wells. Cells were incubated for 30 
minutes, after which cell lysates were obtained and phospho-Thr180/Tyr182 p38, total 
p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using appropriate 
antibodies described in the Materials and Methods section 2.23. The blot shown is a 
representative of three experiments. Shown in the upper panel is the quantification of 
three independent repetitions of this experiment. *, p<0.05; ANOVA compared to 




In addition, KDp38 is a mutated form of p38 that cannot autophosphorylate but is still 
able to be transphosphorylated by upstream kinases such as MKK3b. This, just like the 
SB203580 inhibited WTp38, and will be able to reveal phosphorylation caused by the 
canonical pathway and not by the TAB1-mediated mechanism (see Figure 3.17). 
 
Figure 3.17 Schematic showing whether MKK3 and TAB1 can activate WTp38 
and KDp38.  
MKK3 is able to activate both versions of p38, whereas as TAB1 induces 
autophosphorylation and KDp38 is unable to autophosphorylate, only MKK3 can 
activate this p38 version, permitting observation of MKK3 activated p38 alone. 
 
WTp38 and KDp38 phosphorylation increases when co-transfected with MKK3b and 
though not to a similar level WTp38 phosphorylation also increases when co-transfected 
with TAB1 (see Figure 3.18). However, KDp38 phosphorylation levels with TAB1 are 
similar to that of KDp38 alone. Whereas triple transfection with KDp38, TAB1 and 
MKK3b causes an increase in KDp38 phosphorylation, suggesting that the main 
pathway of phosphorylation is via MKK3b and TAB1 does not interfere with MKK3b 




Figure 3.18 Western blot analysis of WTp38α and KDp38α phosphorylation by 
MKK3 and/or TAB1 in mammalian cells.  
HEK293 cells were transfected as described in the Materials and Methods section 2.9. 
24 hours after transfection, cell lysates were obtained and phospho-Thr180/Tyr182 p38, 
total p38, phospho-Ser423 TAB1 and total TAB1 levels were determined using 
appropriate antibodies described in the Materials and Methods section 2.23. The blot 
shown is a representative of three experiments. Shown in the upper panel is the 
quantification of three independent repetitions of this experiment. *, p<0.05; Student’s 
T-test compared to control, †, p<0.05; Student’s t-test compared to with TAB1-
mediated activation. 
3.12 The localisation of p38 is dependent on its binding partner 
The results obtained in vitro suggest TAB1 and MKK3b (see Figure 3.14) compete for 
p38 access/activation whilst those obtained in cells (see Figure 3.16 and Figure 3.18) 
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suggest they are independent. We hypothesised that this dichotomy maybe the result of 
spatial constraints in the cell-based assays preventing competition between TAB1 and 
MKK3b (Figure 3.16 and Figure 3.18). In order to investigate this, the localisation of 
p38 in response to expression of MKK3b and/or TAB1 was observed.  
In Figure 3.19, MKK3b appears to be localised in the cytoplasm residing close to the 
plasma membrane, whilst TAB1 is located in the nuclear/perinuclear area. It is clear that 
p38 is preferentially co-localised according to which binding partner is co-expressed. 
While MKK3b and TAB1 co-localise with p38 in their respective in-cell locations when 
they are overexpressed with p38 on their own; the majority of p38 appears to co-localise 
with MKK3b when both MKK3b and TAB1 are co-expressed in HEK293 cells (see 
Figure 3.19). This preferential colocation with MKK3b may be the result of the 




Figure 3.19 Immunofluorescence determining the localisation of p38 in HEK293 cells depending on its co-expressed binding 
partner.  
HEK293 cells were transfected with FLAG-p38, HA-MKK3 and CFP-TAB1 as described in the Materials and Methods section 2.9. 24 
hours after transfection, cells were fixed and permeabilised as in the Materials and Methods section 2.14. DAPI, FLAG-p38, HA-MKK3 
and CFP-TAB1 were detected using appropriate antibodies described in the Materials and Methods section 2.23. 
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3.13 The importance of Thr185 in the localization of p38 
The localisation of a protein within a cell determines its ability to perform its function 
due to its proximity to its binding partners, downstream substrates and the in-cell 
location of the other members of the particular signalling pathway. The importance of 
the phosphorylation of the Thr188 residue in ERK1/2 and its role in its localisation has 
been previously discussed in section 1.2.5. This residue is conserved in p38 at the 185 
site and based on the ERK1/2 study and previous mass spectrometry data generated in 
our laboratory regarding this residue, we have hypothesized that it potentially plays a 
role in the localisation of p38. Having determined that the localisation of p38 with 
MKK3b and TAB1 are distinct from each other (see Figure 3.19), and based on our 
findings that the phosphorylation of this residue is associated with TAB1 presence, the 
localisation of p38 was examined using phosphomimetic (T185D) and phosphorylation-
deficient (T185G) mutants of p38 at this residue.  
Inspecting the quantification of the immunofluorescence data and observing the images 
(see Figure 3.20); p38 resides throughout the cell with similar levels in the cytoplasm 
and the nucleus. There does not appear to be an effect of the T185G mutant, except 
possibly a slight increase in the levels of p38 in the nucleus. However, the T185D 




Figure 3.20 Immunofluorescence determining the localisation of p38 and its T185 mutants.  
HEK293 cells were transfected with HA-p38, HA-T185G-p38 and HA-T185D-p38 as described in the Materials and Methods section 2.9. 
24 hours after transfection, cells were fixed and permeabilised as in the Materials and Methods section 2.14. A) DAPI, and HA-p38, HA-
T185G-p38 and HA-T185D-p38 were detected using appropriate antibodies described in the Materials and Methods section 2.23. B) 
Quantification of immunofluorescence images using ImageJ program. **, p<0.01 ANOVA. 
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4 RESULTS – Role of the amino acid response 
pathway in cardiomyocytes 
Amino acid response pathway is one of the basic mechanisms that enables organisms to 
survive starvation by limiting the usage of their resources for the most essential 
processes within cells. Furthermore, as discussed earlier in this thesis, the mechanism of 
halofuginone-mediated activation of the amino acid response pathway is through its 
competition with proline for the EPRS. This leads to an accumulation of uncharged 
tRNAs activating GCN2 which in turn leads to a halt in global translation and the 
induction of the translation of a subset of mRNAs to aid the cell deal with the 
starvation, which is mimicked through halofuginone treatment. In addition, 
halofuginone treatment has previously been associated with improvement in mdx 
models of mice with decreased fibrosis and decreased collagen I and III gene expression 
and collagen protein levels, as well as improving cardiac and respiratory function (222).  
There are several features of heart failure, on which we were interested in testing the 
effect of halofuginone treatment in cardiomyocytes and our hypothesis was that if 
halofuginone is capable of improving cardiac function and decreasing fibrosis in other 
experimental models, amino acid response pathway might be a potential target in 
cardiomyocytes. Therefore, we conducted experiments in iPS cardiomyocytes and 
NRVMs observing hypertrophic markers, autophagy markers, inflammation markers 
and p38 activation, as these are associated with heart failure. Before these experiments, 
several characterisation studies were conducted including the identification of the active 
yet non-toxic concentration of halofuginone in these cells and the activation of 
downstream effectors of the amino acid response pathway, as well as the response of 




4.1 Determining the optimal concentrations of halofuginone to induce 
the amino acid response in cardiomyocytes 
In order to use halofuginone as a tool effectively in the in-cell setting, toxicity and 
activation of the AAR pathway were observed simultaneously. We have found that 
different cell lines have different sensitivities to halofuginone. Toxicity was measured 
by adenylate kinase (AK) release for both iPS cardiomyocytes and NRVMs. The 
optimal concentration of halofuginone to activate the AAR in iPS cardiomyocytes and 










Figure 4.1 A-B. Activation of the AAR pathway and toxicity in response to 
halofuginone treatment in two different cardiomyocyte types.  
Adenylate kinase release assay was performed on iPS cardiomyocytes (A.i) and NRVM 
(B.i) cells treated with increasing concentrations of halofuginone for 24 hours. The 
phosphorylation of GCN2 and eIF2alpha were used as readouts of the activation of the 
AAR pathway by halofuginone in iPS cardiomyocytes (A.ii) and NRVMs (B.ii). 
Samples were boiled with sample buffer and Western blotting was carried out to 
determine the phospho-Thr899 GCN2, total GCN2, phospho-Ser51 eIF2alpha and total 
eIF2alpha levels using appropriate antibodies described in the Materials and Methods 
section 2.23. In the case of NRVMs, proline was added to revert the activation and 
threonine to show actions are specific to proline tRNA synthetase. 
 
The induction of the AAR pathway by halofuginone is confirmed by the 
phosphorylation of GCN2 and eIF2alpha (see Figure 4.1 A.ii and B.ii). In iPS 
cardiomyocytes, protein phosphorylation and gene expression of proteins involved in 
the AAR pathway are observed at a nontoxic dose (see Figure 4.1 and Figure 4.2), 
which is why we have continued our studies in this cell line. I used NRVMs to support 
my observations in iPS cardiomyocytes and gene expression of proteins of interest were 
observed at a nontoxic dose as well. There was an increase in the gene expression of the 
downstream components of the AAR pathway; DDIT3, TRIB3 and ASNS at the optimal 
dose of halofuginone (30 nM) based on the toxicity and AAR pathway induction. These 
changes revert to basal levels upon the addition of proline but not threonine, as expected 




Figure 4.2 Gene expression of downstream components of the AAR pathway in response to halofuginone treatment in iPS 
cardiomyocytes.  
Cells were treated with increasing concentrations of halofuginone for 24 hours and real time reverse transcription-PCR analysis of 





Figure 4.3 Gene expression of downstream substrates of the AAR pathway in response to halofuginone treatment in NRVMs.  
Cells were treated with increasing concentrations of halofuginone for 24 hours, proline was added to revert the activation and threonine to 
show actions are specific to proline tRNA synthetase. Real time reverse transcription-PCR analysis of downstream genes  DDIT3, TRIB3 
and ASNS was performed.  *, p<0.05; ****, p<0.0001 ANOVA compared to control. #, p<0.05; ##, p<0.01, ####, p<0.0001 ANOVA 
compared to without Pro/Thr.
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4.2 Use of ET-1 as a stressor in cardiomyocytes 
As discussed previously, ET-1 is increased in heart failure patients and this appears to 
correlate with an increase in hypertrophic marker levels in plasma (248). In addition, 
iPS cardiomyocytes are a powerful tool for scientific research, albeit they do not 
respond to several hypertrophic agents such as phenylephrine and angiotensin-II 
(unpublished in-house data at GSK), possibly due to the lack of receptors for these 
hormones. Fortunately, they produce the expected response to ET-1 and therefore this 
was used to induce hypertrophic pathways in order to determine whether halofuginone 
has a protective effect in cardiomyocytes. Firstly, the gene expression of several 
hypertrophy marker genes such as ANP, BNP, ATP2A2, and the ratio of MYH7 to MYH6 





Figure 4.4 Gene expression of hypertrophic marker genes in ET-1-treated iPS 
cardiomyocytes.  
Cells were treated with ET-1 for 4 hours and real time reverse transcription-PCR 
analysis of hypertrophy markers ANP, BNP, MYH7/MYH6 and ATP2A2 was performed. 
*, p<0.05; **, p<0.01 ANOVA compared to control. 
 
The gene expression of ANP, BNP and the ratio of MYH7 to MYH6 increase with ET-1 
treatment together with a decrease in ATP2A2 gene expression (see Figure 4.4). 
However, these changes are not of the magnitudes we were hoping to observe based on 
past experience. This could be due to the 4 hour incubation being too short for the ET-1 
treatment to have maximal effect. Therefore, the exposure time was increased from 4 
hours to 24 hours. In addition, several concentrations of ET-1 were used to determine 
the optimal dose to trigger substantial changes in the expression of the classical marker 
genes. More substantial changes are needed to observe any potential influence of 




Figure 4.5 Gene expression of hypertrophic marker genes with different doses of 
ET-1 in iPS cardiomyocytes.  
Cells treated with different ET-1 concentrations for 24 hours and real time reverse 
transcription-PCR analysis of hypertrophy markers ANP, BNP, MYH7/MYH6 and 
ATP2A2 was performed. *, p<0.05; **, p<0.01 ANOVA compared to control. 
 
As discussed previously, upon an increase in ET-1 binding, ET-1 receptors are 
internalised  with time in order to provide a negative feedback system to reduce the 
long-lasting effects of ET-1, which could otherwise be detrimental (238). ANP and BNP 
genes are increased with 1 nM ET-1 treatment in iPS cardiomyocytes, but decrease 
when the dose of ET-1 reaches 10 nM (see Figure 4.5), possibly due to the 
internalisation of receptors. Therefore, 1 nM ET-1 treatment for 24 hours appears to be 
the most optimal dose and incubation time to induce hypertrophic effects in iPS 
cardiomyocytes.  
4.3 The effect of halofuginone on hypertrophy in cardiomyocytes 
Having determined the optimal concentration and incubation time to induce the effects 
of ET-1 in cardiomyocytes as a model of hypertrophy, we have examined whether 
halofuginone plays a role in reducing these effects. The gene expression of hypertrophy 
markers ANP, BNP, and MYH7 to MYH6 ratio were examined upon halofuginone 
treatment.  Using ET-1 as a stressor to increase ANP and BNP levels, halofuginone 
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exposure decreases the gene expression of these hypertrophy markers, significantly in 
the case of ANP (see Figure 4.6).  
Expression of alpha and beta myosin heavy chain (MHC-α/β – gene names MYH6/7) 
are dependent on the stage of development of the organism as well as being controlled 
through hormones (280, 281). Cardiac disease states affect the ratio of the two isoforms 
and in adult mouse heart models of heart failure, an increase in MHC-β expression is 
observed (282). Though MHC-β is the predominant isoform in normal adult human 
hearts, even a small shift in the expression patterns can affect cardiomyocyte function 
(283). MHC-β has been reported to have lower ATPase activity and lower filament 
sliding velocity and can induce cross-bridge force with lower energy use than MHC-α. 
It is possible that the shift in isoforms is an adaptive mechanism to maintain levels of 
energy (284), though this is associated with cardiac pathophysiology progression (285). 
Therefore, the ratio compared to basal levels is a marker of hypertrophy and was 
measured in this experiment. Halofuginone exposure does not alter the ratio of 





Figure 4.6 Halofuginone decreases gene expression of some hypertropy markers in 
cardiomyocytes.  
Cells were treated with ET-1 in the presence and absence of halofuginone for 24 hours 
and real time reverse transcription-PCR analysis of hypertrophy markers ANP, BNP and 
MYH7/MYH6 ratio was performed. *, p<0.05; ANOVA compared to control, #, p<0.05; 
ANOVA compared to with ET-1. 
4.4 The effect of halofuginone on autophagy in cardiomyocytes 
Autophagy is an essential intracellular degradation system for balancing sources of 
energy during development and in response to amino acid starvation. Maladaptive 
autophagy has been implicated in cardiac hypertrophy and an increase in autophagy has 
previously been linked to cardio-protection in the heart (287, 288). The eIF2alpha  
kinase, GCN2, is the ‘starvation-sensor‘ of the cell and is important in initiating the 
amino acid response (AAR) pathway to modulate amino acid metabolism for adaptation 
when one or more amino acids become limiting. I have investigated whether mimicking 
this system would improve autophagy.  
In previous studies, we have observed halofuginone to inhibit fibrosis in cardiac 
fibroblasts and improve several aspects of pressure-induced cardiac hypertrophy in mice 
(unpublished data). As autophagy plays a major role in pathogenesis of 
cardiomyopathies, I have investigated whether halofuginone has an effect on autophagy. 
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4.4.1 Gene expression of the autophagy related genes ULK1, ULK2, 
GABARAPL1, and MAP1LC3B after halofuginone exposure 
In order to investigate whether the GCN2 pathway plays a role in autophagy, iPS 
cardiomyocytes were treated with ET-1 in presence and absence of halofuginone. 
Halofuginone treatment significantly increases the gene expression of autophagy 
markers, ULK1, ULK2, GABARAPL1 and MAP1LC3B (see Figure 4.7). BECN1 gene 
expression is not altered significantly, though there appears to be a trend with 
halofuginone addition to ET-1 increasing BECN1 mRNA compared to ET-1 alone. 





Figure 4.7 Halofuginone increases gene expression of autophagy markers in 
cardiomyocytes.  
Cells were treated with ET-1 in the presence and absence of halofuginone for 24 hours 
and real time reverse transcription-PCR analysis of autophagy markers ULK1, ULK2, 
GABARAPL1, MAP1LC3B and BECN1 was performed. **, p<0.01; ***, p<0.001 
ANOVA. 
4.4.2 Protein levels of p62 decrease with halofuginone 
p62 protein, also referred to as sequestosome 1 (SQSTM1) is a ubiquitin-binding 
scaffold protein, which recruits ubiquitinated proteins to the autophagosomes in the cell 
for degradation (see Figure 4.8). p62 binds directly to Atg8 family members, LC3 and 
GABARAPL1 that are involved in autophagosome formation, and p62 itself is degraded 
through autophagy. Therefore, p62 can be used to measure the level of autophagy 
within cells, with levels of p62 negatively correlating with autophagy, i.e. less p62 





Figure 4.8 Schematic showing the process of autophagy within cells.  
ET-1 is known to activate mTOR which in turn is known to phosphorylate ULK1/2 and 
inhibit autophagy when there is sufficient supply of energy and nutrients within the cell. 
Otherwise, ULK1/2 is involved in inducing autophagy by phosphorylating its substrate 
Beclin1, which leads to the formation of autophagosomes by inducing vesicle 
nucleation by LC3 and GABARAPL proteins. p62 recruits proteins to be degraded into 
the autophagosome and upon docking and fusion of lysosomes, it is degraded in the 
process.  
 
Changes in p62 protein levels suggest that, ET-1 treatment decreases autophagy and this 
is reversed back to basal levels upon addition of halofuginone (see Figure 4.9). 





Figure 4.9 Halofuginone reverses ET-1 induced increase in p62 protein levels in 
cardiomyocytes.  
Cells were treated with ET-1 in the presence and absence of halofuginone for 24 hours 
and protein levels of p62 were observed by Western blot analysis. 
4.4.3 Punctate localisation of LC3A/B is induced by halofuginone 
LC3 is a major component of autophagosomes and critical to the process of autophagy. 
There are three isoforms A, B and C and all are post-translationally modified during 
autophagy. LC3 is cleaved at its carboxy terminus leading to the formation of LC3-I, 
which is in turn conjugated to phosphatidylethnolamine by a ubiquitin-like system 
involving Atg7 and Atg3. Following this conjugation, the LC3-II, autophagic vesicles 
are formed, acquiring a punctate localisation within the cell. Following our data on gene 
expression and protein expression of autophagy markers inferring that halofuginone 
may enhance autophagy, I have attempted to verify this further by investigating 
immunofluorescence of LC3 assessing the presence of autophagosomes. 
It appears that upon addition of halofuginone to ET-1 treated cardiomyocytes, the 
amount of LC3A/B staining is increased in comparison to control (see Figure 4.10) 
verifying our data that halofuginone does increase autophagy. Chloroquine raises the 
lysosomal pH and is therefore an inhibitor of the lysosomal enzymes, which require an 
acidic pH, preventing the fusion of lysosomes with the autophagosomes leading to 
build-up of autophagosomes along with their contents within the cell. Chloroquine was 
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used as a positive control in our LC3A/B staining experiment to give us an insight into 




Figure 4.10 Immunofluorescence of LC3A/B protein upon halofuginone treatment.  
iPS cardiomyocytes have been treated with 1 nM ET-1 and 30 nM halofuginone for 24 hours and stained for LC3A/B (red). 25 µM 
chloroquine has been used as a positive control. Cells were fixed and permeabilised as described in the Materials and Methods section 2.14. 
LC3A/B was detected using appropriate antibodies shown in the Materials and Methods section 2.23 
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4.5 p38 activation by halofuginone and its downstream effects 
4.5.1 Halofuginone-mediated p38 activation mechanism in cardiomyocytes 
The effect of halofuginone on p38 activity in cardiac cells has not been previously 
investigated. Therefore, I was interested to explore activity of p38 in the halofuginone-
treated iPS cardiomyocytes. Surprisingly, halofuginone induces p38 phosphorylation 
and activity and this is reversed with addition of proline but not threonine suggesting 
that the effects of halofuginone on p38 are specific (see Figure 4.11). 
 
Figure 4.11 Western blot anaysis of p38 phosphorylation as a dose-response in 
halofuginone-treated NRVMs.  
Cells were treated with increasing concentrations of halofuginone for 24 hours and 
samples were boiled with sample buffer and Western blotting was carried out to 
determine the phospho- Thr180/Tyr182 p38 and total p38 levels using appropriate 
antibodies described in the Materials and Methods section 2.23 
 
p38 can be phosphorylated by its upstream kinases MKK3/6 or by autophosphorylation 
depending on the stimulus. In order to find out which pathway is involved in 
halofuginone-induced p38 activation, I have used SB239063 to block the kinase activity 
of p38 and therefore its autophosphorylation. Surprisingly, SB239063 increases the 
phosphorylation of p38 further (see Figure 4.12). The paradoxical enhancement of 
phospho-kinase signal when the kinase itself is inhibited has been previously shown 
with several kinases. The underlying hypothesis is linked to the ATP-binding region 
Pelin Arabacilar 
155 
being occupied by the inhibitors leading to intramolecular interactions that restrict 
phosphatase access and sustaining the phosphorylation rather than enhancement of 
upstream activators to compensate for kinase inhibition through a feedback loop (291, 
292).  
 
Figure 4.12 Halofuginone increases p38 phosphorylation and halofuginone-
induced p38 activity is SB-sensitive.  
iPS cardiomyocytes were treated with halofuginone in the presence and absence of 
SB239063, and TNF-alpha as positive control for 24 hours. Samples were boiled with 
sample buffer and Western blotting was carried out to determine the phospho-
Thr180/Tyr182 p38 and total p38 levels using appropriate antibodies described in the 
Materials and Methods section 2.23. 
 
4.5.2 Halofuginone-mediated p38 activation in HEK293 cells overexpressing 
TAK1 
Since I was unable to determine whether p38 activation by halofuginone was through 
the canonical pathway or via TAB1, due to the inhibitor-related phenomenon mentioned 
previously, I decided to have a look at the activity of the members of the canonical p38 
activation pathway, such as TAK1 and MKK3. However, due to a combination of very 
low abundance of these proteins and antibody challenges, I was not able to detect 
analysable signals in this case. Therefore, subsequent studies were performed in 
HEK293 cells, which can easily be transfected with vectors for these proteins to yield 
Pelin Arabacilar 
156 
an adequate signal to analyse the phosphorylation states. First, I determined the lowest 
concentration of halofuginone to induce the AAR pathway using phospho-GCN2 levels 
as the readout (see Figure 4.13).  
 
Figure 4.13 Activation of the AAR pathway in response to halofuginone treatment 
in HEK293 cells.  
Cells were treated with increasing concentrations of halofuginone for 24 hours. The 
phosphorylation of GCN2 and eIF2alpha were used as readouts of the activation of the 
AAR pathway by halofuginone. Samples were boiled with sample buffer and Western 
blotting was carried out to determine the phospho-Thr899 GCN2 and phospho-Ser51 
eIF2alpha levels using appropriate antibodies described in the Materials and Methods 
section 2.23.  
 
Following this, TAK1 overexpression and a TAK1 inhibitor, 5Z-7-oxozeaenol, were 
used to examine whether p38 activation mediated by halofuginone is via the canonical 
pathway. As expected halofuginone and borrelidin increase p38 phosphorylation (see 
Figure 4.14). This increase in p38 phosphorylation is augmented in TAK1-transfected 
cells, possibly due to a synergistic effect of TAK1 and halofuginone on p38 activation. 
Nonetheless, in these transfected cells, proline is unable to block the halofuginone-
mediated increase in phosphorylation, potentially due to the presence of TAK1 
maintaining p38 phosphorylation in the absence of halofuginone. p38 phosphorylation 
increases in response to the other AAR activator, Thr-tRNA synthetase inhibitor; 
borrelidin. As observed with halofuginone, there is a further increase in TAK1-
transfected cells after borrelidin treatment inferring a synergistic effect.  
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Besides their role in p38 phosphorylation, both halofuginone and borrelidin increase 
phosphorylation of TAK1. 5Z-7-oxozeaenol treatment blocks halofuginone and 
borrelidin-mediated TAK1 and p38 phosphorylation.  
 
Figure 4.14 TAK1 overexpression in HEK293 cells to examine the canonical p38 
activation pathway by halofuginone.  
Cells were transfected as described in the Materials and Methods section 2.9. 24 hours 
after transfection, cells were treated with halofuginone, borrelidin, 5Z-7-oxozeaenol and 
proline/threonine as above. Cells were incubated for 24 hours, after which cell lysates 
were obtained, samples were boiled with sample buffer and Western blotting was 
carried out to determine phospho-Thr180/Tyr182 p38, phospho-Thr184/Thr187 TAK1 
and total TAK1 levels were determined using appropriate antibodies described in the 
Materials and Methods section 2.23.  
 
4.5.3 Downstream activity of p38 activated by halofuginone treatment 
Furthermore, I wanted to investigate whether the halofuginone-induced phosphorylation 
of p38 correlates with increased activity. MAPKAPK-2 (MK2) is a well-known 
substrate of p38 and its phosphorylation was used as a measure of p38 activity. 
Halofuginone induces MK2 phosphorylation in an SB-dependent manner suggesting 





Figure 4.15 Halofuginone increases p38 activity in an SB-sensitive manner. 
iPS cardiomyocytes were treated with halofuginone in the presence and absence of 
SB239063, and TNF-alpha as positive control for 24 hours. Samples were boiled with 
sample buffer and Western blotting was carried out to determine the phospho-Thr334 
MK2 and B-actin levels using appropriate antibodies described in the Materials and 
Methods section 2.23. 
 
4.5.4 Negative regulation of the AAR pathway through p38 activity 
AAR pathway has been previously shown to induce the expression of CHOP (182, 293) 
in support of the observations in our studies in halofuginone-induced cardiomyocytes. 
p38 augments the activity of CHOP as a transcription factor by phosphorylating it on 
two adjacent serine residues (78 and 81) (294). However, it has not yet been 
demonstrated whether p38 regulates CHOP at a transcriptional level. As halofuginone 
increases CHOP transcription and activates p38, I tested the hypothesis that p38 plays a 
role in the induction of CHOP transcription by halofuginone. Halofuginone-induced 
CHOP gene expression does not appear to be SB-sensitive, therefore does not occur 




Figure 4.16 The effect of SB239063 on the gene expression of Ddit3, Asns and Gadd34 in halofuginone-treated iPS cardiomyocytes.  
Cells were treated with halofuginone in the presence and absence of SB239063 for 24 hours and real time reverse transcription-PCR 
analysis of Ddit3, Asns and Gadd34 was performed. *, p<0.05; **, p<0.01; ***, p<0.001 ANOVA compared to control. 
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It would have been interesting to examine the phosphorylation state of the CHOP 
residues regulated by p38 upon halofuginone and SB treatment. Unfortunately, as of yet 
there are no antibodies recognising these sites in CHOP. Therefore, downstream targets 
of CHOP-regulated transcription, growth arrest and DNA damage-inducible protein 34 
(GADD34 - gene name PPP1R15A) and ASNS were observed as readouts of CHOP 
activity and to determine SB-sensitivity. Asns gene expression is known to increase in 
response to amino acid limitation (293), and interestingly CHOP has been shown to 
suppress ASNS gene expression (188). I have seen that both CHOP (DDIT3) and ASNS 
increase upon halofuginone treatment.  Upon SB239063 addition to halofuginone-
treated cardiomyocytes, the gene expression of ASNS induced by halofuginone increases 
further (see Figure 4.16). This suggests that the p38-induced enhancement of CHOP 
activity negatively regulates and dampens halofuginone-induced ASNS gene expression. 
GADD34 recruits the serine/threonine phosphatase, PP1, to dephosphorylate eIF2alpha 
in order to reverse the halt in protein translation caused by stress-induced kinases 
upstream of eIF2alpha such as GCN2. Previous studies have shown that GADD34 
(PPP1R15A) gene expression is regulated by p38 and CHOP (295, 296) though in 
different contexts. I have used SB to test our hypothesis that the negative regulation of 
the amino acid response pathway is via p38-induced CHOP activity. The increase in 
PPP1R15A gene expression by halofuginone is SB-sensitive and thus via p38 activity, 
possibly through enhancing CHOP activity by phosphorylation (see Figure 4.16). 
 
4.5.5 The effect of halofuginone on the inflammation response in cardiomyocytes 
Halofuginone is known to be a potent anti-inflammatory agent and has previously been 
associated with inhibition of p38 in activated T-cells (225). As p38 has previously been 
associated with inflammation and interestingly halofuginone, an anti-inflammatory 
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agent, activates p38; I decided to look at some downstream substrates previously 
associated with p38 in inflammation. In iPS cardiomyocytes, these were 
cyclooxygenase-2 (gene PTGS2), IL-1 receptor (IL1R1), IL-6 (IL6), and IL-1 receptor 
antagonist (IL1RN). PTGS2 and IL6 gene expression increase significantly upon 
halofuginone treatment (see Figure 4.17). The results were variable for IL1R1 and 
IL1RN, but halofuginone on its own appears to reduce both of these genes. 
  
  
Figure 4.17 Gene expression of inflammation-related genes in halofuginone-treated 
iPS cardiomyocytes.  
Cells were treated with ET-1 in the presence and absence of halofuginone for 24 hours 
and real time reverse transcription-PCR analysis of IL1R1, IL1RN, IL6 and PTGS2 was 
performed. *, p<0.05; **, p<0.01; ***, p<0.001 ANOVA compared to control. 
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4.6 Characterising lentiviral vectors for overexpression of 
constitutively active GCN2, WT GCN2 and shRNA against GCN2 
The hypothesis of this project is that halofuginone activates several responses through 
GCN2. Nonetheless, from our previous studies I have seen that halofuginone has many 
off-target effects. Therefore, in order to ensure that the effects I see are through the 
AAR pathway, I have utilised lentiviral vectors in order to knock down and overexpress 
GCN2. Below is the list of lentiviral vectors that I have used: 
Table 4.1 Lentiviral vectors used to transduce iPS cardiomyocytes for overexpression 
and knock down of GCN2 
 
Sample ID Sample Comments 
GCN2 2X pLex GCN2 Overexpression vector for 
WT-GCN2 
B. SHC201 TRC2 pLKO.5-puro Empty 
Vector Control 
Empty vector 
pLex GFP pLex GFP GFP control vector for the 
overexpression vectors 
#1 TRCN0000300850 shRNA #1 
#2 TRCN0000300851 shRNA #2 
#3 TRCN0000304216 shRNA #3 – problems 
cloning 
#4 TRCN0000304149 shRNA #4 
#5 TRCN0000304214 shRNA #5 
GCN2 
S808G 
pLex GCN2 S808G Overexpression vector for 




pLex GCN2 F855L Overexpression vector for 
constitutively active GCN2 
#2 
 
Firstly, I have used four of the five shRNAs, as shRNA #3 had extremely low titre, the 
producer group did not recommend using it. In order to test the optimal virus:media 
ratio to transduce the cells with, without causing toxicity; I have designed an 
experiment using three different percentages of the virus and looking at GCN2 (gene 
name EIF2AK4) mRNA levels. 25% virus gave a good gene expression increase (with 
the overexpression vector)/knockdown (with the shRNA vectors) to virus percentage 
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ratio; therefore I went ahead with further experiments using this percentage of virus. 
From the four shRNA vectors, shRNAs 1 and 2 gave the best level of knockdown (see 
Figure 4.18), therefore I have used these two vectors in future experiments.
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Figure 4.18 Characterising the lentiviral vectors and exploring different percentages of virus for optimal transduction of iPS 
cardiomyocytes.  
Cells were transduced with lentiviral vectors; pLexGCN2, SHC201 TRC2 pLKO.5-puro empty vector control and the shRNA vectors 
TRCN0000300850, TRCN0000300851, TRCN0000304149 and TRCN0000304214 as described in Materials and Methods section 2.20. 
10%, 25% and 50% of lentiviral vectors in maintenance media have been used to determine optimal transduction percentages. Real time 
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4.7 Using lentiviral vectors to explore the off-target effects of 
halofuginone 
In order to ensure that GCN2 was successfully overexpressed and knocked down 
depending on the vector used, I checked the mRNA levels of GCN2. It appeared that 
mRNA levels of GCN2 increase with the overexpression vectors, pLEXGCN2 for WT 
GCN2, pLEXGCN2 F855L for constitutively active GCN2 and decrease with the 
shRNA vectors, Sh850 and Sh851, as expected. GCN2 mRNA levels increase further 
with halofuginone treatment when the vector pLEXGCN2 is used (see Figure 4.19). 
However, using the overexpression vector for constitutively active mutant GCN2; 
pLEXGCN2 S808G, transduction does not seem to have worked as there is no increase 
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Figure 4.19 Confirming the overexpression and knock down of GCN2 mRNA 
using lentiviral vectors in halofuginone-treated iPS cardiomyocytes.  
Cells were transduced with lentiviral vectors, pLexGCN2 and shRNA vectors 
TRCN0000300850 and TRCN0000300851, as described in Materials and Methods 
section 2.20. The cells were treated with halofuginone for 24 hours and real time reverse 
transcription-PCR analysis of EIF2AK4 was performed. 
 
To confirm that the knockdown and overexpression were successful, protein levels of 
total GCN2 were evaluated. These results support the observations in mRNA levels, 
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with an increase in total GCN2 levels with the overexpression vectors, pLEXGCN2 and 
pLEXGCN2 F855L and a decrease with the shRNA vectors (see Figure 4.20). As with 
the mRNA levels, there is no increase in GCN2 protein with the pLEXGCN2 S808G 
mutant suggesting that transduction has not worked. 
Once the overexpression and knockdown were successful, the effect on the downstream 
substrates in the AAR pathway were explored. Our hypothesis was that the effects of 
halofuginone would be amplified with overexpression, and diminished or reduced with 
shRNA. Observing the phosphorylation state of eIF2alpha, it is clear that the 
phosphorylation level of GCN2 is not reflected by eIF2alpha phosphorylation. Even 
after knocking down GCN2, eIF2alpha is phosphorylated upon halofuginone addition 
(see Figure 4.20). eIF2alpha is phosphorylated in the presence of the F855L mutant 
despite an absence of halofuginone, though adding halofuginone to these cells reveals 
an further increase in eIF2alpha phosphorylation, possibly due to the additive effect of 
endogenous GCN2 ativating eIF2alpha as well. 
 
Figure 4.20 Halofuginone induces eIF2alpha phosphorylation regardless of GCN2 
overexpression/knock down.  
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Cells were transduced with lentiviral vectors; pLexGCN2 and shRNA vectors 
TRCN0000300850 and TRCN0000300851, as described in Materials and Methods 
section 2.20. The cells were treated with halofuginone for 24 hours. Samples were 
boiled with sample buffer and Western blotting was carried out to determine the 
phospho-Thr899 GCN2, total GCN2, phospho-Ser51 eIF2alpha and total eIF2alpha 
levels using appropriate antibodies shown in the Materials and Methods section 2.23. 
 
 
In addition, observing the mRNA levels of DDIT3, it appears that whether or not GCN2 
is overexpressed or knocked down, the increase in DDIT3 mRNA levels stays the same 
(see Figure 4.21). In the case of knockdown, this could be due to the small amount of 
GCN2 present being sufficient to induce this response. Alternatively, it could be a 
compensation mechanism by the other kinases upstream of eIF2alpha. In the case of 
overexpression, it is possible that increasing GCN2 levels further does not have an 
effect, as the small amount of GCN2 is enough to elicit the response observed with 
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Figure 4.21 Halofuginone induces DDIT3 gene expression regardless of GCN2 
overexpression/knock down.  
iPS cardiomyocytes were transduced with lentiviral vectors; pLexGCN2 and shRNA 
vectors TRCN0000300850 and TRCN0000300851, as described in Materials and 
Methods section 2.20. The cells were treated with halofuginone for 24 hours and real 
time reverse transcription-PCR analysis of DDIT3 was performed. 
 
As previously shown p38 is phosphorylated by halofuginone treatment and it would be 
interesting to explore the mechanism through which this happens. In order to investigate 
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whether this effect of halofuginone is GCN2-dependent, I have looked at cells 
transduced with the constitutively active mutant pLEXGCN2 F855L, and whether p38 
was activated in these cells in the absence and presence of halofuginone. It appears that 
p38 is not active unless halofuginone is present, regardless of GCN2 phosphorylation 
state (see Figure 4.22). Therefore, it is possible that p38 is activated by a GCN2-
independent mechanism.  
 
Figure 4.22 Halofuginone effects on p38 phosphorylation appears to be GCN2-
independent.  
iPS cardiomyocytes were transduced with lentiviral vectors; SHC003 pLKO.1-puro-
CMV-TurboGFP, pLexGCN2 and shRNA vectors TRCN0000300850 and 
TRCN0000300851, as described in the materials and methods. The cells were treated 
with halofuginone for 24 hours and protein levels of phosphorylated and total GCN2 






There is a large body of literature relating to the function of p38α or TAB1. However, 
little is known concerning the mechanism of interaction between these two proteins and 
of the consequent activation of p38α. Even less is known about the substrates 
specifically phosphorylated by this unusual activation pathway. Some studies suggest 
that this TAB1-mediated activation pathway is specific to myocardial ischaemia and 
aggravates myocardial injury. However, this is not the only function of TAB1 as it also 
plays a role in the canonical pathway of p38α activation by binding to TAK1. Once 
p38α is activated, it phosphorylates TAB1. The phosphoform of TAB1 is meant to be 
less able to activate TAK1, closing a negative feedback loop. Nonetheless, if the direct 
effect of TAB1 on p38α activation is proven specific to ischaemia, discovering the 
mechanism of this pathway could provide new therapeutic targets for cardiovascular 
medicine. 
5.1 There is a TAB1-mediated p38α autophosphorylation mechanism 
p38α is involved in many cellular processes ranging from apoptosis to cell 
differentiation depending on cell types and stimuli. The main activation cascade of p38α 
is the MAPKKK pathway and this is involved in response to inflammatory cytokines 
and oxidative stress (71). Nonetheless, the other activation mechanism of p38α via 
autophosphorylation mediated by TAB1 has been described during ischaemia 
aggravating injury in the heart (29). In order to gain more insight into this mechanism I 
have shown that p38α autophosphorylation is increased by co-expression with TAB1 
(see Figure 3.3). It has been shown in other studies that p38α phosphorylation and 
ischaemic injury is increased in mice lacking MKK3, inferring that the canonical 
pathway is not the main contributor to p38α activation during myocardial ischaemia (28, 
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29). Though still in need of further research and confirmation, if TAB1 effects on p38α 
are specific to ischaemia, as suggested by current studies, this mechanism could be 
taken advantage of to combat myocardial infarction by reducing the injury. 
5.2 TAB1-mediated p38α autophosphorylation is SB203580-sensitive 
Being an ATP-mimetic type I inhibitor of p38α, SB203580 blocks p38α activation by 
directly binding to the p38α ATP-binding site (297, 298). I have shown that TAB1-
mediated p38α phosphorylation is diminished upon addition of SB203580 (see Figure 
3.3). SB203580 prevents the binding of ATP and therefore p38α cannot phosphorylate 
itself or its substrates as it requires the gamma phosphate group of ATP. There are 
studies showing that SB203580 does not act on other members of the canonical 
MAPKKK pathway of p38α activation (299) so the inhibition is specific to p38α itself 
and not due to any off-target effects.  
In the cardiac context, a study in MKK3-/- mice reported diminished p38 
phosphorylation and reduced infarct volume with the use of SB203580, but TNF-α 
induced activation of p38 was not affected (29). In addition, p38 was associated with 
TAB1 in ischaemic hearts but not in hearts treated with TNF-α. Using SB203580 as a 
tool to block p38 kinase activity, the reduction in infarct size implies that p38 
autophosphorylation plays at least a partial role in the induction of ischaemic injury and 
it is likely this is through an interaction with TAB1. 
5.3 SB203580 binds to Thr106 of p38α and blocks ATP-binding 
A particular region of p38α structure is important for the unique interaction of the 
fluorophenyl ring of SB203580. In our studies, mutating the key residue for SB-binding 
in this region, Thr106, to Met in the drug-resistant version of p38α, diminishes binding 
of SB203580 and therefore the TAB1-mediated phosphorylation is not affected upon 
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addition of SB203580 (see Figure 3.3). Nonetheless, when Thr106 is mutated to Ala, 
there is no effect on the activity of SB203580 (300). p38γ and p38δ lack the residues 
Thr106, His107 and Leu108 which are important for SB203580 binding so SB203580 is 
only inhibits p38α and p38β. When these residues are introduced into p38γ and p38δ, 
SB203580 is able to inhibit their phosphorylation (301). Therefore, Thr106 is important 
for SB203580 binding and is required for the inhibition of p38α activation. 
5.4 Certain points of interaction are important for TAB1-p38α 
binding 
Identifying interaction points and essential amino acids in protein sequences for 
substrate binding is important in cell biology. It enables the determination of the regions 
which may overlap with other binding partners or give an in-depth insight to the nature 
of the protein-protein interaction in question. There is not much information yet on 
which residues are important to the p38α and TAB1 interaction. Nonetheless, the effect 
of different mutations of TAB1 and p38α and truncated versions of these proteins on 
this interaction has been investigated. It appears that Pro412 in TAB1 and Ile116 and 
Gln120 in p38α are essential for TAB1-p38α recognition. However these residues are 
only important in the direct binding of TAB1 and p38α and their substitution does not 
appear to influence MKK6-mediated p38α activation (302). In addition, mutating the 
CD and ED domains of p38α did not have an effect on TAB1 interaction, suggesting a 
dissimilarity between TAB1 and most other p38α binding partners. Nonetheless, in 
common with other p38α substrates TAB1 also has a D-domain though this differs from 
the consensus motifs in other substrates. 
As already mentioned, I have found through X-ray crystallography that TAB1 interacts 
with p38α on two regions; the common docking region (canonical), which is shared 
with other binding partners of p38α such as MEF2C and MKK3 and a unique 
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hydrophobic groove (non-canonical), which appears to be specific to TAB1 binding 
alone. Using peptides of TAB1 involved in binding to each of these regions I found that 
the canonical region of TAB1 is more important in inducing p38α autophosphorylation 
than the non-canonical region(see Figure 3.5), which is most obvious after 4 hr 
incubation. 
5.5 TAB1 mutations at interaction points decrease p38α 
autophosphorylation 
In order to support the data inferring that the canonical region of TAB1 is more 
important in inducing p38α autophosphorylation, TAB1 versions mutated at either or 
both the common docking binding region and the section binding to the unique 
hydrophobic groove of p38α were used to investigate the effect of mutations in these 
regions. Substituting bulkier residues found in WT TAB1 with smaller residues in order 
to diminish interaction with p38α, TAB1 mutants were tested in bacterial and 
mammalian cell lines. Supportive of our findings of the canonical peptide increasing 
phosphorylation of p38α, there was reduced p38α phosphorylation when the residues 
important in the TAB1-p38α interaction were mutated at the common docking domain 
binding region of TAB1 (see Figure 3.6 and Figure 3.7). However, there was also a 
reduction in p38α phosphorylation when the residues of TAB1 involved in binding to 
the unique hydrophobic groove were mutated. This suggests that both regions of TAB1 
play an important role in p38α phosphorylation in the context of full-length protein. 
5.6 TAB1 mutations affect TAB1 substrate presentation 
Difficulty determining whether TAB1 phosphorylation decreases due to the decreased 
phosphorylation of p38α or due to TAB1 mutations causing a deficiency in TAB1 
substrate presentation to p38α was overcome by mimicking a constitutively active p38α 
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by co-transfecting cells with MKK3b and p38α. It seems that there is no difference in 
p38α phosphorylation upon addition of different TAB1 mutants to this co-transfection, 
except only a slight decrease with the CM/NCM mutant version of TAB1 (see  
Figure 3.8). This suggests that p38α is active enough to give us an understanding of 
differences in TAB1 phosphorylation with different mutants. The phosphorylations of 
p38α caused by MKK3 and TAB1 were analysed separately and in combination to 
confirm that p38α phosphorylation was due to MKK3 and TAB1 addition did not alter 
p38α activation by MKK3. Unlike p38α phosphorylation, TAB1 phosphorylation is 
decreased to basal levels with the CM/NCM mutant of TAB1. Therefore, TAB1 
substrate presentation is markedly reduced when both interaction points are mutated. 
5.7 TAB1 phosphorylation does not affect TAK1 phosphorylation 
As discussed earlier, TAK1 is the MAP3K upstream of MKK3/6 in the p38 canonical 
activation pathway and TAB1 plays a role in its activation. Through the yeast two-
hybrid system, TAB1 and TAB2 have been identified to interact with TAK1 and TAB1 
and TAK1 have been co-immunoprecipitated in mammalian cells (303). In addition, 
TGF-β signal transduction through TAK1 is increased with enhanced TAB1 levels 
(303). It has been reported that autophosphorylation of two Thr residues in the 
activation loop of TAK1 is required for its activation and this is facilitated through an 
association with TAB1 (304). The C-terminal of TAB1 consists of two functional 
subdomains and is essential for full TAK1 activation. 
TAB1β is a splice variant of TAB1 in which the 69 C-terminal residues are replaced 
with an unrelated 27-amino acid sequence. Therefore, as expected, TAB1β does not 
bind or activate TAK1, yet is still able to stimulate p38 activation (35). Ge et al. have 
determined that TAB1β does not bind or activate TAK1 through immunoprecipitations 
and an activity assay using MKK4 as a substrate, respectively. I have verified the lack 
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of TAK1 phosphorylation upon co-expression of TAK1 and TAB1β in HEK293 cells 
using phospho-TAK1 specific antibodies (see Figure 3.9). 
Furthermore, TAK1 activation is enhanced by SB203580 in macrophages stimulated by 
LPS and proinflammatory cytokines, as well as in TNF-α-treated embryonic fibroblasts 
from p38α-/-  mice (279). SB203580 had no effect in cells from p38α-/- mice, suggesting 
that in some way, p38α provides a negative feedback system on TAK1 activity. TAB1 
sites that are phosphorylated by p38α, lie around the regions of TAB1 that are involved 
in p38 and TAK1-binding, which are adjacent to each other. Cheung et al. suggest that 
since TAK1 is not a substrate for p38α, it is probably the phosphorylation of TAB1, 
which prevents TAK1 activation through a conformational change or via the stimulation 
of TAK1 deactivation. Another possibility is a negative feedback system on TAK1 
through a different protein in the complex, such as TAB2, which is downregulated by 
p38α. To our surprise, I did not find the phosphorylation state of TAB1 to affect TAK1 
phosphorylation (see Figure 3.9 and Figure 3.10). The reduction in TAB1 
phosphorylation due to mutations preventing its substrate presentation to p38 or by 
pharmacologic inhibition of p38 by SB203580 did not have an effect on TAK1 
phosphorylation. This, coupled with Cheung et al.’s data suggest that it is possible that 
p38 downregulates TAK1 activity via a different route than TAB1 phosphorylation. 
5.8 The competition between TAB1 and MKK3 in binding to p38 
It has been previously mentioned that p38 plays a role in a wide range of processes 
within a cell, with a main downstream effect being inflammation. The onset and 
progress of the pathophysiology of heart failure has been associated with an elevated 
inflammatory response (305, 306). p38 activation has  been associated with several 
pathological features in the cardiac context such as neuro-hormonal and mechanical 
stimulation, as well as ischaemic injury (307, 308). As already mentioned TAB1 is 
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involved in the canonical activation pathway of p38, as well as an independent 
autophosphorylation mechanism. The evidence that TAB1 might also play a role in the 
negative feedback on the canonical activation mechanism, highlights the multifunctional 
potential of TAB1. 
It has been reported that TAB1 prevents nuclear localisation of p38 and attenuates the 
MKK3-mediated induction of inflammatory gene expression by p38 (32). It appears 
from this study that TAB1 can mediate MKK3-independent activation, while 
simultaneously negatively regulating MKK-dependent effects on p38. In this study in 
rat neonatal ventricular cardiomyocytes (RNVC), p38 is localised throughout the cell 
cytoplasm and nucleus when co-expressed with MKK3, yet upon co-expression with 
TAB1, it is excluded from the nucleus. The authors conclude that intracellular 
localisation of p38 and its complex interactions determine downstream effects. 
Homologous docking sites exist in MAPK scaffold proteins (276) and all of the docking 
site sequences identified contain a basic region and a hydrophobic region (277). One of 
the consensus motifs shared by some of these proteins is R/K-X4-φA-X-φB (where φA 
and φB are hydrophobic residues [Leu, Ile, or Val]). A study on the crystal structure of 
p38 and peptides derived from two of its binding partners MKK3b and MEF2A 
revealed that these two proteins share a common docking groove that interacts with the 
hydrophobic φA-X-φB motif of docking peptides (278). The docking groove on p38 
shared by these peptides contains residues Ile116 and Gln120, which are key to 
recognition of the φA-X-φB motif. Both MKK3b and MEF2A bind in the same groove 
and trigger similar changes in local conformation, but different conformational changes 
occur in the active site. As mentioned previously, two regions of interaction were 
identified for TAB1 and p38, the canonical upper domain and the unique hydrophobic 
groove i.e. the non-canonical domain. The canonical upper site of p38 referred to in De 
Nicola et al.’s study, as well as in our studies, overlaps with the region of p38 used for 
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interaction by its binding partners such as MKK3b and MEF2A (34). Therefore, due to 
the above evidence, I have hypothesised that there is potential for competition between 
TAB1 and MKK3b to compete in binding to p38. 
Through ITC, I have observed that the interaction between MKK3b and p38 is altered 
by the addition of the TAB1 peptide (see Figure 3.11), which suggests that there is 
potential for competition in binding to p38 between these two proteins. This data is 
supported by IVK assays, in which the presence of TAB1 decreased MKK3b-mediated 
p38 phosphorylation. This is more obvious when TAB1-mediated phosphorylation of 
p38 is blocked by SB203580 whilst binding remains unaffected, however MKK3b-
mediated p38 phosphorylation remains reduced (see Figure 3.14). Nonetheless, to our 
surprise, there appears to be no competition between TAB1 and MKK3b in p38 binding 
in HEK293 cells (see Figure 3.16 and Figure 3.18). One possible reason to explain these 
discrepant results is that in ITC and IVK assays the native in-cell localisation of 
proteins is irrelevant since close proximity is forced by purity and artificial nature of the 
assay. Therefore, the likelihood of an alteration in existing interactions by addition of 
another protein is possible through mere steric hindrance due to the presence of the 
newly added protein. However, in the in-cell system, proteins are located where they 
would be natively and the results obtained from these methods are more reliable 
regarding the biological function of proteins.  
To confirm the differential localisation of p38 in the presence of TAB1 and MKK3b, 
immunofluorescence of these proteins when co-expressed with p38 on their own or both 
at the same time were observed. TAB1 appears to be localised more in a perinuclear 
fashion, whereas MKK3b is confined to sub-cell membrane region (see Figure 3.19). 
When p38 was co-expressed with each of these binding partners it appears to be co-
localised with its binding partner. Nonetheless, when both MKK3b and TAB1 are 
overexpressed beside p38, p38 predominantly localises with MKK3b. This is different 
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from what is observed in Lu et al.’s study (32) in that TAB1 triggers the relocation of 
p38 towards the nucleus, instead of excluding it from there. In addition, another 
difference from Lu et al.’s study is that I have not observed a competition or difference 
in MKK3-mediated activity whereas they have. This could be due to the difference in 
cell type and transfection methods. Nonetheless, in both cases, TAB1 and MKK3b have 
differential locations and they alter the location of p38. This explains why the MKK3b-
mediated phosphorylation of p38 is not altered by the presence of TAB1 as they are in 
different locations within the cell and MKK3b is more dominant at attracting p38 to it. 
5.9 ET-1 release in stress and its effects in the cardiac context 
As previously discussed, ET-1 is synthesised in and acts on the ETA and ETB receptors 
in cardiomyocytes, cardiac fibroblasts and heart endothelial cells. Plasma ET-1 
concentrations are increased in various pathological conditions such as myocardial 
infarction (309), atherosclerosis (310) and chronic heart failure (CHF) (248, 311, 312) 
in humans as well as in experimental models. In chronic heart failure, the severity of 
symptoms and hemodynamic malfunction appear to correlate with plasma levels of ET-
1, which can also be used as a prognostic guide in these patients (311, 313). ET-1 has a 
broad range of downstream effects, with a main feature being its role in the induction of 
neurohormones such as vasopressin, angiotensin II and norepinephrine, important in the 
progression of heart failure. ET-1 stimulates cardiac hypertrophy and plays a key role in 
ventricular remodelling (244, 314, 315). Aortic banding in rats leads to an increase in 
the mRNA levels of ET-1, BNP and β-myosin heavy chain (β-MHC – gene name 
MYH7) (315). ET-1 treatment in isolated rat aorta leads to an increase in BNP gene 
expression (316) and ET receptor antagonist improved the changes observed in various 
hypertrophy-related genes in failing hearts of CHF rats. ANP, β-MHC, ryanodine 
receptor, sarcoplasmic reticulum Ca2+-ATPase (SERCA2A), angiotensin-converting 
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enzyme (ACE), angiotensin II type 1 receptor, and prepro-ET-1mRNA levels were 
improved in these rats (317). The natriuretic peptides are active hormones involved in 
diuresis and the reduction of blood pressure and the plasma levels of these hormones 
can be used as a prognostic indicator of left ventricular ejection fraction and mortality in 
CHF patients. I have shown in our experiments that mRNA levels of ANP, BNP, ratio 
of β-MHC to α-MHC (gene name MYH6) and SERCA2A are altered in response to ET-
1 treatment in cardiomycytes (see section 4.2). As discussed earlier, internalisation of 
ET receptors have been proposed as a negative feedback system (238) and using 
different concentrations of ET-1, I have found that above a certain concentration the 
responses to ET-1 are blunted, possibly due to an internalisation of receptors (see Figure 
4.5). 
In the case of chronic heart failure in patients and animal models, acute administration 
of bosentan, a competitive antagonist of ET-1 at the  ETA and ETB receptors, decreases 
vascular resistance and improves left ventricular function (318-320). ETA selective 
antagonism using BQ-123 in patients resulted in an increased cardiac index. 
Nonetheless, though it appears logical to target the ET-1 pathway in heart failure, 
clinical trials with compounds targeting this system have not been successful (321). In a 
recent clinical trial, Endothelin Antagonist Bosentan for Lowering Cardiac Events in 
Heart Failure (ENABLE), treatment with bosentan lead to worsening of heart failure 
and subsequent hospitalisation, as a result of fluid retention (322). 
5.10 Hypertrophy in cardiomyocytes and the role of the AAR pathway 
Left ventricular hypertrophy is one of the main risk factors for heart failure. 
Hypertrophy induces myocardial tissue remodelling and can lead to disturbances in 
myocardial blood flow and diastolic dysfunction. 
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The role of ET-1, its receptors and downstream effects in heart failure has been 
discussed previously. ET-1 plays an important role in the heart and regulates myocardial 
contractility, and increases in both experimental models of heart failure and in patients 
(248, 323). In order to maintain the circulatory homeostasis, several endogenous 
vasodilators and antagonists of ET-1 exist. Two of these are ANP and BNP, with 
increased levels in heart failure positively correlating with severity of the disease (324), 
suggesting an adaptive mechanism to balance the effects of vasoconstrictor hormones 
such as ET-1. 
As ANP and BNP levels are indicators of the disease severity, a cardioprotective 
compound would reduce these levels. Upon exposure of ET-1-treated cardiomyocytes to 
halofuginone ANP and BNP levels are reduced (see Figure 4.6). This result, in 
combination with the other cardioprotective effects of halofuginone observed suggests 
the AAR pathway is a promising target with therapeutic potential in heart failure.  
Nonetheless, the efforts of several groups aiming to explore the potential benefits of 
increasing ANP and BNP levels must be considered (325-327). Authors have concluded 
that a prominent increase in natriuretic action improves ventricular dysfunction in 
patients with heart failure. Therefore, caution must be taken when analysing such 
decreases in ANP and BNP levels to ensure that these decreases do not block the 
protective mechanisms present in the cell as a response to the stress but indeed are a 
result of the cardioprotective effects of halofuginone. 
MHC-β to MHC-α ratio was not altered by ET-1 treatment or by exposure to 
halofuginone (see Figure 4.6). This could be due to the induction time required for the 
changes to occur being different than the one applied in these experiments. It is possible 
that ANP and BNP act much faster than the transition of MHC isoforms in response to 
ET-1. In experiments in animal models to induce changes in MHC expression levels, 
much longer induction times were employed (328). Another possibility is that MHC 
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proteins are not a target of the AAR pathway, though this is a low possibility as the 
MHC-β is an energy-preserving protein, which would fit in well with the starvation 
response. 
Furthermore, a recent study in GCN2 knockout mice that have undergone transverse 
aortic constriction (TAC) has reported a protected phenotype compared to the wild-type 
controls, which is surprisingly contrary to our hypothesis and data. The expression of 
the anti-apoptotic protein Bcl-2 was elevated in GCN2 knockout hearts and the authors 
concluded that GCN2 prevents ventricular adaptation to pressure overload through a 
reduction of Bcl-2 making cardiomyocytes more susceptible to apoptosis. Nonetheless, 
the explanation for this could be the fact that GCN2 is a stress-response kinase and can 
induce apoptosis depending on the level of stress. In terms of autophagy in this model, 
beclin-1 and LC3B levels are significantly attenuated in GCN2-/- hearts and increased in 
wild-type controls. This supports our data in that GCN2 is involved in increasing 
autophagy, which is a controversial mechanism in heart failure regarding its 
adaptive/maladaptive status. Taking into account the data in GCN2 knockout animals, 
further research is required to explore the role of the AAR pathway in heart failure. 
5.11 Autophagy in cardiomyocytes and the role of the AAR pathway 
Autophagy is the degradation process within a cell important to maintain cell function, 
remove damaged organelles and provide the building blocks for new protein synthesis. 
In heart failure, characteristics of autophagy can be observed in damaged 
cardiomyocytes and it appears to be a failed repair mechanism or a pathway to result in 
apoptosis. Evidence for autophagy was observed in tissue samples of dilated 
cardiomyopathy in end-stage heart failure patients (329). Upon adrenergic overload in 
cardiomyocytes, there was an increase in punctate staining of LC3 (330). In a TAC 
model of mice, autophagosome accumulation was observed as early as 24 hr after TAC 
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and remained at increased levels for 2 weeks (331). Another group reported that 
autophagy is suppressed 1 week following TAC, but upregulated simultaneously with 
left ventricular dysfunction after 4 weeks (137). As discussed in section 1.6.6, 
autophagy in the cardiac context is controversial and there is evidence for its occurrence 
in heart failure being both adaptive and maladaptive depending on the context. 
Amino acid homeostasis is regulated by the integrated stress response and autophagy. 
Mechanistic target of rapamycin complex 1 (mTORC1) plays a key role in autophagy 
and it inhibits autophagy by phosphorylating the kinase involved in the induction of 
autophagy, ULK1 (332). Several studies have shown that ER stress leads to the 
induction of autophagy as a survival mechanism and it has been reported that the 
eIF2alpha/ATF4 pathway plays an important role in autophagy (333, 334). Induction of 
an increase in the gene expression of Map1lc3b in response to ER stress and hypoxia 
has been reported in recent studies (335). The upregulation of autophagy appeared to be 
essential to maintain autophagy and for cell survival. Upon amino acid starvation, it was 
reported that GCN2-mediated phosphorylation of eIF2alpha is crucial to induce 
autophagy (336, 337). The role of eIF2alpha in the initiation of the autophagy response 
is not yet clear, however one highly likely mechanism is through its effects on the 
physical formation of autophagosomes at the ER. Another possible mechanism is the 
ATF4-mediated stimulation of genes involved in autophagy. Though it appears that 
ATF4 is involved in the autophagy response through eIF2alpha (338), the target genes 
involved in this process remains to be elucidated. A third possibility is the interaction of 
eIF2alpha with core autophagy proteins, though the importance of these interactions is 
yet to be determined (339).  
Using halofuginone to trigger the AAR pathway through eIF2alpha phosphorylation, 
several genes were identified to be upregulated in response to this pathway in 
cardiomyoyctes. ULK1, ULK2, GABARAPL1 and MAP1LC3B gene expression were 
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increased significantly in response to halofuginone treatment alone and in the presence 
of ET-1 treated cells (see section 4.4.1) suggesting that the activation of the AAR 
pathway does increase autophagy, at least in part, at the gene expression level.  
To date, a well-established method to identify the occurrence of autophagy is the 
detection of LC3 processing by Western blot analysis and the observation of 
immunofluorescence of autophagosome components. Observing immunofluorescence 
of LC3A/B, I have identified an increase in autophagosome formation in halofuginone 
treated cardiomyocytes (see Figure 4.10) which was in support of our gene expression 
data inferring that the activation of the AAR pathway does appear to induce autophagy. 
However, there is a caveat in this readout, which is the fact that autophagy is a dynamic 
and multi-step process. The accumulation of autophagosomes could suggest an increase 
in overall autophagy or it could be due to the malfunctioning of the proteins 
downstream of this process, such as a decrease in lysosomal fusion. A good example of 
this is chloroquine, a lysosomotropic agent which accumulated inside the acidic parts of 
the cell such as the lysosomes. Lysosomal enzymes require an acidic pH to function 
(340, 341) and chloroquine inhibits autophagy as it raises the lysosomal pH preventing 
the fusion of lysosomes with autophagosomes, leading to the accumulation of 
autophagosomes (342). Therefore, the mere detection of an increase in autophagosome 
formation is not a reliable measure of the overall autophagy within the cell. As already 
discussed in section 4.4.2, p62 protein levels correlate negatively with the level of 
autophagy within a cell. p62 is degraded itself after recruiting proteins to be degraded 
into the autophagosome, and can therefore be used to measure autophagic flux i.e. the 
dynamic process of autophagy and the turnover of amino acids during autophagy. In 
support of the increase in the expression of genes involved in autophagy, p62 levels also 
indicated an increase in autophagy following halofuginone treatment (see Figure 4.9). 
Therefore, it appears that the activation of the AAR pathway with halofuginone 
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treatment increases autophagy at several different steps in cardiomyocytes. This could 
be due to the mechanisms discussed above, as eIF2alpha activation appears to induce 
changes in gene expression and this is supported by downstream readout of autophagic 
flux. 
5.12 p38 activation in inflammation and halofuginone 
As previously discussed in section 1.6.7, p38 plays a key role in inducing inflammation 
and its pharmacological inhibition is beneficial in the context of heart failure. It has 
been previously reported that halofuginone inhibits TGF-β (343), an important 
immunomodulator that is downstream of p38. Halofuginone treated T cells exhibit a 
dose-dependent decrease in NFκB besides an inhibited secretion of TNF-α, interferon γ 
(IFN-γ), IL-4, IL-13 and TGF-β (225). More importantly, halofuginone treatment 
inhibits the phosphorylation of p38. In addition, in human corneal fibroblasts, 
halofuginone treatment reduced protein expression of Smad3 (344), a signal transducer 
and transcriptional modulator activated by TGF-β and involved in several signalling 
pathways. p38 inhibitors can prevent the activation of Smad3 and attenuate its TGF-β-
induced expression (345). Besides the halofuginone-mediated inhibition of cytokines 
and inflammatory agents as well as the similarities between the effects of p38 inhibitors 
and halofuginone, inhibition of p38 phosphorylation would be expected upon 
halofuginone treatment. However, the effect of halofuginone on the activity of p38 in 
cardiomyocytes has not been previously investigated. Therefore, as I am exploring the 
potential cardioprotective effects of the AAR pathway using halofuginone as a tool, 
considering that halofuginone has anti-inflammatory effects and p38 activity and 
inflammation aggravates heart failure; I have hypothesised that halofuginone treatment 
in cardiomyocytes would be anti-inflammatory. To our surprise, halofuginone activates 
p38 in a dose-dependent fashion (see Figure 4.11). In addition, using the dose of 
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halofuginone that activates the AAR pathway and is not toxic in cardiomyocytes; p38 
activity, measured by the phosphorylation of its substrate MK2, is increased by 
halofuginone and appears to be SB-sensitive (see Figure 4.15). 
The gene expression of one of the main inflammation-associated substrates of p38, 
COX-2, was increased in a SB-sensitive manner in response to halofuginone (see Figure 
4.17). COX-2 mediates the production of prostacyclins, a family of prostaglandins that 
induce platelet activation and vasodilatation and thromboxane A2, which has 
prothrombic effects. While prostacyclins prevent cardiac arrhythmias and platelet 
aggregation and have been reported as cardioprotective (346, 347), thromboxane, 
promotes platelet aggregation, acts as a vasoconstrictor and induces ventricular 
arrhythmias (348). This explains why COX-2 inhibitors can potentially lead to 
thrombotic cardiovascular events (349). Therefore, the halofuginone-mediated increase 
in COX-2 gene expression, could play a protective role and must be analysed beside the 
other cardioprotective effects of halofuginone.  
Constitutively active form of MKK6 induces IL-6 transcription and IL-6 release in a 
p38-dependent manner in cardiac myocytes (116). IL-6 appears to protect cardiac cells 
against apoptosis in an autocrine/paracrine manner to increase cell survival during 
stresses known to activate p38. In contrast, there is evidence for the involvement of IL-6 
in the pathophysiology of the failing heart (350). Elevated levels of IL-6 in plasma and 
in the heart of patients with congestive heart failure (351, 352) and the correlation with 
left ventricular function and cardiac injury with these levels suggests an important role 
for IL-6 in the cardiac context. However, despite the evidence of involvement in the 
progression of cardiovascular diseases, it is yet to be determined whether the increase in 
IL-6 levels is causative or a consequence of the pathophysiology. Halofuginone 
treatment in Th17 cells inhibit cell differentiation and increase levels of IFN-γ, TNF-α, 
and IL-6 leading to a reduction in disease severity in the context of graft versus host 
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disease (353). It appears that IL-6 levels increase in a SB-sensitive manner with 
halofuginone treatment in cardiomyocytes (see Figure 4.17). Taken together with the 
protective role of COX-2, this could be an adaptive mechanism in the cardiac context. 
Increased levels of IL-1β have been reported in atherosclerotic plaques (354) and a 
reduction in the expression of activity of this cytokine has been associated with a 
reduction in plaque size (355, 356). A recent phase 3 clinical trial Canakinumab Anti-
inflammatory Thrombosis Outcomes Study (CANTOS; NCT01327846) aims to reduce 
cardiovascular events in patients with a recent myocardial infarction and increased C-
reactive protein (CRP) levels using an antibody against IL1β (357) after the promising 
results of the phase 2b trial which reported reduced inflammation and fibrinogen (358). 
A study on IL1R1−/−apolipoprotein E−/− (ApoE−/−) mice reported decreased plaques, 
though plaque stability and vascular remodeling was reduced in areas where 
haemorrhage occurred in these animals (359). The evidence suggests that although 
blocking IL1β pathway appears to be protective, there is potential that this pathway 
plays a dual role in advanced atherosclerosis by facilitating plaque stability. Though the 
results were not significant, halofuginone appears to reduce the mRNA levels of the 
IL1R1 and its antagonist IL1RN, with a trend in this reduction being SB-sensitive (see 
Figure 4.17). The reduction in the gene expression of the receptor suggests that 
halofuginone mediates the reduction in the response to the inflammatory signal, which 
correlates with a reduction in levels of IL1RN, which is possibly no longer required to 
attenuate the signal as the reduction in receptors provides this feedback. 
5.13 Use of lentiviral vectors to study gene function 
Though gene therapy emerged as a tool to rectify the resulting hereditary diseases due to 
a missing or dysfunctional protein, it is currently a well-established method to study the 
function of genes of interest within cells and tissues of living organisms. Exploring the 
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function of genes could involve the insertion of a modified form of the gene at a specific 
location in the host genome, in order to replace the existing gene. This could enable 
researchers to elucidate the importance of certain regions of a specific gene, such as the 
interaction points of TAB1 identified to be important in p38 binding. Organisms 
without the functional regions of TAB1 would have reduced TAB1 binding to p38, 
potentially having a lower risk of injury upon ischaemia as this appears to be TAB1-
mediated (see section 1.2.3). This is further discussed in section 8. 
A second method of exploring gene function through gene therapy is by genetic 
engineering of knock-out animals, where the gene of interest is switched off. This could 
lead to embryonic or neonatal lethality which would highlight the importance of the 
gene in development, such as in the case of p38 (57) and TAB1 (360).  
A similar approach to knock-out animals, in the cell-based system is knocking the gene 
down using RNA interference (RNAi). There are two types of RNA molecules that 
naturally exist within cells, microRNA and small interfering RNA (siRNA), which are 
products of genes and play the role of binding to mRNA of certain genes to alter their 
activity. A small hairpin RNA (shRNA) is an artificial RNA molecule with a hairpin 
turn that is used to silence the target gene through RNAi. An enzyme called Dicer forms 
siRNA from shRNA, which then binds to mRNA and cleaves it, leading to the 
inhibition of protein synthesis from that particular mRNA. shRNA is a more 
advantageous tool for RNAi as it has a relatively low rate of degradation and turnover 
compared to siRNA. 
Exploring the AAR pathway induction by halofuginone is a feasible way to explore the 
potential impacts of the activation of this pathway. However, in order to confirm the 
effects that are observed are mediated by GCN2 and not by an off-target effect of 
halofuginone upstream, GCN2 was knocked-down by the use of shRNA-packed 
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lentiviruses and some of the readouts that were previously altered upon halofuginone 
treatment were observed, once again. 
Following the confirmation of the knock-down of GCN2 at mRNA (see Figure 4.19) 
and protein level (see Figure 4.20), the phosphorylation of eIF2alpha was observed. To 
our surprise, eIF2alpha is still phosphorylated despite knocking down GCN2 (see 
Figure 4.20). In addition, the downstream effects of activated eIF2alpha, such as the 
increase in DDIT3 mRNA (see Figure 4.21), still persist despite knockdown of the 
upstream GCN2. As previously discussed in section 1.8.5, there are three other kinases 
upstream of eIF2alpha. Though these kinases are activated in response to different 
stresses, there is potential of functional redundancy between them. In a study in PERK-/- 
fibroblasts, phosphorylation of eIF2alpha is attenuated, though not completely lost in 
comparison to wild-type cells. This suggests another kinase fulfils, at least at low levels, 
the role of PERK in phosphorylating eIF2alpha. In PERK-/- GCN2-/- double knock out 
cells, the downstream effects of eIF2alpha, in this case cyclin D1 loss, is attenuated 
inferring that it is GCN2 which functions as the redundant kinase  (361). For our 
experiments, there are two explanations for the presence of eIF2alpha phosphorylation, 
despite knocking down GCN2 successfully. One mechanism could be due to the 
redundancy of upstream kinases due to their cooperation as discussed. Another 
explanation is that the knockdown of the GCN2 gene was not complete, so the low level 
of GCN2 present might still have the ability to induce the phosphorylation of eIF2alpha 
as without the knock-down.  
In addition, the overexpression of the wild-type GCN2 and the constitutively active 
GCN2 (F855L) increases the protein levels of GCN2, yet the effect on eIF2alpha 
phosphorylation was similar independent of the presence of overexpression vectors. 
Nonetheless, eIF2alpha is phosphorylated basally with the constitutively active GCN2 
mutant, as expected. This could be due to the fact that eIF2alpha is already maximally 
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phosphorylated by the basal levels of GCN2 and there is no excess eIF2alpha which 
could be phosphorylated to correlate with the overexpressed levels of GCN2. 
Nonetheless, effects of halofuginone and the specificity of the AAR pathway as the 
mediator of these effects require further investigation to confirm findings. This is 










Despite the importance and additions of the findings and results in this thesis to the 
cardiology research field, there are a few limitations to the study, which should be 
addressed. Quantification is the conversion of a concept to numbers, which would 
represent the property linked to this quantity. It is an important aspect of data analysis 
and aids to visualise the results easily, as well as providing a platform on which 
statistical tests could be performed, allowing scientists to derive the significance of the 
acquired results. Though most of the results are quantified in this thesis, all of the 
results should be quantified in order to boost the strength of the results, their 
reproducibility and statistical significance. Data acquired from this point on should be 
quantified for the above reasons. 
An essential part of an experiment consists of tests referred to as controls which 
establishes the baseline that the experimental samples are compared to, as well as 
testing that the system being used works as it should. In addition, controls also allow 
scientists to discover potential errors in the case that the result is different from expected 
in the controls. Though having the correct controls for each experiment in this thesis has 
been given substantial consideration, certain controls are missing from the displayed 
results. An example of this missing control is the localisation of p38, TAB1 and 
MKK3b transfected alone in Figure 3.19. This would help to establish the differences 
the presence of the binding partner makes more clearly, even though the main difference 
looking examined for in this particular experiment is the difference the presence of 
TAB1 makes to the binding between MKK3b and p38. In future experiments, this 
should be paid further consideration in order to have the correct controls for the 
comparison of the experimental results. 
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In addition, just like the experimental control samples, loading controls are essential for 
proper interpretation of Western blots. They are used to normalise the levels of 
phosphorylated and total protein, confirming that the observed differences are true and 
not due to loading errors during the Western blotting process. Housekeeping genes with 
high-level and constitutive expression in the tested system are used as loading controls. 
Although in most experiments analysed in this thesis, either a housekeeping gene or the 
total protein of interest, in the analysis of phosphorylation levels, has been used, it 
would have been preferable to use expression of a housekeeping protein as a loading 
control for all performed experiments, in the event of the total protein also being altered 
by the treatment in question. 
In the light of above limitations, future research questions should be addressed in an 
appropriate manner with reference to controls and quantification. These would enable 




To summarise TAB1 induces p38 autophosphorylation without the activation of the 
canonical pathway confirming there is a TAB1-mediated p38 activation pathway 
independent of the canonical activation mechanism. TAB1-mediated p38 
autophosphorylation is sensitive to SB203580, and the key residue in this inhibitor-
kinase interaction is Thr106, which when mutated renders p38 resistant to SB203580. In 
this study, I have found TAB1 residues Val390 and Tyr392 (mutated to Gly and Ala 
respectively in the CM TAB1 mutant) and Val408 and Met409 (mutated to Gly and Ala 
respectively in the NCM TAB1 mutant) are important in TAB1-p38 interaction and 
mutations of these residues lead to a reduced binding of TAB1 to p38.  
This is found to consequently and independently affect p38 autophosphorylation and 
TAB1 substrate presentation. Furthermore, though TAB1 appears to have an effect on 
p38 interaction with MKK3b in in vitro assays, no competition between MKK3b and 
TAB1 are observed in experiments in the mammalian cell system. This appears to be 
due to a difference in the in-cell location of MKK3b and TAB1, with MKK3b able to 
attract p38 to its location despite the presence of overexpressed TAB1. This suggests 
that the in-cell location of p38 along with its binding partners and inducing stimuli 
potentially determines the differential downstream function. In addition, TAB1 
phosphorylation state did not affect phosphorylation of TAK1, despite previous findings 
that TAK1 activity is modulated negatively by TAB1. Though preliminary, our findings 
motivate to encourage further investigation into p38 and TAB1 interaction mechanism, 
especially in the in vivo setting in order to elucidate the role of TAB1-p38 interaction in 
the context of cardiac ischaemia. 
Moreover, the AAR pathway has not been examined previously in cardiomyocytes. Our 
study provides evidence for the presence of this pathway in different lines of cardiac 
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cells along with the induction of established downstream substrates of the pathway. It 
appears that halofuginone is able to induce this pathway in a specific, reversible way. In 
addition to previously identified substrates of this pathway such as ASNS, DDIT3 and 
TRIB3, our experiments provide evidence for further novel potential mechanisms 
mediated by p38 i.e. the potential regulation of the AAR pathway initiated by 
halofuginone-mediated activation of p38. Though the protective potential of 
halofuginone has been previously examined in the DMD setting, the data generated in 
this thesis provides promising evidence that halofuginone or the activation of the AAR 
pathway via other means could potentially alleviate the features observed in the 
pathophysiology of heart failure. These include changes in inflammation, autophagy, 
hypertrophy and MAPK activation. 
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8 FUTURE WORK 
In order to verify that the effects of TAB1 mutations on p38 autophosphorylation 
observed in vitro and in bacteria are reflected in systems of higher organisms, a 
mammalian cell line has also been tested.  The next step to obtain stronger evidence 
verifying the interaction points of TAB1 and p38α would be using a cell line in which 
the canonical pathway of p38α activation is disabled. TAK1-deficient MEFs could be 
used to remove the effect of the canonical pathway almost completely and attribute any 
resulting p38α phosphorylation to the TAB1-mediated mechanism providing a deeper 
understanding of the impact of this pathway. 
TAB1 has recently been found to be modified by O-GlcNAcylation on Ser395 (4) and 
this modification has been found to play a role in the TAK1 cascade. O-GlcNAcylation 
may alter substrate specificity on adjacent regions by steric hindrance. Therefore, since 
this single site modification appears to play a role in the canonical pathway, it might be 
enlightening to further investigate whether this has an impact on p38 
autophosphorylation. A potential way this could be done is by using an O-
GlcNAcylated form of TAB1 to do IVK assays to see its effect on p38 
autophosphorylation. A potential problem I could observe is that the full-length TAB1 
is not soluble and the modification on Ser395 could make it even more insoluble. 
Nonetheless, current evidence shows that these experiments would provide valuable 
information into understanding TAB1-mediated activation of p38α. 
Another regulation of TAB1 protein is via an E3 ubiquitin ligase called Itch. As 
discussed earlier, Itch binds TAB1 directly and inhibits the activation of p38. It appears 
that p38-mediated inflammation is suppressed by the direct interaction of Itch with 
TAB1 inducing its ubiquitylation and degradation (33). This mechanism could be 
manipulated when targeting TAB1-mediated activation of p38 to perturb the system 
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using different pathways. Nonetheless, caution must be exercised when approaching 
TAB1 from this pathway as Itch is also involved in the proteasomal degradation of 
TAK1. Therefore, this could have nonspecific effects on the p38 pathway and block its 
other crucial activities and it is important that manipulations are targeted if they are to 
provide meaningful results. 
In addition, the function of this pathway in vivo can be studied using proteomic 
methods. The stable-isotope labelling of amino acids in cell culture (SILAC) proteomics 
methodology could be used to identify the consequences of different TAB1 mutations. 
The transactivator of transcription (TAT) peptide (GRKKRRQRRRPQ) is a cell 
penetrating peptide from human immunodeficiency virus and is a useful tool for 
translocating molecules across cell membranes efficiently. This peptide has been used to 
transfect cells with the TAB1 peptides. We have recently found the TAT peptide on the 
TAB1 peptide to be a stressor on cells and this could be used as a control to understand 
pathologic and adaptive changes in the heart associated with pressure overload and 
exercise leading to discovery of critical kinases and identify their function. 
Furthermore, current ongoing work in our laboratory involves TAB1 knock-in mice, 
which harbour the mutations I have examined in this thesis, which affect the interaction 
between p38 and TAB1. Langendorff experiments of isolated hearts subjected to 
ischaemia could provide valuable information about the importance of TAB1-p38 
interaction and its involvement in ischaemia. In the case that infarct size is reduced in 
mutant mice, it would be extremely promising to pursue this further by investigating 
compounds to target these interaction points to minimise ischaemic injury in high-risk 
patients. 
Regarding the potential of the protective effects of activating the AAR pathway to 
minimise features of heart failure, the data in this thesis is preliminary and on its own is 
not sufficient to determine whether this protective role exists or not in whole hearts. 
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However, in house data at GSK treating heart failure models of mice with halofuginone 
as well as proteomics and transcriptomics studies (unpublished data) support the 
protective role that is provided by halofugione in these studies. Therefore, taking into 
account all published and unpublished evidence besides the data in this thesis, there are 
promising indications to investigate this pathway further. As halofuginone acts 
relatively upstream in the pathway, it might be more feasible to approach the pathway in 
a more direct and specific manner. A method to investigate this could be by looking at 
compounds, which would activate GCN2 directly, preventing potential upstream effects 
of amino acid starvation within cells, which is a complex mechanism known to cross-
link different pathways including the mTOR system. 
Furthermore, though the effect of halofuginone on p38 activity and downstream 
effectors has been investigated, this is a mechanism that should be investigated further. 
The potential negative feedback system provided by p38 on the AAR pathway 
activation could play an important role in the dampening of the effects of the activation 
of this stress pathway. This could have a protective effect on the cell, by keeping the 
activation under regulation and alter it according to the stress and the adaptive 
mechanisms required for cell survival. p38 activation is usually detrimental in the 
cardiac context and contributes to injury. Nonetheless, due to its role in a wide range of 
cell processes, its specific downstream effects depend on the activation mechanism and 
might therefore be protective depending on the stimuli. Therefore, despite being active, 
it could trigger cardio-protective mechanisms such as through the dampening of the 
AAR pathway, which perhaps should only be activated at low levels to achieve the 
prevention of features of heart failure. This would be akin to p38’s known protective 
role in ischaemic preconditioning. 
In addition, due to time limitations at GSK, as well as technical complication in the 
production of viruses targeting GCN2, the lentiviral studies in this thesis are preliminary 
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and need to be replicated. The issues with the downstream effects of GCN2 still  being 
present upon its knockdown could be an artefact of the experiment and must be repeated 
to ensure veracity. Nonetheless, another way to investigate this would be using 
compounds to inhibit GCN2 to determine that the effects of halofuginone are through 
this kinase. It must be considered that finding specific, potent compounds is a 
complicated and challenging process and this might not be easily done. However, 
previous evidence suggests that it is a pathway worth investigating further and could 
provide valuable results relevant to the pharmaceutical industry and human health, since 
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